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ABSTRACT 
GFI1B is a transcriptional repressor that is a major regulator of megakaryocytic and erythroid 
differentiation and development. The cause of a bleeding disorder in a four- generation Australian 
family, with cell changes consistent with aberrant platelet structure and function, and red blood cell 
morphology, showing autosomal dominant inheritance, was identified as being caused by a single 
nucleotide insertion into the GFI1B gene (c.880_881insC). The aims of this thesis were to study the 
effects of this mutant GFI1B on erythrocyte development in a cell culture model; to study how loss 
of Gfi1b function affects megakaryocytic development in a conditional knockout mouse model; and 
to examine the effects of human GFI1Bc.880_881insC on megakaryocytic / erythroid cell development in 
a transgenic mouse model, with correlation to the human phenotype. 
 
Separate lines of erythroleukaemic K562 cells were transfected with GFI1BWT and GFI1Bc.880_881insC for 
studies into red cell formation. Inconclusive results from constant loss of transfection led to the view 
that a cell model derived from iPSC from affected family members would provide a more stable 
system for this study. 
 
For the conditional knockout mouse model, C57BL/6J mice with floxed Gfi1b alleles were cross-bred 
to transgenic mice expressing Cre recombinase under the platelet factor 4 (Pf4) promoter to create a 
null allele. Mice with retained floxed alleles were controls. The effects of the loss of Gfi1b along the 
megakaryocytic lineage included 60-fold reduction in platelet count; aberrant megakaryocyte 
morphology, with high DNA ploidy and increased numbers in bone marrow and spleen; high plasma 
TPO level; enlarged spleens with evidence of stress erythropoiesis; and reduced red cell indices. 
Reported studies in the literature corroborated these findings. 
 
 
C57BL/6J transgenic mice with either GFI1BWT or GFI1Bc.880_881insC with a lox-STOP-lox cassette 
inserted at the collagen Col1a1 locus were crossed with transgenic mice expressing Pf4-Cre for the 
transgenic mouse model. The premise, that the human mutant GFI1B would cause a dominant 
negative effect on the endogenous mouse Gfi1b, was not seen in the lack of a bleeding phenotype, 
and evidence of normal haematological parameters in these mice. A knock-in model with 
GFI1Bc.880_881insC replacing Gfi1b may be more effective. 
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1. Literature review 
1.1 Introduction 
Bleeding disorders and haematological abnormalities can have serious and sometimes life- 
threatening consequences for those who are affected by them. The inability of blood platelets 
(thrombocytes) to clot normally and the presence of defective red blood cells (erythrocytes), whose 
normal function is to carry oxygen to body tissues and remove accumulated carbon dioxide, can 
have a severe impact on the outcomes of routine surgical procedures or sustained trauma in such 
individuals. Discerning the causes and mechanisms of abnormal haematological features in such 
instances can lead to better understanding of the processes involved and the means to apply 
possible solutions in treating these problems. 
 
1.2 Haemostasis and bleeding disorders 
1.2.1 Haemostasis 
Haemostasis is the process by which any bleeding at the site of an injury is stopped, with the aim of 
containing the blood in the damaged blood vessel. It is the first stage of wound healing, and involves 
sequential processes: primary and secondary haemostasis, followed by the fibrinolysis pathway 
(Gale, 2011, Minors, 2007) (Figure 1.1). Primary haemostasis involves local vascular contraction; the 
adhesion of platelets to the damaged blood vessel wall; further platelet activation, resulting in shape 
change and exposure of ligand binding sites on the platelet cell surface, which are critical for the 
aggregation of platelets and the formation of the platelet plug. Secondary haemostasis consists of 
the activation, from exposure to phospholipids on the platelet cell surface, of a cascade of blood 
clotting factors down one of two pathways (depending on initial exposure) to a common pathway 
which culminates in the conversion of prothrombin to its active form, thrombin. Thrombin converts 
fibrinogen to insoluble fibrin, which is then incorporated into and around the platelet plug, 
stabilising it. Finally, the fibrinolytic system, consisting of plasminogen activators, which convert 
plasminogen to plasmin, is engaged. Plasmin then cleaves and breaks down fibrin, thus dissolving 
the clot during the process of wound healing. In these processes, bleeding disorders can arise from: 
either too few or abnormal platelets; abnormal or decreased concentrations of clotting factors or 
fibrinolytic agents; or abnormal blood vessels. 
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Figure 1. 1 Schematic representation of the haemostasis process. 
 
 
Primary haemostasis consists of platelet adhesion, activation and aggregation, resulting in a 
primary haemostatic platelet plug. Vasoconstriction reduces blood flow, promoting the 
formation of this plug. Simultaneously, the process of secondary haemostasis occurs, which 
involves the blood coagulation cascade on the platelet surface. This generates thrombin and 
thence fibrin, which becomes incorporated around the platelet plug. This stable plug then 
ultimately undergoes fibrinolysis. 
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Table 1. 1 Acquired and inherited bleeding disorders resulting from coagulation and platelet- 
related deficiencies or defects. 
 
CONDITION CAUSE / INHERITANCE 
ACQUIRED  
Coagulation disorders 
Acquired coagulation factor 
inhibitors 
Auto-antibodies to clotting factors 
Acute traumatic coagulopathy Impaired thrombin generation, hyperfibrinolysis 
Liver disease Impaired hepatic function with decreased synthesis of clotting 
factors 
Disseminated intravascular 
coagulopathy (DIC) 
Widespread activation of coagulation system, intravascular 
fibrin formation 
Vitamin K antagonists Prevention of activation of clotting factors and anticoagulant 
proteins 
Platelet-related disorders  
Renal disease Anaemia from platelet dysfunction 
Immune thrombocytopenia 
purpura 
Development of anti-platelet IgG autoantibodies 
Thrombotic 
thrombocytopenic purpura 
Deficiency of ADAMTS-13 (cleaves vWf) 
Haemolytic uraemic 
syndrome 
Overactivation of complement system 
Platelet inhibitor use Overuse of anti-platelet medication 
Heparin-induced 
thrombocytopenia 
Antibodies against PF4 and heparin 
INHERITED  
Coagulation disorders  
Haemophilia A Severe deficiency in Factor VIII, X-linked 
Haemophilia B Severe deficiency in Factor IX, X-linked 
Platelet-related disorders  
von Willebrand disease Type 1, quantitative defect / autosomal dominant 
 Type 2, qualitative defect / autosomal dominant or recessive 
 Type 3, quantitative defect / autosomal recessive 
Glanzmann thrombasthenia Deficiency in GPIIb/IIIa (fibrinogen) receptors / autosomal 
recessive 
Bernard-Soulier syndrome Deficiency in GPIb/IX/V (vWf) receptors / autosomal recessive 
Storage pool disease Various: deficiencies in α-granules, δ-granules (dense 
granules)/ autosomal dominant; autosomal recessive; X-linked 
May-Hegglin anomaly (MYH9- 
related disorder) 
Mutation in MYH9 gene (myosin heavy chain IIA) / autosomal 
dominant 
Gray platelet syndrome Mutation in NBEAL2 gene (vesicular trafficking - absence of α- 
granules) / autosomal recessive 
Quebec platelet disorder Mutation of PLAU gene (urokinase plasminogen activator) / 
autosomal dominant 
Paris-Trousseau syndrome Hemizygous deletion or homozygous missense of transcription 
factor FLI1 / autosomal dominant 
Platelet-type bleeding 
disorder 17 
Mutation in transcription factor GFI1B / autosomal dominant 
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Table 1. 2 Presentation of clinical features distinguishing platelet or vascular disorders from 
coagulation disorders (adapted from (Patton, 2008)). 
 
Presentation Platelet or vascular disorder Coagulation disorder 
Bleeding from superficial cuts and 
scratches 
Persistent, often perfuse Minimal 
Delayed bleeding Rare Common 
Spontaneous gingival (gum) 
bleeding 
Characteristic Rare 
Petechiae (bleeding into skin) Characteristic Rare 
Ecchymoses (skin bruising) Characteristic, usually small and 
multiple 
Characteristic, usually 
large and solitary 
Epistaxis (nose bleed) Common Common 
Deep dissecting haematomas 
(bleeding in deep soft tissue) 
Rare Characteristic 
Haemarthroses (bleeding into 
joints) 
Rare Characteristic 
 
1.2.2 Bleeding disorders 
These disorders constitute a group of conditions, either acquired or inherited, in which there is an 
abnormal tendency to bleed (haemorrhage) due to failure of haemostasis (Hurwitz et al., 2014, 
McDonald and Austin, 2017, Mensah and Gooding, 2015, Patton, 2008, Stevenson et al., 2013, 
Stevenson et al., 2015, Vo et al., 2017, Hayward and Rivard, 2011) (Table 1.1). This group of 
tabulated disorders is by no means exhaustive. Other classifications, as mentioned, include vessel 
wall disorders, and deficiencies of components of the fibrinolytic pathway. Determination of causes 
of bleeding in the former can be recognised from the clinical features, which can distinguish platelet 
or vascular disorders from coagulation disorders (Patton, 2008) (Table 1.2). This study, however, is 
concerned with bleeding disorders arising from deficiencies or anomalies in platelets and their 
physiology, function, and origin. 
 
1.3 Platelets 
Platelets are the central cellular elements in haemostasis (Berndt et al., 2014). They remain in an 
inactive state, only becoming activated when a blood vessel is damaged. They then move through 
the stages of: adhesion to the exposed subendothelial matrix of the damaged blood vessel; 
activation of the platelet leading to shape change and granule release; and aggregation, the 
adherence of platelets to each other in the formation of the haemostatic plug. 
6  
 
 
 
Figure 1. 2 Schematic representation of platelet structure and platelet content. 
 
 
(A) Platelet structure, showing distribution of organelles (α-granules, dense granules, 
lysosomes, mitochondria), metabolites (glycogen), and tubular systems (canalicular system, 
microtubules). (B) Platelet content, denoting representative membrane glycoproteins 
(GPIb/IX/V complex (CD42b/CD42a/V)), examples of α-granule content (P-selectin (CD62P)), 
and cell surface receptors (PAR-1 and PAR-4 (thrombin receptor, high affinity and low affinity, 
respectively)). (Images: (Zapata et al., 2014)). 
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1.3.1 Platelet structure 
Platelets are anucleate cells, with a diameter of 1-3μm, and are generated from megakaryocytes in 
the bone marrow (Hou et al., 2015, Ghoshal and Bhattacharyya, 2014, Duerschmied and Massberg, 
2017). Each megakaryocyte can produce between 5,000 and 10,000 platelets, with the normal 
platelet count in blood spanning 150 – 400 x 103 per μL. Platelets circulate in close proximity to the 
endothelial cell surface in blood vessels (Heijnen and Korporaal, 2017), ensuring that they can 
monitor the endothelium for any damage. They have a discoid shape, which is maintained by 
microtubules around the circumference, and a membrane cytoskeleton of actin, spectrin, tubulin, 
and filamin. The plasma membrane is contiguous with an open canalicular system (OCS) which opens 
to the extracellular space (Figure 1.2 (A)). The OCS supplies membrane surface to the platelet when 
it spreads on activation, and provides a route for the release of the contents of the three different 
types of platelet granules: dense granules, α-granules, and lysosomal granules (Drelich and Bray, 
2015, Flaumenhaft and Koseoglu, 2016, Flaumenhaft, 2017) (Table 1.3). Both dense granules and α- 
granules are required for normal haemostasis and thrombosis. 
 
Table 1. 3 Examples and types of contents of platelet granules. 
 
Type of 
granule 
 
Content category 
 
Examples 
Dense Ions Ca2+, Mg2+, K+, polyphosphate 
3-8 per 
platelet 
Nucleotides ADP, ATP, GDP, GTP 
Bioactive amines Serotonin, histamine 
Membrane proteins CD63 (granulophysin), LAMP-2, GPlb, αllbβ3 
Transporter proteins MRP4, VNUT, VMAT2 
α-granules Adhesion proteins Fibrinogen, vWf, thrombospondin 
50-80 per 
platelet 
Chemokines CXCL4 (PF4), CXCL7 (β-TG), CXCL8 (IL-8), CCL5 
(RANTES) 
Coagulants, anticoagulants, 
fibrinolytic proteins 
FV, FIX, FXIII, ATlll, protein S, TFPI, 
plasminogen, PAI-1, α2-macroglobulin 
Growth factors VEGF, PDGF, FGF, EGF, IGF, TGF-β 
Immune mediators Complement C3 and C4 precursors, IgG 
Integral membrane proteins αIIbβ3, GPIbα-IX-V, GPVI, TLT-1, P-selectin 
(CD62-P) 
Microbicidal proteins Thymosin-β4, thrombocidins 1 and 2 
Lysosomes 
Carbohydrate- degrading 
enzymes 
Arabinofuranosidase, fucosidase, 
galactosidase, glucosidase 
0-3 per 
platelet 
Phosphate ester cleaving Acid phosphatase 
Protein-degrading enzymes Carboxypeptidase, cathepsins, collagenase, 
elastase 
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1.3.2 Platelet adhesion 
Exposure of subendothelial proteins, such as collagen, causes the initial recruitment of platelets 
from the circulation to bind to the damaged vessel through interactions of adhesive glycoproteins on 
the platelet surface with these proteins (Chen and Lopez, 2005). This platelet adhesion occurs 
at both low (venous system) and high (e.g. coronary arteries) shear conditions, which are mediated 
through separate mechanisms (Hou et al., 2015). During high shear, plasma von Willebrand factor 
(vWf) (produced by endothelial cells, megakaryocytes, and thus platelets) binds to the exposed 
collagen. Glycoprotein (GP) Ibα (CD42b), the major subunit of the GPIb-IX-V membrane receptor 
complex on platelets for vWf, binds to the A1 domain on the immobilised vWf, initiating platelet 
tethering to the site. Platelet collagen-binding receptors GPVI, integrin α2β1 (GPla/lla), and GPIV then 
bind to the exposed collagen, leading to platelet signalling and activation. Stable adhesion is 
established by several integrins binding to their ligands on the blood vessel wall, such as αllbβ3 
(GPllb/llla), which binds to fibrinogen, fibrin, and fibronectin, and α5β1 which also binds to 
fibronectin or collagen. However, at low shear, such as in veins, the interactions of the platelet 
integrins αllbβ3 with fibrinogen or fibrin, and those of the α2β1 integrin with collagen, directly initiate 
platelet adhesion. 
 
1.3.3 Platelet activation 
The platelet signalling and activation that result from the interactions between platelet surface 
receptors and their ligands lead to rearrangement of the platelet cytoskeleton (shape change), 
increase in intracellular calcium, and the release of granule contents (Drelich and Bray, 2015). This 
change in platelet shape progresses from discoid of approximately 2 μm diameter to a spherical 
shape with numerous pseudopodia and finally to a spreading shape, which is flat with a large 
adhesive surface (Shin et al., 2017). This reorganisation of the platelet cytoskeleton promotes the 
exocytosis of granule contents (Table 1.3), which act to further activate platelets through many 
positive feedback loops. ADP is released from dense granules and interacts with platelet receptors 
P2Y1, P2Y12 and P2X1. α-granules fuse with the platelet plasma membrane, releasing their contents, 
which include adhesion proteins, such as fibrinogen and vWf; integral membrane proteins, such as P- 
selectin (CD62-P), and chemokines, such as platelet factor 4 (PF4) and interleukin-8 (IL8). The 
coagulation system is also activated on the platelet cell surface, generating the most potent platelet 
activation factor, thrombin, which binds to GPlbα on platelets and cleaves protease-activated 
receptor (PAR) 1 (high affinity) and PAR 4 (low affinity) (Hou et al., 2015). 
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1.3.4 Platelet aggregation, platelet plug, and fibrinolysis 
The activation of platelets is critical for their aggregation (Gale, 2011). During shape change, the 
most abundant platelet membrane glycoprotein, integrin αllbβ3, is exposed and activated, and 
platelet-platelet aggregation is initiated. αllbβ3 binds to many different ligands that promote this 
aggregation, including fibrinogen, vWf, collagen, fibronectin and vitronectin. Nearby platelets are 
then activated in a feedback manner mediated by agonists released by the activated platelets 
themselves. These include ADP, thromboxane A2, which is synthesised from arachidonic acid in the 
platelet plasma membrane, serotonin, and epinephrine. Cross-linking of platelets occurs through 
integrin αllbβ3 via fibrinogen, creating an initial unstable platelet plug. The simultaneous onset of 
secondary haemostasis, which involves the coagulation cascade on the platelet surface, produces 
the formation of insoluble fibrin which then stabilises the formed platelet plug. Finally, as wound 
healing proceeds, the plug or clot is broken down by the fibrinolytic system, which involves the 
conversion of plasminogen to plasmin, which then cleaves and breaks down fibrin. 
 
1.4 Overview of haematopoiesis, megakaryopoiesis and thrombopoiesis, and 
erythropoiesis 
Thrombopoiesis, or platelet formation, is the process by which platelets are released from 
megakaryocytes (Sim et al., 2016). They are the end products of megakaryocytic differentiation and 
development (megakaryopoiesis) whereby a haematopoietic progenitor cell (HPC) has differentiated 
into a large polyploid megakaryocyte (Deutsch and Tomer, 2006). The process of haematopoiesis 
from HPCs is a dynamic system, in which all blood cell lines are derived from common pluripotent 
stem cells, being subject to a complex array of factors to produce mature, functioning blood cells. 
 
1.4.1 Haematopoiesis 
The formation of blood cells occurs during embryonic development and continues throughout 
adulthood to maintain the blood system. In humans, this involves two waves of development: the 
primitive wave, which temporarily produces erythrocytes and macrophages in the yolk sac, then 
moves to the liver during embryonic development; and the definitive wave, where haematopoiesis is 
established in the bone marrow and thymus (Figure 1.3) (Jagannathan-Bogdan and Zon, 2013, Ho et 
al., 2015). The purpose of the transitory primitive wave is to produce red cells that promote 
oxygenation of tissues as the embryo grows. These cells are not pluripotent, however, and are not 
able to renew themselves. They are derived from the haemangioblast, a common precursor for 
endothelial and haematopoietic cells, which arises from the mesoderm (Loges et al., 2004). 
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The establishment of definitive haematopoiesis occurs in the aorta-gonad-mesonephros (AGM) 
region of the developing embryo, giving rise to haematopoietic stem cells (HSC) which migrate to the 
foetal liver and then to the bone marrow (Tavian et al., 2010). These cells derive from haemogenic 
endothelium in the embryo, are pluripotent and renewable, and are responsible for the production 
of all cell types during this stage of haematopoiesis. Mature haematopoietic cells develop from two 
distinct lineages: the lymphoid and the myeloid (Iwasaki and Akashi, 2007). The lymphoid lineage, 
through the common lymphoid progenitor (CLP), produces the lymphocytes T-cells, B-cells, and 
natural killer (NK) cells. The myeloid lineage branches into several distinct cell lines through the 
common myeloid progenitor (CMP). It differentiates separately into erythrocytes and platelets down 
through the megakaryocyte-erythroid progenitor (MEP), as well as different sub-classes of 
granulocytes (neutrophils, eosinophils, and basophils), monocyte-macrophages, and mast cells down 
through the granulocyte-monocyte progenitor (GMP) (Figure 1.3). 
 
 
 
Figure 1. 3 Schematic representation of haematopoiesis. 
 
Primitive haematopoiesis (top), derived from haemangioblasts, produces primitive erythrocytes 
and macrophages to oxygenate tissue as embryo forms. Definitive haematopoiesis (bottom), 
derived from haemogenic endothelium, produces all blood cell lines from pluripotent, renewable 
human stem cells (HSC). (Figure: (Jagannathan-Bogdan and Zon, 2013)). 
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1.4.2 Megakaryopoiesis and thrombopoiesis 
Megakaryopoiesis occurs through the differentiation of the bipotent MEP (Deutsch and Tomer, 
2006). These megakaryocyte progenitors express CD41 (Miyawaki et al., 2017), and continue to 
divide, generating cells that express platelet proteins, such as CD41 and CD42, which are markers of 
early differentiation (Figure 1.4) (Mazzi et al., 2018). These cells are promegakaryoblasts, which have 
DNA ploidy of 2N and switch from mitosis to endomitosis to produce polyploid megakaryoblasts and 
megakaryocytes. 
 
Thrombopoiesis occurs after the arrest of polyploidisation, which can be as high as 128N, whereby 
megakaryocytes increase cytoplasm area by increasing protein production, generating the 
demarcation system (DMS), a network of invaginated plasma membranes, and specific platelet 
granules, which are then organised into platelet islands. Cytoskeletal proteins are then reorganised 
to form long pseudopods which fragment into proplatelets (Machlus and Italiano, 2013, Patel et al., 
2005). Megakaryocyte differentiation in humans takes place in the bone marrow, near sinusoidal 
walls, through which the generation of platelets takes place by the shedding of the proplatelets into 
the blood circulation (Sharathkumar and Shapiro, 2008). 
 
Figure 1. 4 Schematic overview of megakaryopoiesis and thrombopoiesis. 
 
Megakaryopoiesis originates from haematopoietic stem cells through the megakaryocyte- 
erythroid progenitor, undergoing mitotic division to promegakaryoblasts, through the 
promegakaryocyte stageto the production of long pseudopods which then release mature 
platelets into the blood circulation. 
CFU-MK, colony-forming unit megakaryocyte; MK-P, megakaryocyte progenitor (also MEP); 
PMKB, promegakaryoblasts; MKB, megakaryoblast; proMK, promegakaryocyte; MK, 
megakaryocyte. (Figure: (Mazzi et al., 2018)). 
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1.4.3 Erythropoiesis 
The primitive haematopoietic wave, occurring in the yolk sac, produces large numbers of erythroid 
cells that support the growth of the foetus (Baron et al., 2012). These are relatively large cells which 
are characterised by expression of embryonic haemoglobin (Dzierzak and Philipsen, 2013). However, 
production of these primitive cells is transient, as the definitive haematopoietic wave originating 
from HSC replaces primitive erythropoiesis (Ingley et al., 2004). 
 
Definitive erythropoiesis takes place, through various phases, in the foetal liver, and postnatally, in 
the bone marrow (Palis, 2014). From the HSC down through the CMP, erythropoiesis progresses 
through the engagement phase where megakaryocyte-erythroid common progenitors progress to 
the burst-forming unit-erythroid (BFU-e), the first progenitor cells committed only to the erythroid 
lineage (Figure 1.5) (Zivot et al., 2018, Dzierzak and Philipsen, 2013). These cells then differentiate to 
the colony-forming unit-erythroid (CFU-e), after which the second phase of terminal differentiation 
occurs. This is carried out in niches known as erythroblastic islands, consisting of a central 
macrophage surrounded by terminally differentiating erythroid cells at various stages of maturation. 
 
The second phase involves the progressive maturation of these nucleated precursor cells from 
proerythroblasts to basophilic, polychromatophilic and orthochromatic erythroblasts. The 
accumulation of haemoglobin occurs during this time, with a steady decrease in cell size, and 
condensation of the nucleus, which is ultimately expelled. The final maturation of erythroid cells 
involves the progression of reticulocytes to erythrocytes, which then assume their biconcave shape 
through reorganisation of the membrane, and are released to the blood stream. 
 
The most commonly used cell markers to distinguish the different stages for these cells include KIT, a 
tyrosine kinase, which is expressed in the early differentiation stages, and is phased out as CD71, the 
receptor for transferrin, is expressed, which, in turn overlaps the expression of glycophorin A, an 
integral membrane protein, on mature cells (Figure 1.5). 
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Figure 1. 5 Schematic representation of erythropoiesis. 
 
Graduating band lines indicate cell surface markers identifying the various stages. 
HSC, haematopoietic stem cell; CMP, common myeloid progenitor; MEP, megakaryocyte- 
erythroid progenitor; BFU-e, burst-forming unit-erythroid; CFU-e, colony-forming unit-erythroid. 
Figure modified from (Dzierzak and Philipsen, 2013). 
 
 
1.5 Regulation of haematopoiesis 
The onset of definitive haematopoiesis produces HSC division whereby one cell replaces the stem 
cell (i.e. is self-renewing), while the other is committed to differentiation (Hoffbrand and Moss, 
2016). The regulation of this ongoing process is carried out by a number of haematopoietic growth 
factors and transcription factors. 
 
1.5.1 Haematopoietic growth factors 
These factors are glycoprotein hormones which regulate the proliferation and the differentiation of 
both haematopoietic progenitor cells and mature cells. They derive from bone marrow stromal cells, 
except for erythropoietin (Epo), which comes from the kidney, and thrombopoietin (Tpo), which is 
made in the liver. A pool of haematopoietic stem and progenitor cells is maintained by these growth 
factors, so that later-occurring factors, such as Epo, granulocyte colony-stimulating factor (G-CSF), 
macrophage colony-stimulating factor (M-CSF), interleukin-5 (IL-5), and Tpo, can respond to the 
need to produce mature cells along those lineages (Figure 1.6) (Aster and Scadden, 2016). 
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Figure 1. 6 Schematic representation of haematopoietic growth factors. 
 
 
Growth factors act on bone marrow stem cells and progenitors to influence the regulation of the 
proliferation and differentiation of haematopoietic cells. SCF, stem cell factor (also known as c-KIT 
ligand); Tpo, thrombopoietin; IL-2, IL-3, IL-6, IL-7, IL-12: interleukins 2, 3, 6, 7, 12; GM-CSF, 
granulocyte-macrophage colony-stimulating factor; Epo, erythropoietin; M-CSF, monocyte colony- 
stimulating factor; SDF-1, stromal cell-derived factor-1; FLT-3, FMS-like tyrosine kinase; TNF-α, 
tumour necrosis factor alpha; TGF-β1, transforming growth factor beta 1. Image adapted from 
(Aster and Scadden, 2016). 
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1.5.2 Haematopoietic transcription factors 
Transcription factors (TFs) are proteins with domains that recognise and bind to specific sites or 
elements in regulatory regions of DNA, known as promoters or enhancers, where they control the 
transcription or expression of target genes. There are different families of TFs, each with different 
types of motifs of the DNA-binding domains which include, among others, zinc-finger, leucine 
“zipper”, and helix-loop-helix, each of which binds to specific DNA sequences. TFs also have an 
activation domain (Aster and Scadden, 2016) which promotes the assembly of the transcription 
complex at a gene promoter, interacts with RNA polymerase II or other transcription co-regulators, 
consequently regulating the amount of messenger RNA (mRNA) produced by the gene. TF activators, 
either alone or in a complex, promote the recruitment of RNA polymerase II to specific genes, 
whereas TF repressors block it. 
 
 
Figure 1. 7 Regulation of gene transcription by transcription factor. 
 
Transcription factors (TFs) bind to specific DNA sequences preceding the gene that they 
regulate, along with other co-factors, which leads to the binding of RNA polymerase. 
Messenger RNA (mRNA) is then synthesised. This occurs in the case of activator TFs. However, 
those TFs that repress transcription (repressors) block basal TFs or RNA polymerase, so that 
transcription does not occur. Figure adapted from (Waly, 2014). 
 
Low levels of TFs are expressed during early commitment of progenitors from HSC, directing which 
lineages are to be differentiated and matured. TFs such as TAL1(/SCL), GATA-2, and NOTCH-1, 
regulate the survival of the HSC (Figure 1.8) (Orkin and Zon, 2008), while others regulate 
differentiation along the major cell lines. PU.1 and C/EBPα direct cells along the myeloid line, 
whereas GATA-2, and then GATA-1, FOG-1 (Friend Of GATA-1) and GFI1B promote erythropoietic 
and megakaryocytic differentiation from the MEP (Hoffbrand and Moss, 2016). Mutually exclusive 
expression of transcription factors can influence lineage divergence, as in the case of CMPs which 
can differentiate into MEPs or into GMPs through GATA-1 or PU.1, respectively (Grech and von 
Lindern, 2012). Haematopoietic development can be blocked by the absence of TFs (Figure 1.8) 
(Orkin and Zon, 2008, Mancini et al., 2012). 
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Figure 1. 8 Transcription factors in haematopoiesis. 
 
Critical transcription factors (TFs) in haematopoiesis are indicated by red bars where 
haematopoietic development is blocked in the absence of denoted TFs, as determined by gene 
knockout models. LT-HSC, long-term hematopoietic stem cell; ST-HSC, short-term haematopoietic 
stem cell; CMP, common myeloid progenitor; CLP, common lymphoid progenitor; MEP, 
megakaryocyte/erythroid progenitor; GMP, granulocyte/macrophage progenitor; RBCs, red blood 
cells. (Figure: (Orkin and Zon, 2008)). 
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1.5.3 Overview of transcription factors in erythro-megakaryopoiesis 
The differentiation and development of erythroid cells and megakaryocytes from the MEP (erythro- 
megakaryopoiesis) are regulated by a balance of a number of transcription families, working either 
together or antagonistically (Dore and Crispino, 2011). Since specific genes need to be activated 
while other multilineage- and cell division-directed genes need to be suppressed, TFs involved in 
erythro-megakaryopoiesis are thereby both activators and repressors in the development of both 
these lineages (Tsiftsoglou et al., 2009). The initial ratio of the TF GATA-1 (binds to GATA 
sequences) (erythro-megakaryopoietic line) to the TF PU.1 (binds to the PU (purine) box on 
promoters) (granulocyte-macrophage line) protein at an early, critical time point in the CMP 
determines the subsequent lineage-restricted fate of the cell (Figure 1.8) (Zhu and Emerson, 2002). 
The subsequent differentiation of the MEP towards the erythroid or megakaryocytic lineage 
depends on the antagonistic actions of the TFs, KLF1 (Krueppel-like factor 1) (erythroid) and FLI1 
(Friend Leukaemia Integration 1) and RUNX1 (Runt-related factor 1)(megakaryocytic) (Kuvardina et 
al., 2015). These opposing TFs are usually down-regulated or lost in the opposing lineage. The TFs 
TAL1(/SCL) (T-cell lymphocytic leukaemia / stem cell leukaemia), GATA1, FOG1, and GFI1B (growth 
factor independent 1) are maintained in both lineages (Figure 1.9). 
 
 
Figure 1. 9 Transcription factor regulation of erythro-megakaryopoiesis. 
 
Erythrocytes and megakaryocytes are derived from the MEP. Determination of lineage from 
this progenitor relies on the mutually exclusive actions of the TFs KLF1 and FLI1 for erythroid 
or megakaryocytic line, respectively. TFs GATA1, TAL1(/SCL), FOG1, NF-E2 and GFI1B continue 
to regulate the maturation of both lineages. Image adapted from (Crispino and Weiss, 2014). 
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Although these TFs that regulate erythro-megakaryopoiesis may be common to both lineages, they 
nevertheless have unique and essential roles to play in each line (Pimkin et al., 2014). Occupancy 
sites for the same TF in the two different cell lineages show a lineage-specific pattern, binding to 
distinct DNA sequence motifs. Lineage-specific TFs, however, such as KLF (erythroid) and FLI1 
(megakaryocytic) regulate the divergence of the erythroid and megakaryocytic phenotypes. A model 
for the programming of this divergence was proposed by (Goldfarb, 2007) (Figure 1.10), which 
accounted for those TFs that are shared (such as GATA1 and FOG1), combined with those TFs which 
are lineage-specific (such as FLI1 and KLF1) and binding sites of promoters. Megakaryocyte 
GATA1/FOG1 complexes activate megakaryocytic promotors, repressing erythroid promoters, while 
erythroid GATA1/FOG1 complexes do the reverse. Lineage selection is activated by the incorporation 
of the lineage-specific TF into the GATA/FOG1 complex though its DNA-binding domain (DBD). 
However, if there are no binding sites available within the promoter, then the exposed DBD of the 
specific TF causes gene repression. 
 
 
Figure 1. 10 Programming of common erythro-megakaryopoietic transcriptions factors (TFs) to 
create lineage divergence. 
 
Common TF complexes, such as GATA1/FOG1, recruit the binding of lineage-specific TFs, such as 
FLI1 (megakaryocytic) and KLF1 (erythroid) to promote lineage differentiation in erythro- 
megakaryopoietic cell lineages. These lineage-specific complexes then activate that lineage’s 
promoters, while repressing those of the opposing lineage. Image adapted from (Goldfarb, 
2007). 
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1.5.3.1 Overview of common and specific transcription factors in erythropoiesis 
Common erythroid TFs 
GATA1 is the critical TF for erythropoiesis (Tsiftsoglou et al., 2009), and represses almost as many 
genes as it activates. Its consensus DNA binding site (T/AGAGAA/G) can be found in regulatory 
elements of many erythroid-specific genes, such as those for the globins; the red cell membrane 
anion transport protein, Band 3; the Epo-receptor; and enzymes for haem synthesis (Ingley et al., 
2004). In mouse studies, Gata1 null embryos were found to die at embryonic day 10.5 (E10.5) due to 
defective primitive erythropoiesis (Fujiwara et al., 1996). 
 
The interaction of GATA1 with co-factor, the transcription factor, FOG1, promotes the bifurcation of 
lineages at the MEP. FOG1 is co-expressed with GATA1 during development of both erythroid and 
megakaryocytic cells, recruiting additional factors to modulate GATA1 activity and acting at times as 
a transcriptional co-repressor. They work together, among other functions, to activate β-globin 
expression during erythropoiesis (Welch et al., 2004), and down-regulate c-Kit expression, a receptor 
on HSC, in maturing erythrocytes to promote terminal differentiation (Dore and Crispino, 2011). 
 
TAL1(/SCL) is a TF that is expressed in erythroid cells, megakaryocytes, and mast cells (Tsiftsoglou et 
al., 2009). It constitutes another critical factor in erythroid differentiation as conditional knockout of 
this gene in adult haematopoiesis has been found to lead the loss of erythropoiesis (Mikkola et al., 
2003). In conjunction with a complex of co-factors, this TF interacts with GATA1 to bind to DNA 
motifs that are present in many erythroid genes, including the regulatory elements of GATA1 and 
TAL1(/SCL) themselves, as well as another critical, erythroid-specific TF, KLF1. 
 
The maturation of erythroid cells is also dependent on the transcription factor, NF-E2 (nuclear 
factor, erythroid-derived) which is involved with the regulation of globin gene transcription 
(Shivdasani and Orkin, 1995). It is also required for erythroid colony formation, and is able to 
influence erythroid maturation in the absence of erythropoietin (EPO), reprogramming precursor 
cells towards erythroid differentiation (Mutschler et al., 2009). It is also expressed in haematopoietic 
precursors, and erythroid, megakaryocytic and granulocytic cells. 
 
The transcriptional repressor, GFI1B, controls both erythroid and megakaryocytic development by 
combining with GATA1 and a complex of enzymes that modify chromatin and inhibit gene 
expression (Crispino and Weiss, 2014). A knockout mouse model of Gfi1b found that mouse embryos 
die in utero at gestational age E15, due to defective maturation of erythroblasts, showing its critical 
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role in erythroid differentiation (Saleque et al., 2002). Overexpression of Gfi1b in haematopoietic 
progenitors has been found to produce increased expansion of erythroblasts, which were unable to 
progress to erythroid maturation (Osawa et al., 2002). Gfi1b also been observed to play an 
important role in the repressive regulation of the expression of mouse embryonic globin genes 
(Vassen et al., 2014). GFI1B is upregulated by GATA1 in early erythropoiesis, with levels gradually 
reducing as it represses its own promoter in a negative feedback loop (Huang et al., 2005). 
 
Specific erythroid TFs 
KLF1 directly regulates the formation of the α- and β-globin subunits of haemoglobin (Tallack et al., 
2010). It is responsible for the direct co-ordination and control for nearly all features of erythroid cell 
development and maturation (Tallack and Perkins, 2010). It regulates the erythroid cell membrane 
and cytoskeleton, and acts as a negative regulator of the cell cycle, thus promoting cell 
differentiation. Co-operative binding of KLF with GATA1 is found at regulatory elements of these 
erythroid-specific genes, indicating the close functioning between the two TFs. It has an antagonistic 
relationship with the megakaryocytic TF, FLI1, whereby it represses FLI1-mediated transcription in 
the megakaryocytic line (Dore and Crispino, 2011). Conversely, FLI1 is able to repress KLF1 target 
genes (Figure 1.9). 
 
1.5.3.2 Overview of common and specific transcription factors in megakaryopoiesis 
Common megakaryopoietic TFs 
The major megakaryocytic TFs in common with erythropoiesis, which are responsible for the 
development and differentiation of megakaryocytes through interaction with their target genes, 
include GATA1, FOG1, TAL1(/SCL), NF-E2, and GFI1B (Guo et al., 2015, Tijssen and Ghevaert, 2013, 
Pimkin et al., 2014, Randrianarison-Huetz et al., 2010, Wijgaerts and Freson, 2014, Bianchi et al., 
2016). 
 
As in erythropoiesis, GATA1 is the central regulating TF for the development and differentiation of 
the megakaryocytic lineage (Figure 1.11) (Guo et al., 2015). Lack of GATA1 in this line produces 
abnormal megakaryocytes, with reduced polyploidisation, a lack of cytoplasmic maturation, few or 
no platelets, and increased expansion of megakaryocyte progenitors in the bone marrow (Shivdasani 
et al., 1997). Any platelets that are produced are enlarged, with abnormal structural features, and 
contain few α-granules (Orkin et al., 1998). In similar GATA1 knockout studies, lower levels of mRNA 
for the megakaryocyte-associated genes for glycoproteins lbα and lbβ, platelet factor 4 (Pf4), and 
the thrombopoietin receptor, c-mpl, were also observed (Vyas et al., 1999). GATA-1–deficient 
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platelets also showed small, selective defects in platelet activation in response to thrombin, and to 
the combination of ADP and epinephrine (Matsumura and Kanakura, 2002). 
 
GATA1 works in conjunction with its co-factor, FOG1, and other lineage-specific and general TFs to 
promote megakaryopoiesis. FOG1 plays a highly crucial role, as mice deficient in Fog1 do not 
generate any megakaryocytic cells (Tsang et al., 1998). Mouse studies that generated a Gata1 
mutant that did not interact with Fog-1 showed a phenotype similar to that of a Gata1 knockout, 
indicating that FOG1 can function independently of GATA1 (Chang et al., 2002). 
 
Similarly, conditional knockout models for TAL1 (/SCL), NF-E2, and GFI1B show severe deficiencies in 
megakaryopoiesis. For TAL1 (/SCL), absence also produces lack of proliferation, of polyploidisation, 
and of cytoplasmic maturation in megakaryocytes, as well as decreased numbers of platelets, but 
not platelet function (Chagraoui et al., 2011). A critical function of SCL in influencing maturation of 
megakaryocytes is to control the progression of the cell cycle. 
 
In the case of NF-E2, knockout of this TF produces mice that have no circulating platelets at all, 
despite having increased numbers of megakaryocytes in the bone marrow (Shivdasani et al., 1995). 
NF-E2 regulates the formation of proplatelets, by enabling megakaryocytes to mature to the point 
where they are able to shed formed platelets, through action on its direct transcriptional targets 
(Tijssen and Ghevaert, 2013). 
 
As GFI1B is a major transcriptional repressor in both the erythroid and megakaryocytic lineages, its 
absence or disruption in adult haematopoiesis up-regulates its target genes in megakaryocyte 
progenitors, with increased numbers of these in the bone marrow (Foudi et al., 2014). The 
megakaryocytic lineage develops past the progenitor stage, arresting at the promegakaryocytic stage 
post-polyploidisation, but before maturation of the cytoplasm. Subsequently, there is the failure to 
produce platelets. Disruption in embryos results in the defective formation of megakaryocytic 
colonies in cultured cell lines, with fewer instances of markers of mature megakaryocytes, such as 
von Willebrand factor (vWf), the c-mpl receptor, and the surface glycoprotein llb (Saleque et al., 
2002). 
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Figure 1. 11 Regulation of megakaryopoiesis through major transcription factors and 
thrombopoietin (TPO). 
 
The stages of differentiation of megakaryocytes (MK) from haematopoietic stem cells (HSC) 
to platelets are modulated by the actions of TPO and its MK receptor, c-MPL, and 
transcription factors, GATA1, FLI1, RUNX1, GFI1B at specific timepoints throughout 
development. (Image: (Wijgaerts and Freson, 2014). 
 
Specific megakaryopoietic TFs 
In the modulation of the bifurcation point of erythropoiesis and megakaryopoiesis, the action of 
antagonistic transcription factors determines the establishment of either the erythroid or the 
megakaryocytic lineage. The TF RUNX1 is expressed in MEPs, but is absent during erythroid 
differentiation (Kuvardina et al., 2015). It interacts with TAL1 (/SCL) on the erythroid-specific TF, 
KLF1, as a transcriptional repressor, downregulating erythropoiesis and shifting the balance of 
differentiation to the megakaryocyte lineage, through the megakaryopoiesis-specific TF, FLI1 (Figure 
1.9). FLI1 regulates both early and late megakaryocytic-related genes that modulate platelet number 
and function, such as those for glycoprotein llb, glycoprotein lbα, glycoprotein lX, c-mpl, and PF4 
(Songdej and Rao, 2017). 
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1.6 Transcription factor defects in erythropoietic and megakaryopoietic disorders 
The transcription factors (TFs) that regulate erythromegakaryopoiesis have had, in recent years, 
various defects identified as being the underlying causes of many haematological disorders that 
affect cell differentiation, production, structure and function in both erythroid and megakaryocytic 
lineages (Songdej and Rao, 2017).  These defects or mutations create multiple downstream effects 
by the concurrent alteration of numerous target genes activated or repressed by these transcription 
factors. Lineage-shared major TFs, such as GATA1, RUNX1, and GFI1B, as well as lineage-specific TFs, 
FLI1 (megakaryocyte) and KLF1 (erythrocyte), play essential roles in the clinical manifestations of 
haematological diseases in humans. Through the dysregulation of the genes for these TFs, from 
acquired and hereditary mutations and defects, characteristic phenotypes have emerged which have 
been found to be complex and difficult to diagnose by conventional methods. In medical 
investigations of patients, these transcriptional anomalies have had distinctive genotype-phenotype 
relationships. However, different mutations in the same TF often produce variable phenotypes, and 
in many cases, have been observed as having a propensity to develop malignancies. These major TFs 
are discussed below in greater detail with regard to their transcription functions. 
 
1.6.1 GATA1 
GATA1 is an X-linked gene that codes for GATA1, the TF that has two zinc fingers and a 
transactivation domain (Crispino and Horwitz, 2017). The C-terminal zinc finger (C-ZF) of GATA1 
binds to DNA to a (A/)GATA(A/G) consensus sequence, while the N-terminal zinc finger (N-ZF) 
stabilises the binding of GATA1 to DNA, and the binding of GATA1 to target gene promoter sites that 
have a palindromic motif. GATA1’s major co-factor, FOG1, also binds to the N-terminal zinc finger 
domain (Figure 1.12) (Gao et al., 2015). GATA1 is an essential gene for erythromegakaryopoiesis, 
and mutations in the N-terminal activation domain, and in the N-ZF, can be found in human disease. 
Figure 1. 12 GATA1 transcription factor (TF) protein. 
 
 
The TF contains an N-terminal activation domain (AD) and two zinc finger domains: N-ZF, 
which interacts with co-factor FOG1, stabilises DNA binding in the protein; C-ZF, which binds 
to specific DNA motifs. Image adapted from (Gao et al., 2015). 
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Several types of GATA1 mutations have been found to occur in human disease: those that are 
inherited, those that have been acquired, and those associated with GATA1 downregulation 
(Crispino and Horwitz, 2017). 
 
Inherited missense mutations in the GATA1 gene have been associated with X-linked 
thrombocytopenia (XLT), where, in all cases described thus far, a single amino acid substitution on 
the FOG1 binding site on the N-ZF domain decreases the affinity of GATA1 for its co-factor, FOG1 
(Ciovacco et al., 2008). Shared clinical manifestations include macrothrombocytopenia and 
dyserythropoietic anaemia. However, depending on the extent of the destabilisation of the 
GATA1:FOG1 interaction, the associated phenotypes can range from mild macrothrombocytopenia 
and dyserythropoiesis without anaemia, to severe macrothrombocytopenia, dyserythropoietic 
anaemia, and early mortality. Specific symptoms include bleeding from infancy, pale platelets with 
reduced α-granules, red cell anisopoikilocytosis, and, in several cases, bilateral crypto-orchidism. 
 
A missense mutation in the DNA-binding site on the N-ZF domain causing lower affinity of GATA1 for 
its target genes is associated with X-linked thrombocytopenia with thalassaemia (XLTT). The 
resultant phenotype consists of mild thrombocytopenia, splenomegaly, haemolytic anaemia and 
disturbed globin chain synthesis which resembles β-thalassaemia (Balduini et al., 2004). Platelets 
have widespread structural abnormalities, with severely reduced numbers of α-granules; secretory 
proteins not packaged into these organelles, and uneven distribution of tubulin throughout the cell, 
away from its normal organisation at the periphery of the cell. 
 
Missense mutations at the last nucleotide of the exon 2 donor splice site of GATA1 have been found 
in patients with Diamond-Blackfan anaemia (DBA) (Sankaran et al., 2012). These affect the splicing of 
GATA1, favouring the production of a shortened form of the mRNA, which lacks exon 2. DBA is an 
inherited syndrome, characterised by macrocytic anaemia caused by reduced erythroid precursors in 
the bone marrow, previously attributed only to mutations in ribosomal protein genes (Gao et al., 
2015). Clinical features can range from mild to severe physical abnormalities, including small head 
size, cleft palate, and defects of the hands (Da Costa et al., 2018). However, GATA1 mutations have 
since been associated with the clinical features of DBA, especially in the severe anaemia manifested. 
 
Acquired somatic mutations in exon 2 of GATA1 have been found in children with Trisomy 21 which 
have led to haematopoietic disorders (Ciovacco et al., 2008). This transient myeloproliferative 
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disorder (TMD) can lead to Trisomy 21-AMKL (acute megakaryoblastic leukaemia). The shortened 
form of GATA1 is found in all the pre-malignant cells of TMD, and in Trisomy-21-AMKL. 
 
1.6.2 RUNX1 
RUNX1, or runt-related transcription factor gene, is found on the long arm of chromosome 21 in 
humans, and transcribes three major isoforms, 1A, 1B, and 1C (Figure 1.13 (A)) (Sood et al., 2017). 
Isoform 1C is expressed when definitive haematopoietic stem cells emerge, while 1A and 1B are 
expressed throughout haematopoietic differentiation. All isoforms contain the runt-homology 
domain (RHD), while 1B and 1C also contain the transactivation domain (TAD) (Figure 1.13 (B)), 
which consists of activating and inhibitory domains that bind to activator and repressor proteins, 
respectively. Through these domains and proteins, RUNX1 controls the expression of genes in such 
areas as haematopoietic differentiation, such as shifting differentiation from erythropoiesis to 
megakaryopoiesis, ribosome synthesis, and cell cycle regulation. 
 
The RHD binds to DNA and interacts with its heterodimeric co-factor, CBFβ (Figure 1.13 (C)). The 
CBFB gene, as well as RUNX1, are the target genes for more than 50 chromosome translocations, the 
most common being t(8;21) in acute myeloid leukaemia (AML), t(12;21) in paediatric acute 
lymphoblastic leukaemia (ALL), and t(3;21) in myelodysplastic syndrome (MDS) (De Braekeleer et al., 
2011). Point mutations in leukaemia and somatic mutations in RUNX1 have been documented in 
MDS, AML, ALL, and chronic myelomonocytic leukaemia (CMML) (Osato, 2004). 
 
Familial platelet disorder with predisposition to AML (FPDMM or FPD/AML) is an autosomal 
dominant disorder characterised by dysmegakaryopoiesis, qualitative and quantitative platelet 
defects, and a predisposition to develop myelodysplastic syndromes MDS and/or AML (Bluteau et 
al., 2012) Several types of heterozygous germ-line mutations or deletions in RUNX1, including 
missense, frameshift, and nonsense mutations in the RHD domain have been identified in this 
disorder. Progression to AML is often linked to the somatic alteration of the second RUNX1 allele. 
This leads to a complex platelet phenotype, with reduced responses to agonists such as ADP, 
adrenaline, arachidonic acid and collagen. There is a deficiency of platelet dense granules, and 
thrombocytopenia, but with normal-sized platelets. 
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Figure 1. 13 RUNX1 transcription factor (TF) protein. 
 
 
(A) A schematic representation of the 3 major isoforms of RUNX1 (1A, 1B, and 
1C). Isoform 1A contains only the RHD and differs by 9 amino acids (red section). (B) 
Representation of the protein encoded by the largest isoform, 1C, with main functional 
domains marked: RHD (runt-homology domain) and TAD (transactivation domain. numbers 
indicate amino acid residues. (C) Heterodimerisation of RUNX1 with its binding co-factor, 
CBFβ, and their interaction with DNA at promoters of target genes that carry the specific DNA 
binding sequences: YGYGGTY, where Y is C or T. Image adapted from (Sood et al., 2017). 
 
 
1.6.3 FLI1 
FLI1 (Friend Leukaemia Virus Induced erythroleukaemia-1) is a transcription factor (TF) that was first 
recognised as being causative in the development of erythroleukaemia (Ben-David et al., 1990). It 
belongs to the ETS gene family of TFs, that all have the DNA binding domain, ETS (E26-virus 
transformation-specific) , which contains sequences of helix1-loop-helix2 (H-L-H) (Figure 1.14) 
(Vecchiarelli-Federico et al., 2011). Its expression is mainly in haematopoietic cells and its regulation 
of genes is of those expressed both early and late in megakaryocytopoiesis. These include the 
platelet surface glycoproteins (GP), GPVI, GPIb-IX, and GP11b. Its major relevance in 
megakaryocytopoiesis has been definitively demonstrated by the identification of mutations in its 
gene, producing phenotypes, in families, involving excessive bleeding and defects in platelet 
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development (Stockley et al., 2013). This phenotype is also associated with markedly reduced dense 
granule secretion and defective platelet aggregation responses to agonists. 
Patients who present with Paris-Trousseau syndrome (PTS), are hemizygous for FLI1 as a result of a 
deletion of chromosome 11q23, also have an increased tendency to bleed, which is associated with 
thrombocytopenia, abnormal megakaryocyte morphology, and enlarged platelets with giant α- 
granules (Stevenson et al., 2015). There are also indications of growth restriction and intellectual 
disability in these patients. Temporary monoallelic expression of FLI1 is seen at an early stage during 
megakaryocytopoiesis, and there is hemizygous loss of FLI1. This results in a complete lack of FLI1 
expression, and explains the presence of two distinct subpopulations of normal and immature 
megakaryocytes in patients with PTS. 
 
FLI1 is also implicated in auto-immune diseases, such as systemic lupus erythematosus (SLE), where 
patients display over-expression of FLI1 in blood leukocytes, and scleroderma (Li et al., 2015). It is 
also a proto-oncogene, and over-expression of it in erythroblasts has inhibited differentiation and 
promoted erythroid proliferation in erythroleukaemia. It can also induce other haematological 
malignancies, such as AML, and promotes development of solid tumours, such as the EWS-FLI1 
translocation, t(11;22) in Ewing sarcoma. 
 
Figure 1. 14 FLI1 transcription factor (TF) protein. 
 
Functional domains of FLI1 consist of the ATA domain, which incorporates the 5’ETS domain 
(amino acids 121-196) and the FLI1-specific region (FLS) (amino acids 205-292); a 3’ETS 
domain (amino acids 277-360); and a CTA domain (amino acids 402-452). The 3’ETS domain 
is responsible for sequence-specific DNA-binding activity. The CTA domain is involved in 
transcriptional activation, and protein-protein interaction. The 5’ and 3’ETS domains contain 
a helix1-loop-helix 2 (H-L-H) secondary structure, while the FLS and CTA domains contain 
turn-loop-turn (T-L-T) secondary structures. These ATA and CTA domains conduct the 
transcriptional activity of FLI1. ATA, amino terminal transcriptional activation; CTA, carboxy 
terminal transcriptional activation. Image adapted from (Vecchiarelli-Federico et al., 2011). 
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1.6.4 KLF1 
KLF1 (Krüppel-Like Factor-1) is the major regulator of erythropoiesis, activating genes for globins, 
enzymes for haem synthesis, structural membrane and cytoskeletal proteins, ion and water 
channels, metabolic enzymes, and cell cycle regulators (Perkins et al., 2016). It contains two N- 
terminal transactivation domains (TAD1 and TAD2), and, at the C-terminus, three zinc finger 
domains (ZF1, ZF2, ZF3) that bind to specific DNA sites (Figure 1.15). KLF1 binds to the CACCC motif, 
and related GC-rich sequences. In recent years, large numbers of individuals have been reported 
carrying KLF1 variants, with phenotypes ranging from the clinically unremarkable to the most 
extreme cases, such as hydrops fetalis secondary to profound anaemia (Magor et al., 2015). 
 
Figure 1. 15 KLF1 transcription factor (TF) protein. 
 
Functional domains of KLF1. The protein contains two N-terminal transactivation 
domains (TAD1 and TAD2) for transcriptional activation. The 3 zinc fingers (ZF1, ZF2, and 
ZF3) at the C terminus constitute the DNA-binding domain, which binds to CACCC boxes 
and related GC-rich elements. Image adapted from (Perkins et al., 2016). 
There are four distinct functional classes of KLF1 variants, that are involved with defective coding of 
proteins , which have been defined by this broad range of phenotypes in patients: missense variants 
outside the DNA binding domain; missense mutations or in-frame deletions in the DNA binding 
domain; stop codon or frameshift variants that produce truncated KLF1 without the DNA binding 
domain; and a single variant in ZF2, p.E325K. This last variant causes a severe congenital 
dyserythropoietic anaemia (Perkins et al., 2016). The first human mutations in KLF1 were reported 
as nine different loss-of-function mutations that affected the rare In(Lu) blood group (Singleton et 
al., 2008). Target genes included BCAM (basal cell adhesion molecule) of the Lutheran blood group, 
and CD44, that carried the Indian blood group antigens (Borg et al., 2011b). In other investigations, 
there has been identification of variants in promoters of target genes of KLF1 that have affected its 
transcription. In the case of the HBB gene, which encodes β-globin, promoter variants, that had been 
seen to cause β-thalassaemia with raised haemoglobin F (HbF), also affected the binding of KLF1. 
This suggested that KLF1 was involved in regulating the switch from foetal γ-globin to adult β-globin. 
 
 
KLF1 has been proven to be an important gene to investigate in diagnosing hitherto unexplained red 
blood cell disorders, in which its variants were not previously considered to be involved in the 
aetiology of the phenotype. 
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1.6.5 GFI1B 
The role of GFI1B as a major transcription factor, with expression found in HSCs, common myeloid 
and erythroid / megakaryocytic progenitors, and erythroid and megakaryocytic lineages points to 
the potential of its involvement in haematological disease in previously undiagnosed disorders as the 
increasing trend of genetic-based approaches to diagnose uncharacterised haematological disorders 
advances. The overexpression of GFI1B in patients with erythroleukaemia and megakaryocytic 
leukaemia confirmed its role as a proto-oncogene, and its effect on the proliferation of malignant 
cells in these lineages (Elmaagacli et al., 2007). 
 
GFI1B is a transcriptional repressor which modifies chromatin structure and reduces transcription of 
target genes by recruiting histone methyl transferases, histone demethylases such as LSD1, and 
histone deacetylases (HDACs) in a complex to the promoters of these target genes (Moroy et al., 
2015). These histone-modifying proteins interact with the conserved N-terminal SNAG (Snail/Gfi1) 
domain of GFI1B, effectively repressing transcription (Figure 1.16) (Anguita et al., 2017). The C- 
terminal domain of GFI1B consists of a highly conserved region with six C2H2 zinc fingers (ZnFs). 
ZnFs 1, 2, and 6 are needed for protein interaction, while ZnFs 3-5 are required for binding to DNA 
sequence containing AATA (TAAATCAC(T/A)GC(A/T). The middle region of between the two 
domains is yet to be characterised and has an unknown function. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 16 GFI1B transcription factor (TF) protein. 
 
Functional domains of GFI1B. The N-terminal Snail/Gfi1 (SNAG) domain (amino acids 1-20) 
binds histone-modifying proteins for transcriptional repression. The intermediate domain 
(amino acids 21-163) is yet uncharacterised. The C-terminal zinc finger (ZnF) domain 
(amino acids 164-330) has ZnFs 3, 4, and 5, which bind to DNA sequences containing the 
motif AATA. A reported instance of a frameshift mutation at ZnF 5 is indicated (Stevenson 
et al., 2013). 
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There is a large network of target genes repressed by GFI1B, including proto-oncogenes myc, myb; 
GFI1; the tumour suppressor genes, Socs1 and Socs2; transforming growth factor (TGF)-β; GFI1B 
itself; GATA3; and haematopoietic master transcription factors, PU.1 and GATA2 (Anguita et al., 
2017). However, the focus of this research is the identification of GFI1B variants or mutations that 
are manifested in clinical phenotypes showing initially uncharacterised thrombocytopenia, a 
bleeding diathesis, defective platelets with α-granule deficiency and cytoskeletal changes, and 
abnormal blood cell morphology (Stevenson et al., 2013, Rabbolini et al., 2017b, Rabbolini et al., 
2014). 
 
The first reported variant in GFI1B associated with unexplained thrombocytopenia described a 
mutation in GFI1B that caused a platelet-type bleeding disorder (Stevenson et al., 2013). The 
disturbance in the DNA-binding function of the ZnF domain in this investigation was confirmed by 
genetic analysis. This has led to the reporting of other variants in GFI1B which have been manifested 
in a range of clinical phenotypes with features of varying severity and symptoms (Rabbolini et al., 
2017b). The locations of the GFI1B variants also influenced the determination of the clinical 
phenotypes. However, although some variants had been identified, but not necessarily characterised 
to date, in other sections of the transcription factor, the majority of all GFI1B variants to date had 
been identified in the ZnF domains of the TF. So, as a consequence of GFI1B dysregulation, the 
bleeding disorder associated with GFI1B-related thrombocytopenia was attributed to an associated 
defect in platelet function, secondary to the deficiencies in platelet granules and the associated 
cytoskeletal changes. It was interesting to note, however, that those GFI1B variants that were 
located in ZnFs 3-5 (the DNA-binding site) were also characterised as displaying anisopoikilocytosis in 
red cells, while those variants not at this location, did not. These also included those variants at ZnFs 
1, 2 and 6. 
 
Some of these other GFI1B variants with similar characteristics include a report of a dominant - 
negative GFI1B mutation in “gray” platelet syndrome (Monteferrario et al., 2014) with a nonsense 
mutation in exon 6 (c.859C→T, p.Gln 287* [Q287*]) which impacted ZnF 5, and hence DNA-binding 
of GFI1B. Manifestations of this mutation in this investigated family included low platelet count, 
increased platelet size, and few α-granules. This was first detected by observations of mild to severe 
bleeding episodes of family members. 
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1.7 Investigation into a familial bleeding disorder due to GFI1B mutation 
1.7.1 Background 
A bleeding disorder was recently investigated by our group and initially characterised across four 
generations of an Australian family (Figure 1.17 (B)) (Stevenson et al., 2013). This disorder had 
previously been noted in earlier investigations of the family and its pattern of inheritance 
determined as autosomal dominant (Figure 1.17 (A)) (Ardlie et al., 1976) . The current affected and 
unaffected family members were further investigated, with some affected individuals reporting 
serious bleeding after surgery or trauma, while others presented with spontaneous haemorrhage, 
including intracranial haemorrhage. 
 
 
 
 
 
 
 
Figure 1. 17 Family pedigree with an autosomal dominant pattern of inheritance. 
 
 
(A) The phenotype of the first generation and part of the second generation, as indicated by 
the grey background, was determined by initial investigation of the family by (Ardlie et al., 
1976). Red asterisk denotes initial patient investigated by (Stevenson et al., 2013). (B) Third 
and fourth generations of family investigated. Platelet counts are noted under each family 
member investigated. 
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1.7.2 Laboratory investigations 
Laboratory investigations of those affected showed prolonged bleeding with abnormalities in 
platelet morphology, count, and function, and in red cell morphology, with slight elevation of 
haemoglobin F. Blood films showed abnormalities in red cell size and shape (anisopoikilocytosis), 
and moderate thrombocytopenia, with variable platelet size, and many “gray” or agranular platelets 
(Figure 1.18 (A)). 
 
 
 
 
Figure 1. 18 Blood film and electron micrograph from family members. 
 
 
(A) Blood film from affected family member, lll.12, showing large, agranular platelets 
(circles) and red cell anisopoikilocytosis (black arrows). (B) Electron micrographs of affected 
(A) and unaffected (B) platelets. Platelet α- granules were counted in affected platelets (C) 
and unaffected platelets (D) and results expressed as N / µm2. (Affected 1.3 vs 3.1 
unaffected per 1μm2, p<0.01) (Stevenson et al., 2013). 
 
Further laboratory investigations revealed that there was a consistent and severe defect in collagen- 
induced aggregation, with varying responses to ADP and adrenaline. Electron microscopy showed 
marked reduction in α-granules (Figure 1.18 (B)), which was reflected in confirmation of depleted 
protein content, such as fibrinogen, and P-selectin (CD62P), in Western blot assays. The causes of 
these phenomena were first proposed as a type of inherited macrothrombocytopenia, but the 
presence of red cell abnormalities in this family were inconsistent with this proposal. 
 
1.7.3 Genetic testing 
Genetic testing on 8 unaffected and 8 affected family members by single nucleotide polymorphism 
(SNP) analysis identified a single linkage region on chromosome 9 known to be associated with 
thrombocytopenia. Massively parallel sequencing (MPS) of this region then identified a 
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heterozygous nucleotide insertion, C, in exon 7 of the GFI1B gene as the cause of the disorder 
(Figure 1.19). The insertion of nucleotide C was found to disrupt the fifth DNA-binding zinc finger 
domain of GFI1B, causing a frameshift mutation, changes in the amino acids coded, and so a 
premature stop (Figure 1.20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 19 DNA sequence of cDNA clones derived from CD34-positive peripheral blood cells 
of family member III.12. 
 
(A) Reference DNA sequence. (B) The GFI1B mutation (c.880-881insC) predicts the protein 
to run out of frame (p.H294fsX307). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 20 Schematic representation of GFI1B, showing placement of mutation. 
 
(A) Wild-type GFI1B protein showing intact zinc finger (ZnF) domains. Red asterisk and bar 
denote ZnFs 3-5, which are involved in sequence-specific DNA binding. (B) Mutant GFI1B 
with the affected last two ZnF domains (light blue-green boxes). SNAG, the N-terminal SNAG 
domain which recruits lysine-specific demethylase 1 (LSD1) (Lin et al., 2010). 
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1.8 Hypotheses and aims 
1.8.1 Hypothesis 
The mutant GFI1B acts as a dominant-negative modulator of platelet and red cell differentiation, 
producing changes in platelet and red cell development, and subsequent morphology and function 
 
1.8.2. Aims 
• To investigate the effects of the mutant GFI1B on red cell development in an erythroleukaemic 
cell culture model (Chapter 3); 
• To study the function of the Gfi1b gene on blood formation in the bone marrow of conditional 
knockout mice to better understand how Gfi1b controls platelet formation (Chapters 4, 5 and 6); 
• To show that the mutant GFI1B causes abnormal cell proliferation and differentiation compared 
to wild type GFI1B at different stages of cell development in a transgenic knock-in mouse model 
(Chapter 7). 
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CHAPTER 2: 
GENERAL MATERIALS 
AND METHODS 
36  
2. General materials and methods 
2.1 K562 cell culture 
The erythroleukaemic cell line, K562 (ATCC® CCL-243TM) was used as an in vitro model to study the 
effects of transfected human mutant GFI1Bc.880-881insC on erythroid differentiation. A separate line of 
K562 cells transfected with wild-type GFI1B, and one line of K562 cells not transfected, were used as 
controls. The cells were treated with cytarabine to induce differentiation into erythrocytic cells, and 
studies on growth rates, differentiation, cell markers, and associated proteins were carried out. 
 
Chapter 3 deals with experimental design, methods and materials used, cell culture conditions, and 
results. 
 
2.2 Mouse models 
Mouse lines on a C57BL/6 genetic background were generated at the Walter and Eliza Hall Institute 
of Medical Research, Melbourne, Australia (WEHI), and transferred to the Kearns Facility, Kolling 
Institute, University of Sydney, Royal North Shore Hospital, Sydney, for final cross-breeding and 
experimentation. Mice were bred and maintained in a pathogen-free environment, according to the 
Facility’s guidelines, with unlimited access to food and water. All conducted experiments were 
approved by Northern Sydney Local Health District (NSLHD) Animal Ethics Committee (AEC) 
(protocols: 1311-006A; RESP/17/354). 
 
2.2.1 Mouse lines 
Two mouse models of altered Gfi1b / GFI1B gene expression were used to determine the effect of 
Gfi1b on blood, and, specifically, platelet formation. These were generated in collaboration with Dr 
Ashley Ng, Dr Tracy Willson, Elizabeth Viney and Professor Warren Alexander (WEHI). 
 
Chapters 4, 5 and 6 deal with Gfi1b conditional knock-out mice (denoted Gfi1b KO): experimental 
design, breeding protocols, and results. 
 
Chapter 7 deals with the 2 mouse lines for transgenic knock-in human wild-type (WT) GFI1B mice 
and transgenic knock-in human mutant (Mut) GFI1Bc.880-881insC mice: experimental design, breeding 
protocols, rationale, and results. 
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2.2.2 DNA extraction and PCR genotyping 
2.2.2.1 DNA extraction 
Experimental mice and those used as breeders were genotyped using genomic DNA (gDNA) 
extracted from either mouse tail tips (~1 – 2mm of tissue) or ear punches. These tissue samples 
were collected by the Kearns facility staff after mice had been weaned (at 3 weeks of age) usually at 
~4 weeks old, then stored in 1.5mL Eppendorf tubes at -20°C until processing. 
 
 
gDNA was extracted from mouse tissue by a modified version of the protocol for Animal Tissue 
(Mouse Tail) in the Promega Wizard® Genomic DNA Purification Kit (Promega Australia, Sydney, 
Australia). Briefly, 200μL of Nuclear Lysis Solution (Ref A7941) along with 10μL of 20mg/mL 
Proteinase K (Ambion®, Invitrogen™ Life Technologies, Thermo Fisher Australia) were added to the 
mouse tissue in 1.5mL Eppendorf tubes, vortexed, then incubated overnight at 55°C in a heat block. 
100μL of Protein Precipitation Solution was then added to the lysis-tissue mixture, vortexed for 20 
seconds, then centrifuged in a microfuge (Heraeus Biofuge Pico) at 16,163xg for 10 minutes. The 
supernatant was collected into fresh tubes and the protein precipitate discarded. 
300μL of isopropanol was added to the retained supernatant, mixed, and centrifuged at 16,163xg for 
10 minutes. The supernatant was discarded, and 300μL of 70% ethanol (v/v) was added. Tubes were 
again centrifuged at 16,163xg for 10 minutes, and the supernatant carefully aspirated. Tubes were 
then left to air dry in the heat block set at 65°C for up to 10 minutes until all traces of ethanol had 
evaporated. The extracted DNA pellet was then dissolved in 30μL of the DNA Rehydration Solution 
(Ref A796A) and heated for 60 minutes at 65°C in the heat block. gDNA concentrations were then 
determined on the NanoDropTM 1000 spectrophotometer (Thermo Fisher) on DNA-50 setting, with 
DNA Rehydration Solution as blank. gDNA samples were then stored at 4°C until genotyping. 
 
2.2.2.2 PCR 
All primers for PCR genotyping were purchased from Invitrogen™ Life Technologies, Thermo Fisher 
Australia. Three different PCR protocols for gDNA were set up to detect: floxed Gfi1b alleles 
(Gfi1bfl/fl) for Gfi1b conditional knockout mice; the presence of transgenic GFI1B – human wild-type 
or mutant (c.880-881insC) – in transgenic mice; and Cre gene in all groups of mice. Original PCR 
protocols, including primer sequences and expected band sizes (Table 2.1), were provided by Dr 
Ashley Ng, WEHI, and modified to our laboratory’s conditions. 
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Table 2. 1 Primers used for genotyping. 
 
Allele Primer name Sequence 
Annealing 
temp (°C) 
Product 
size (bp) 
Gfi1b fl/fl WA1 (forward) 5'-GGAGCTGAAACTGCAGTGAA-3' 60 350 
WA2 (reverse) 5'-AGAGATCTGCTTGCCTCTGC-3' 
GFI1B WT or Mut 
TG (KI) 
 
 
*Transnetyx 
 
 
*Transnetyx – proprietary (see text) 
 
 
*Transnetyx 
 
 
*Transnetyx Hygromycin 
cassette 
 
GFI1B WT TG 
GFI1BTgInsF2 
(forward) 
5'-AAGCGTTTCCACCAGAAGTC-3' 60 377 
GFI1BTgInsR2 
(reverse) 
5'-ATGTATCTTATCATGTCTGCTCGAA-3' 
 
GFI1B Mut TG 
GFI1BTgInsF2 
(forward) 
5'-AAGCGTTTCCACCAGAAGTC-3' 60 305 
GFI1BTgInsR2 
(reverse) 
5'-ATGTATCTTATCATGTCTGCTCGAA-3' 
Cre recombinase iCre F (forward) 5’-TGCCCAAGAAGAAGAGGAAA-3’ 55 238 
iCre R (reverse) 5’-TCCCTCACATCCTCAGGTTC-3’ 
 
Gfi1bfl/fl PCR 
Genotyping for floxed Gfi1b alleles in Gfi1b KO mice was carried out by PCR on approximately 100ng 
of gDNA in a 25μL mixture, consisting of 0.5μL of 5u/μL MyTaq™ HS Red DNA Polymerase (BIO21115, 
Bioline (Australia)) with 5μL of 5x MyTaq™ Red Reaction Buffer (which included optimised 
concentrations of dNTPs and MgCl2 and red dye), 0. 5μL each of 20μM primers, WA1 (forward) and 
WA2 (reverse) (Table 2.1), and RNase-free water to 25 μL. Amplification was carried out using a Hot 
Start protocol i.e. thermal cycler (Bioer GeneTouch) block temperature was allowed to come to 95°C 
before PCR tubes were actually placed in the block. The program cycle then consisted of: initial 
incubation at 95°C for 1 minute, followed by 35 cycles of: 95°C for 15 seconds, 60°C for 15 seconds, 
72°C for 10 seconds; then 1 cycle at 72°C for 3 minutes, then 4°C ad infinitum. PCR products with 
included red dye from MyTaq™ Red Reaction Buffer were visualised on a 2% agarose gel (2g agarose 
(Agarose 1™, Amresco, Biotechnology Grade, Code: 0710-500G) in 100mL of 1 x TBE buffer – 89mM 
Tris, 89mM boric acid, 2mM EDTA disodium salt, pH 8.3 - plus 5μL SYBR®Safe DNA gel stain 
(Invitrogen™ Life Technologies, Thermo Fisher Australia) per 100mL of gel), running at 125V in 0.5 x 
TBE. Bands in the gel were detected on a ChemiDoc™ Gel Imaging System (BioRad Laboratories, 
Australia) using Image Lab™ software. Positive controls consisted of previously assayed and proven 
mouse gDNA showing floxed Gfi1b alleles that were homozygous (one band at 350bp), heterozygous 
(two bands – 190bp, 350bp) or absent (one band at 190bp) (Figure 2.1). Negative control was RNase- 
free water. Confirmatory PCR was also performed on approximately 100ng of gDNA extracted from 
tail tips collected at the time of surgery. 
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Figure 2. 1 Gfi1bfl/fl PCR - 2% agarose gel depicting amplicon bands. 
Representative 2% agarose gel showing PCR products for: Gfi1bfl/fl; Gfi1bfl/-; and Gfi1b-/-. 
Legend at right shows size of bands in molecular weight marker, HyperLadder™ 50bp 
(Bioline (Australia)). Labels above well origins showed representative mouse tag numbers, 
and controls. homC, homozygous control; hetC, heterozygous control; wtC, wild-type 
control; neg, negative control (RNase-free water). 
 
 
 
GFI1B transgene (TG) (WT or Mut) PCR 
Determination of the presence of the GFI1B transgene in the Col1a1 locus in both alleles was carried 
out by the use of the genotyping services of *Transnetyx, Inc. (Cordova, Tennessee, USA), who used 
real-time PCR to determine the presence of a hygromycin cassette (HYGRO) in either allele, along 
with an indication of an insertion in the Col1a1 locus (Col1a1-1 WT) (Table 2.2). Information on the 
required genotyping and the construct of the transgene insert (acquired from WEHI) was sent to this 
company, which then proceeded to devise and optimise PCR protocols to detect the required gene 
products. Transnetyx also tested for the presence (iCre) of the Cre recombinase gene in these mice. 
Those mice with hygromycin detected in both alleles were considered homozygous for the 
transgene; heterozygous, if only one allele; and wild-type if none detected in either allele. This 
genotyping was used for both the GFI1B WT TG mouse line and the mutant GFI1Bc.880-881insC TG 
mouse line, which were housed and bred separately. 
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Table 2. 2 Example of Transnetyx genotyping report for GFI1B knock-in transgene for both GFI1B 
WT and GFI1B Mut mice. 
 
 CAGGS x 
PF4 Cre 
HYGRO 
Col1a1- 
1 WT 
iCre Results 
Wellplate: T606986 
A1 CAGGS Mut 1174 + - - k/k c- 
B1 1175 + - + k/k c+ 
C1 1176 + - + k/k c+ 
D1 1177 + - - k/k c- 
E1 1178 + - + k/k c+ 
F1 1179 + - + k/k c+ 
G1 1180 + - - k/k c- 
H1 1181 + - + k/k c+ 
A2 1182 + - - k/k c- 
B2 1183 + - - k/k c- 
C2 1184 + - - k/k c- 
D2 1185 + - - k/k c- 
E2 CAGGS WT 1186 + - - k/k c- 
F2 1187 + - - k/k c- 
G2 1188 + - + k/k c+ 
H2 1189 + - + k/k c+ 
 
For testing the presence of either a GFI1B WT transgene or a mutant GFI1Bc.880-881insC transgene to 
confirm that the correct mice were being studied, a confirmatory PCR, targeting the transgene 
insertion itself, was performed in-house on approximately 100ng of gDNA extracted from tail tips 
collected at the time of surgery. The MyTaq™ HS Red protocol was used with identical conditions, 
reagents and volumes to those used for the detection of floxed Gfi1b alleles in Gfi1b KO mice (see 
above). Primers (GFI1BTgInsF2, GFI1BTgInsR2) were designed to detect a PCR product with the 
forward primer in the penultimate exon of the inserted GFI1B cDNA and the reverse primer targeting 
a sequence following the GFI1B cDNA within the transgene construct (Table 2.1). The volume of 
0.5μL of primers, each at a concentration of 20μM were used in this PCR. Amplified products were 
visualised on 2% agarose gel as described above. As the length of this PCR product was different for 
each of the two inserted GFI1B genes, a distinction could then be made between GFI1B WT TG and 
GFI1B Mut TG mice (Table 2.1) (Figure 2.2). 
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Figure 2. 2 GFI1B TG transgene confirmatory PCR - 2% agarose gel depicting amplicon bands. 
 
Representative 2% agarose gel showing PCR products for: inserted GFI1B WT transgene – 
band at 377bp; inserted mutant GFI1Bc.880-881insC transgene - band at 305bp. Legend at 
right shows size of bands in molecular weight marker, HyperLadder™ 50bp (Bioline 
(Australia)). Labels above well origins showed representative results and controls. 
(WT, human wild-type GFI1B; wt, wild-type, non-transgenic mouse). 
TgIns WT, hGFI1B WT transgene; TgIns Mut, mutant hGFI1Bc.880-881insC transgene; Mut ctrl, 
TgIns Mut control; WT ctrl, TgIns WT control; wtC, mouse wild-type control (no insert) – 
no band; neg, negative control (RNase-free water) – no band. 
 
 
Cre recombinase PCR 
Genotyping of all mice for Cre recombinase was carried out by PCR on approximately 100ng of gDNA 
in a 25μL mixture, consisting of 0.5μL of 5u/ BIOTAQ™ DNA polymerase (BIO21040, Bioline 
(Australia)) with 2.5μL of 10 x NH4 Reaction Buffer (BIO37025, Bioline (Australia)), 1.5μL of 50mM 
MgCl2 (BIO37026, Bioline (Australia)), 0.5μL of 10mM dNTPs (4x 2.5mM) (Bioline (Australia)), 0. 65μL 
each of 20μM primers, iCreF (forward) and iCreR (reverse) (Table 2.1), and RNase-free water to 25 
μL. Amplification was carried out on Bioer GeneTouch thermocycler using a program cycle that 
consisted of: initial incubation at 95°C for 5 minutes, followed by 35 cycles of: 95°C for 30 seconds, 
55°C for 30 seconds, 72°C for 30 seconds; then 1 cycle at 72°C for 10 minutes, then 4°C ad infinitum. 
PCR products were then mixed 1/10 with Invitrogen BlueJuice™ Gel Loading Buffer 10x (10 mM Tris- 
HCl (pH 7.6), 60 mM EDTA, 0.03% bromophenol blue, 60% glycerol) and visualised on a 2% agarose 
gel (as per the PCR protocol for Gfi1bfl/fl) on a ChemiDoc™ Gel Imaging System (BioRad Laboratories, 
Australia) using Image Lab™ software. Positive controls consisted of previously assayed and proven 
mouse gDNA showing Cre recombinase, initially from the 4 male Cre recombinase mice that were 
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transported from WEHI. Cre recombinase-positive mice showed a single band at 238bp (Figure 2.3). 
Negative control was RNase-free water. 
 
Figure 2. 3 Cre recombinase PCR - 2% agarose gel depicting amplicon bands. 
Representative 2% agarose gel showing PCR products for Cre recombinase – band at 238bp. 
Legend at left shows size of bands in molecular weight marker, HyperLadder™ 50bp (Bioline 
(Australia)). Labels above well origins showed representative mouse tag number and controls. 
#688, mouse tag; pos, positive control; neg, negative control (RNase-free water). 
 
2.2.4 Mouse surgery 
All surgery was carried out in the animal procedure rooms in the Kearns Facility, Level 3, Kolling 
Institute. All mouse ear tags were checked before surgery to confirm correct mice being studied. 
Each mouse was weighed while still anaesthetised and before any surgery or blood collection. A 
Mouse Work sheet was devised and used to record data, and to note blood and specimen collection 
(Figure 2.4). 
 
2.2.4.1 Anaesthesia 
Each mouse was anaesthetised with a mixture of 2% isoflurane and oxygen flow of 1L/minute 
(Kearns Facility Standard Operating Procedure (SOP) #1). An anaesthetic induction chamber was 
filled for about 2 minutes before the mouse was placed in it, until it reached unconsciousness. It was 
then kept anaesthetised by being taken out of the chamber and having a nose cone, with the 
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rerouted anaesthetic mix, positioned over its face while lying supine. The mouse was checked for 
unconsciousness by having paws pinched. No response then indicated that the mouse was ready for 
surgery. 
 
2.2.5 Mouse blood and tissue collection 
2.2.5.1 Blood collection 
Murine blood was collected by a retro-orbital procedure while the mouse was anaesthetised. A 
heparinised micro-haematocrit capillary tube (#FSB22-362-566, Fisherbrand™, ThermoFisher 
Scientific, Australia) was used to draw blood from the venous sinus behind the eyeball into a 0.5mL 
K2EDTA-coated paediatric blood collection tube (#365975, Becton Dickinson Pty Ltd, North Ryde, 
NSW, Australia). Immediately following this procedure, the mouse was sacrificed by cervical 
dislocation. 
 
2.2.5.2 Blood films 
Immediately after blood collection, a drop of well-mixed blood from the K2EDTA tube in a fresh 
capillary tube was spread on each of 2 microscope slides (Thermo SuperFrost® /Menzel-Glaser, 
ThermoFisher Scientific, Australia). These were air-dried and stained with May-Grünwald-Giemsa 
stain on a Sysmex® SP-1000i automated staining system by staff in the Department of Haematology, 
Royal North Shore Hospital, St Leonards, NSW, Australia, and then lacquered. Mean platelet 
numbers were determined by light microscopy by manual counting of platelets of random fields per 
film. 
 
2.2.5.3 Blood count 
Full blood count was carried out on the Ac•T diff haematology analyser (Beckman Coulter Pty Ltd, 
Australia). As mouse platelets are smaller than human platelets (average murine mean platelet 
volume (MPV) 4.7 fL vs. 7.5-10 fL, human) (Jirouskova et al., 2007), it was necessary to use the 
Veterinary Applications Software card. Of the 3 analysis modes available (dog, cat, horse), horse 
mode was used as average equine platelet size (MPV) most closely resembled that of mice (5.0 fL, 
compared with canine, 7.2 fL, and feline, 11.0 fL) (Boudreaux and Ebbe, 1998). For the veterinary 
application, the haematology parameters measured were white blood cell (WBC) count; red blood 
cell (RBC) count; haemoglobin (Hgb); haematocrit (Hct); mean corpuscular volume (MCV) 
(erythrocyte); mean corpuscular haemoglobin (MCH) (erythrocyte); mean corpuscular haemoglobin 
concentration (MCHC) (erythrocyte); platelet count (only – no other platelet parameters). 
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Northern Blood Research Centre Mouse Work Sheet (Version I ws) 
 
Experiment Date: 
Mouse Number: 
 
Anaesthetic: 
Live testing: 
Blood collection (L) eye [  ] / (R) eye [ ] Blood film and counts [ ] 
Flow Cytometry [ ] 
Other [ ] 
Tail Bleeding Time 
 
 
Autopsy: 
Inspection 
Organ Weights 
 
Histopath 
 
DNA/RNA/Protein 
Total Body Weight 10% formalin  
Thymus [ ] [ ] 
Heart [ ] [ ] 
Lungs [ ] [ ] 
Liver [ ] [ ] 
Spleen (sectioned length) [ ] [ ] 
Kidney [ ] [ ] 
Sternum [ ] [ ] 
Lymph node (salivary/mesenteric) [ ] [ ] 
 
Cell Suspensions (DMEM with 10% FCS) 
Bone marrow [ ] 
Spleen [  ] 
Thymus [  ] 
 
BM [  ], Sp [  ], Thy [ ] Cytospin (200,000 cells per mL/ 5min 189xg) 
BM [  ], Sp [  ], Thy [ ] Flow cytometry 
BM [  ], Sp [  ], Thy [ ] Cell culture 
BM [  ], Sp [  ], Thy [ ] other 
 
 
 
 
Figure 2. 4 Mouse surgery work sheet and checklist for collection of blood and the harvesting of 
tissue. 
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2.2.5.4 Tissue and organ collection 
After blood was collected, surgery was then carried out on the mouse in order to collect tissue and 
organs. Following cervical dislocation (Kearns Facility SOP #3) - or euthanasia by CO2 (Kearns Facility 
SOP #2) in other surgeries - and confirmation of death, the mouse was positioned on its back and its 
body disinfected by being sprayed with 70% ethanol (v/v). An incision was made down the centre of 
the mouse, and the skin and the peritoneum carefully peeled away to expose the abdominal organs. 
 
Bone marrow – cell suspension 
For access to the bone marrow in the femur, skin and muscle were dissected with surgical scissors 
away from the femur, exposing the bone, which was cut at either end – across the knee joint and at 
the hip joint – so that the bone marrow was exposed. A 21G needle attached to a 1mL syringe 
containing an appropriate filtered (0.22μm) medium such as CATCH solution (Levine and Fedorko, 
1976) (1mM adenosine, 2mM theophylline, 0.38% Na3 citrate, 3.5% bovine serum albumin (BSA) 
(#05470, Sigma-Aldrich Pty Ltd, Castle Hill, Australia) in Ca-free and Mg-free Hank’s balanced salt 
solution (HBSS) (#14175HBSS, ThermoFisher Scientific, Australia), pH 7.1, (for megakaryocyte ploidy) 
or 10% foetal calf serum (FCS) (v/v) (AusGeneX Pty Ltd, Australia) in Dulbecco’s Modified Eagle 
Medium (DMEM) (#12800017, Gibco®, ThermoFisher Scientific, Australia) or Iscove’s Modified 
Dulbecco’s Medium (IMDM) with 2% FCS (Gibco®, ThermoFisher Scientific, Australia) was inserted 
into one end of the femur, and the bone marrow flushed into 2mL total volume medium solution in 
15mL Corning® tubes (Sigma-Aldrich Pty Ltd, Castle Hill, Australia). Similarly, if required, bone 
marrow was also extracted from tibias. 
 
Bone marrow cells were then suspended in the medium by trituration of needle and syringe, and 
kept on ice until processed. For transmission electron microscopy (TEM) of Gfi1b conditional KO 
mice, bone marrow was flushed out with CATCH onto parafilm, and 1mm cubes were cut and placed 
into 2.5% glutaraldehyde in 0.1M cacodylate buffer (0.1M sodium cacodylate (arsenate), pH 6.5) 
fixative overnight. 
 
Bone marrow (sternum) for histology 
After access was gained into the mouse body cavity, the sternum was clipped from the centre of the 
rib cage and placed in 15mL 10% neutral buffered formalin (3.7% formaldehyde – from 37% solution 
(v/v) (#809 Univar Ajax, ThermoFisher Scientific, Australia)); 46mM Na2HPO4; 29mM NaH2PO4.H2O; 
pH 7.01) overnight. This solution was also used for all other organs that were to be processed for 
histology. 
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Spleen 
The spleen was dissected out, weighed, and photographed next to a ruler, indicating length. It was 
divided up (cross-section) into sections for different procedures. For cell suspension, a section was 
placed into 10%FCS-DMEM or into 2% FCS-IMDM and kept on ice until processed. For histology, a 
cross-section was placed in 10% neutral buffered formalin. For transmission electron microscopy of 
Gfi1b conditional KO mice, a slice of approximately 1mm width was placed in 2.5% glutaraldehyde in 
cacodylate buffer (0.2M sodium cacodylate (arsenate), pH 6.5) fixative overnight. 
 
Liver 
The liver was dissected out, weighed, and sections incised and placed into 10% neutral buffer 
formalin (histology) and into a 1.5mL Eppendorf tube on ice for later DNA extraction and genotyping 
confirmation, if required. 
 
Thymus, heart, lungs, kidney 
Each of these organs was dissected out, weighed, and sections placed into 10% neutral buffered 
formalin for histology. 
 
Tail 
A piece of tail, approximately 2-3mm, was cut and placed into a 1.5mL Eppendorf tube on ice for 
later DNA extraction and genotyping confirmation. 
 
2.2.6 Pregnancy trial 
Pregnant breeding mice for Gfi1b KO colonies (genotype Gfi1bfl/fl -Pf4-Cre negative) were studied at 
day E16-E17 gestation (calculated by Kearns Facility staff). Maternal mice were culled by exposure to 
CO2 and death confirmed after all breathing had been stopped for at least 15 minutes. The mouse 
was then weighed, positioned on its back and its body disinfected by being sprayed with 70% 
ethanol. An incision was made down the centre of the mouse, and the skin and the peritoneum 
carefully peeled away to expose the uterine horns (McKelvey et al., 2016). Connective tissue was 
clipped away, and the uterine horns were severed and removed from the abdominal cavity. They 
were then photographed, the numbers of foetuses / pups counted, and any resorbed pups 
(indicated by small clotted bags of cells) noted. Each pup was separated from its sac, as was each 
placenta. Observations of colour (pinkness) and any evidence of bleeding were carried out for each 
one. Pups and their placentas were then photographed, and their sizes measured with a ruler (mm). 
Each was then weighed, and the tail removed for DNA extraction and genotyping and kept on ice. 
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The remainder of each pup and its associated placenta were then placed in separate tubes each with 
10% neutral buffered formalin for histological processing. Maternal liver tissue and tail tip (~2mm) 
were collected for DNA extraction and confirmatory genotyping in 1.5mL Eppendorf tubes and 
stored at -20°C until processing. 
 
2.2.7 Mouse tail bleeding times 
Matched pairs of control and Gfi1b KO mice were anaesthetised as per section 2.2.4.1, but with the 
mouse prone. Each mouse’s tail was extended over the surgical pad so that it hung over the side, 
pointing towards a positioned piece of Whatman No. 1 filter paper. A 2mm piece of tail was excised 
with a scalpel blade and the resulting blood was adsorbed onto the paper without any direct contact 
(Haining et al., 2017). Blood drops were collected every 20 seconds until the mouse stopped actively 
bleeding (the point at which no more blood could be collected onto the paper) or up to a maximum 
of 20 minutes’ bleeding time. Mice were then culled with exposure to CO2 for at least 20 minutes 
until they had definitively stopped breathing. 
 
2.2.8 Mouse thrombopoietin (TPO) 
Blood was collected as per section 2.2.5.1. After blood was taken out for blood films and platelet 
count, the remainder was then centrifuged in a microfuge (Heraeus Biofuge Pico) at 6819xg for 3 
minutes. The supernatant plasma was carefully transferred to a separate 1.5mL Eppendorf tube and 
stored at -20°C until assayed. Mouse thrombopoietin (TPO) was then assayed with the Mouse TPO 
(THPO) ELISA kit (#EMTHPO, ThermoFisher Scientific, Australia), according to the manufacturer’s 
instructions, and read against a prepared standard curve on BioTek® PowerWave XS microplate 
reader at 450nm minus 550nm, using Gen5™ software (BioTek® Instruments Inc, ThermoFisher 
Scientific, Australia). Results were reported in pg/mL. 
 
2.2.9 Cytospin 
For bone marrow, the harvested, mixed cell suspension was filtered (pore size 100μm) to remove 
cell aggregates. For the spleen section in medium, the tissue was mashed with a glass rod, mixed 
with 1mL syringe and 21G needle, then also filtered (100μm). These cell suspensions were then 
counted on the Ac•T diff haematology analyser (Beckman Coulter Pty Ltd, Australia) using the 
Veterinary Applications Software card. 2.5 x 105 cells / mL of either bone marrow cell suspension or 
spleen cell suspension were required to produce approximately 5 x 104 cells per glass slide. The 
appropriate volume of cells was taken out of the counted, filtered suspensions, and made up to 1mL 
with 10% FCS phosphate-buffered saline (PBS), pH 7.4 (#09-9400-100, Medicago AB, Uppsala, 
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Sweden from Astral Scientific, Gymea, Australia). The cytospin was then carried out in the 
Department of Haematology, Royal North Shore Hospital, on a Thermo Shandon Cytospin 3 
(ThermoFisher Scientific, Australia). 200μL of this suspension was pipetted through the appropriate 
funnels onto microscope slides (Thermo SuperFrost® /Menzel-Glaser, ThermoFisher Scientific, 
Australia). These were spun at 17g for 4 minutes, then air-dried and stained with May- Grünwald-
Giemsa stain on a Sysmex® SP-1000i automated staining system by staff in the Department of 
Haematology, Royal North Shore Hospital. Slides were then viewed on an Olympus CKX41_31 
microscope with an Olympus DP21 digital camera. 
 
2.2.10 Flow cytometry – mouse tissue 
All cells harvested from mouse tissue for flow cytometry were processed as for cytospin (see 
2.2.4.6). All flow cytometry assays had data acquired and analysed on the BD LSRFortessa™ 4-laser 
flow cytometer, using BD FACSDiva™ software (BD Biosciences Australia, Becton-Dickinson Pty Ltd, 
North Ryde, Australia). Compensation profiles were set up by BD Biosciences application specialists. 
Table 2.3 shows the properties of antibodies used for each cell line and assay. All antibodies were 
raised in rats, and were purchased from BD Horizon™ or BD Pharmingen™ (BD Biosciences, Becton- 
Dickinson Pty Ltd, North Ryde, Australia). Matching isotype negative controls were used with each 
antibody of interest, with matching protein concentrations. Manufacturers’ recommendations were 
followed, in regard to volumes and concentrations used for each isotype control and specific 
antibody, for the optimal staining for 106 cells. 
 
2.2.10.1 Megakaryocyte DNA ploidy – bone marrow 
Two tubes of 2 x 106 bone marrow cells each were used for the DNA ploidy flow cytometry assay per 
mouse, so the appropriate volume of cells was calculated from cell count of the suspension, and 
transferred to separate tubes. These were then spun at 68xg (Heraeus Megafuge 1.0, ThermoFisher 
Scientific, Australia) for 4 minutes, the supernatant aspirated, and cells resuspended in 100μL of 
CATCH. A volume of 50μL of cell suspension (~2 x 106 cells) was then added to each of 2 flow 
cytometry tubes, the first containing 4μL IgG FITC (isotype control) and the second containing 4μL 
CD41 FITC. Tubes were incubated at room temperature in the dark for 30 minutes then washed once 
with 1mL of CATCH at 60xg for 4 minutes, resuspended in 1mL of a hypotonic propidium iodide (PI) 
solution (0.1% Na3 citrate dihydrate; 50μg/mL final concentration (fc) PI (P4170, Sigma-Aldrich Pty 
Ltd, Castle Hill, Australia); 0.2mg/mL (fc) RNase (R4875, Sigma-Aldrich Pty Ltd, Castle Hill, Australia)) 
and kept on ice for 2 hours. Tubes were then spun at 60xg for 4 minutes, resuspended in 0.5mL 
CATCH, and analysed immediately. Gates were set up for isotype control versus PI, and then 
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CD41 FITC-positive cells versus PI were redefined on a histogram for count versus PI. Separate peaks 
in this histogram were assigned DNA ploidy from 2N onward. 
 
Table 2. 3 Antibodies used in flow cytometry assays of harvested mouse cells. 
 
 
Cell Line 
 
Antibody: Clone 
 
Epitope 
 
Fluorochrome 
Volume for 
1μg/106 
cells 
Catalogue 
Number 
 
Company 
MK/ CD41: MWReg30 GP IIb/IIIa FITC 2μL 553848 BD Pharmingen™ 
DNA Ploidy PI NA intercalator PE channel N/A P4170 Sigma-Aldrich 
Erythroid CD71: C2 Transferrin R PerCP Cy5.5 5μL 562858 BD Pharmingen™ 
TER119: TER-119 GlyA FITC 2μL 557915 BD Pharmingen™ 
Lymphoid CD3: 145-2C11 T-cell marker PE-Cy7 ]   
CD4: RM4-5 T-helper cell PE ] 20μL (mix) 558431 BD Pharmingen™ 
CD8a:53-6.7 Cytotoxic T-cell APC ]   
CD45: 30-F11 LCA BV786 5μL 564225 BD Pharmingen™ 
Myeloid CD45R/B220: RA3-6B2 B-cell marker FITC 2μL 553087 BD Pharmingen™ 
Ly6G: EL4J Neut/gran APC 5μL 560599 BD Pharmingen™ 
F4/80: T45-2342 Macrophage BV421 5μL 565411 BD Horizon™ 
CD45: 30-F11 LCA BV786 5μL 564225 BD Pharmingen™ 
MK: megakaryocyte; PI: propidium iodide; GP: glycoprotein; NA: nucleic acid; Transferrin R: transferrin 
receptor; GlyA: glycophorin A; LCA: leucocyte common antigen; Neut/gran: neutrophil/granulocyte. 
N/A: not applicable. 
 
 
2.2.10.2 Erythroid subsets – bone marrow and spleen 
Two tubes each of 1 x 106 cells from bone marrow or from spleen were used for the erythroid flow 
cytometry assays per mouse. After cell count, the appropriate volume of cells was spun at 200xg for 
5 minutes, supernatant aspirated, and cells resuspended in 1mL of 0.1% BSA-PBS. This was then 
spun again at 200xg for 5 minutes, supernatant aspirated, and cells resuspended in 100μL 0.1%-BSA-
PBS. 50μL of cell suspension (~1 x 106 cells) was then added to each of 2 flow cytometry tubes, the 
first containing isotype controls (see Table 2.3), and the second containing antibodies for CD71 
(transferrin receptor) and for TER119 (murine equivalent of Glycophorin A). Tubes were incubated at 
room temperature in the dark for 30 minutes, washed once with 1mL 0.1% BSA-PBS, aspirated and 
then resuspended in either 0.5mL 0.1% BSA-PBS (if being analysed on same day) or 0.5mL 0.2% 
paraformaldehyde (PFA)-PBS (stored overnight at 4°C and analysed the next day). Gating was set up 
initially to define single cells by plotting forward scatter area (FSC-A) (linear) vs forward scatter 
height (FSC-H) (linear). Single-cell population was then gated on TER119 (log) vs CD71 (log). High 
TER119 cells were redefined as subsets (EryA, basophilic erythroblasts; EryB, poly-chromatic 
erythroblasts; EryC, orthochromatic erythroblasts) according to their CD71 expression and cell size 
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(FSC) (Liu et al., 2006) (Koulnis et al., 2011). Proerythroblasts were defined as the population 
CD71High TER119Low. 
 
2.2.10.3 Lymphoid subsets – bone marrow and spleen 
Cells for lymphoid flow cytometry assays were processed as for erythroid assays. Antibodies tested 
were those against CD3 (T-cell marker), CD4 (T-helper cell), CD8a (cytotoxic T-cell), CD45R/B220 (B- 
cell marker), and the leucocyte common antigen, CD45 (Table 2.3). Single cells were initially gated on 
FSC-A vs FSC-H. Lymphocyte sub-populations were then defined, based on side scatter height (SSC- 
H) vs FSC-H, and on SSC vs CD45 (leucocyte common antigen) characteristics (Allan et al., 2008, 
Arnoulet et al., 2010). This lymphocyte population was analysed for total T-cells (CD3- positive), 
which were further subdivided into T-helper cells (CD4) and cytotoxic T-cells (CD8a). B-cells 
(CD45R/B220) were analysed within the myeloid assays, to allow for the optimal distribution of 
fluorochrome detection in each assay set-up. Proportion of each sub-population of lymphocytes (T- 
cells and B-cells) was then calculated as a percentage of total number of cells for each population. 
 
2.2.10.4 Myeloid subsets – bone marrow and spleen 
Cells for myeloid flow cytometry assays were processed as for erythroid assays. Antibodies tested 
were those against Ly6G (neutrophil / granulocyte marker) (Rose et al., 2012), F4/80 (macrophage 
marker), and the leucocyte common antigen, CD45 (Table 2.3). Cells were acquired and analysed as 
for lymphoid cells, with myeloid sub-populations being defined based on FSC vs SSC, and on SSC vs 
CD45 characteristics. Proportion of each sub-population of myeloid cells (neutrophils, macrophages) 
was then calculated as a percentage of total number of cells for each population. 
 
2.2.11 Histology 
Harvested organs (sternum, spleen, liver, thymus, heart, lung, kidney) were collected in 15mL 10% 
neutral buffered formalin and left at room temperature for 24 hours. They were then transferred to 
40mL 70% ethanol and left at room temperature until processing. Specimens were cut for paraffin 
embedding, placed in plastic cassettes (#MEI10-0113, Trajan Medium Uni-Safe, ThermoFisher 
Scientific, Australia) (Table 2.4) and stored in fresh 70% ethanol. Specimens in cassettes were then 
embedded in paraffin on the Shandon Excelsior ES automated tissue processor (ThermoFisher 
Scientific, Australia) and Leica EG1150 modular tissue embedder system (Leica Biosystems, Mt 
Waverley, Australia) by staff in the Core Histology Department, Level 10, Kolling Institute, University 
of Sydney, Royal North Shore Hospital, St Leonards, NSW, Australia. Sternum specimens were 
decalcified by immersion in 14% neutral EDTA (disodium salt), 1.5% NaOH, pH 7.4, for 7 days at 4°C 
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(with one change of solution at day 3), rinsed in water for 15 minutes, and transferred to 70% 
ethanol before being embedded in paraffin. Tissue cutting from paraffin blocks was done on a Leica 
RM2235 manual rotary microtome (Leica Biosystems, Mt Waverley, Australia) by staff in the 
Anatomical Pathology Department, Royal North Shore Hospital, St Leonards, NSW, Australia. 
Sections of embedded tissue were cut at 4μm thickness, floated on a water bath at 45°C, put onto 
glass slides (#T7611, Trajan Series 3 Adhesive, Large Frost, Trajan Scientific Australia), and left 
upright in a 37°C oven overnight for the tissue to bind to the slide. Slides were then processed 
either for haematoxylin and eosin (H & E) staining or immunohistochemistry. 
 
2.2.11.1 Haematoxylin and eosin (H & E) staining 
Tissue staining was carried out for basic histological analysis by staff in Cancer Diagnosis and 
Pathology Group, Level 8, Kolling Institute, and Department of Anatomical Pathology, Royal North 
Shore Hospital, St Leonards, NSW, Australia, on the Tissue-Tek® Prisma® Automated Slide Stainer & 
Glas™ g2 Coverslipper (Sakura Finetek Europe B.V., The Netherlands). The staining method on this 
instrument uses 2 separate dyes: one to stain the nucleus and the other to stain the cytoplasm and 
connective tissue (Chan, 2014). Haematoxylin is a deep blue-purple colour and stains nucleic acids; 
eosin is orange-pink and is used as a counter-stain, staining proteins non-specifically and acting as a 
sharp contrast to the blue nuclear stain. The staining was carried out in a series of automated steps 
with slides immersed in decreasing proportions of ethanol to rehydrate the tissue to allow the stains 
to bind to the tissue. Once the staining was completed satisfactorily, the tissue was dehydrated in 
ethanol, cleared in xylene, and automatically coverslipped. Stained slides were viewed by light 
microscopy and megakaryocytes were counted. The mean number of megakaryocytes seen was 
determined from counts made by 2 independent observers. 
 
2.2.12 Immunohistochemistry 
2.2.12.1 Staining 
A selection of formalin-fixed, paraffin-embedded (FFPE) mouse tissues representing all mouse 
genotypes studied was examined for immunohistochemistry (IHC). This was carried out by Ms Ellen 
Tsui, head of Histology, WEHI, Melbourne, Australia. Blocks of FFPE tissue were sent to the Histology 
Department, WEHI, where staff processed tissue sections for IHC. All IHC procedures were carried 
out on the Dako Omnis automated staining station (Dako Australia Pty Ltd). Paraffin blocks were cut 
into 4μm slices, and all specimens were dewaxed by ClearifyTM clearing agent (#GC810, Dako) and 
rinsed with water. 
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For Gfi1b KO mice and their controls, epitopes CD34, myeloperoxidase (MPO), and von Willebrand 
factor (vWF) were investigated (Table 2.5). Target retrieval was then carried out for each epitope by 
heat-induced epitope retrieval (HIER). For the detection of CD34, this involved exposure to 
EnVisionTM FLEX TRS in 0.1% citrate buffer at low pH of 6.1 (#GV805, Dako) at 97°C for 20 minutes. 
For CD34 staining, the specimen was blocked with EnVisionTM FLEX peroxidase-blocking reagent 
(Dako) for 5 minutes, then washed for 10 cycles with wash buffer (#GC807, Dako). Primary antibody 
rabbit anti-mouse CD34 (#ab81289, Abcam) at a dilution of 1:250 was applied for 1 hour at room 
temperature, then washed off. Rabbit HRP-labelled polymer (#K4003, Dako, RTU (ready-to-use)) was 
applied and incubated for 30 minutes at room temperature. This was washed off with alternating 
cycles of wash buffer and water, and EnVisionTM FLEX substrate chromogen was applied for 10 
minutes at room temperature. This was then washed off in several cycles of wash buffer and water, 
and air-dried. For myeloperoxidase (MPO) staining, target retrieval was achieved with EnVisionTM 
FLEX TRS in EDTA buffer at high pH of 9 (#GV804, Dako) at 97°C for 30 minutes. After washing, a 
1:1000 dilution of primary antibody rabbit anti-mouse MPO (#A0398, Dako) was applied and 
incubated for 1 hour at room temperature. This was washed off, and EnVisionTM FLEX peroxidase- 
blocking reagent (Dako) was applied for 4 minutes at room temperature. This was then washed off, 
and as for CD34, rabbit HRP-labelled polymer (#K4003, Dako) was applied neat and incubated for 30 
minutes at room temperature. This was washed, and EnVisionTM FLEX substrate chromogen was 
applied for 10 minutes at room temperature. This was then washed and air-dried. For vWF, staining 
was carried out as for CD34, starting with low pH HIER. Primary antibody used was rabbit anti-mouse 
vWF (#A0082, Dako) at 1:200 dilution. 
 
During the investigations, it was necessary to confirm that the FLAG-tagged protein was being 
expressed in the transgenic mice. For the detection of FLAG-tagged human GFI1B expression in 
megakaryocytes in tissue of GFI1B TG mice and their controls, several methods were used to 
optimise epitope retrieval and labelling. These involved low pH and high pH HIER, and the use of 
proteinase K solution (20μg/mL in Tris-EDTA (TE) buffer, incubated with dewaxed specimen for 20 
minutes at 37°C, then rinsed in PBS-Tween-20) as another method to break the protein cross-links 
caused by fixation of the specimen. For detection of FLAG using mouse anti-FLAG primary antibodies 
(Table 2.5), specimens were blocked in several ways in order to minimise the reactivity of secondary 
anti-mouse antibody with endogenous immunoglobulin present in the mouse tissue. Dako ARKTM 
(Animal Research Kit) (#K3954, Dako) Peroxidase blocking reagent was incubated with mouse tissue 
for 5 minutes at room temperature, then the biotinylated mouse anti-FLAG antibody was applied for 
15 minutes at room temperature at a dilution of 1:100. This was followed by a 15-minute incubation 
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with streptavidin-peroxidase, then stained by a 5-minute incubation with DAB (diaminobenzidine)+ 
substrate-chromogen. Another blocking agent that was used for mouse antibodies on mouse tissue 
was the Mouse-On-Mouse (M-O-M) Basic Kit from Vector Laboratories, Inc. (#41207, Abacus DX, 
Queensland)), which uses a similar protocol. For rabbit polyclonal anti-FLAGTM / DYDDDDK protein 
primary antibodies, specimens were blocked and visualised also by goat anti-rabbit HRP-conjugated 
secondary antibody. Direct (no secondary antibody) and indirect (with secondary antibody) methods 
of antibody binding were also attempted during the optimisation. 
 
Table 2. 4 Antibodies and their targeted epitopes used in immunohistochemistry of formalin-fixed, 
paraffin embedded mouse tissue. 
 
Mouse Epitope Antibody: Host Concentration Catalogue Company Conjugate 
Genotype Clone Animal Number 
Gfi1b KO CD34 EP373Y Rabbit 1:250 ab81289 Abcam - 
MPO Polyclonal Rabbit 1:1000 A0398 Dako - 
vWF Polyclonal Rabbit 1:200 A0082 Dako - 
GFI1B TG FLAGTM M2 Mouse 1:100 F9291 Sigma- 
Aldrich 
Biotin 
DYDDDDK 6F7 Rat 1:100 ab213519 Abcam - 
Both Rabbit Ig Polyclonal Goat neat K4003 Dako HRP-Polymer 
MPO, myeloperoxidase; vWF, von Willebrand factor; FLAGTM, polypeptide protein tag (DYKDDDDK; 
D, aspartic acid, Y, tyrosine, K, lysine). 
 
 
2.2.12.2 Quantification 
Positive tissue controls were processed along with experimental tissues. For quantitation of IHC 
results, positively-stained cells for each investigated epitope were counted per high-power field 
across each type of tissue tested (Fedchenko and Reifenrath, 2014), and mean counts per group of 
fields were calculated. 
 
2.2.13 Transmission electron microscopy (TEM) 
Harvested bone marrow and spleen tissue specimens of matched pairs of control and Gfi1b KO mice 
that had been stored in 2.5% glutaraldehyde in 0.1M cacodylate buffer overnight (section 2.2.5.4) 
were transported to the Westmead Research Hub Electron Microscope Core Facility, Level 1, 
Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, NSW, Australia for 
processing and imaging by core facility staff, Dr Dongwei (Lucy) Wang and Dr Emma Kettle. 
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2.2.13.1 TEM – bone marrow processing 
Because of the friable nature of the fixed bone marrow tissue, the specimens had to be initially 
encapsulated in 10% BSA (w/v) in water: tissue was washed twice in 0.1M cacodylate buffer, spun at 
1500xg for 10 minutes, the supernatant aspirated, and tissue resuspended in 10% BSA. This was left 
to stand at room temperature for 20 minutes, spun again at 1500xg for 10 minutes, and the 
supernatant aspirated. The tissue then underwent Karnovsky fixation which consisted of layering 
~250μL of modified Karnovsky fixative (2.5% glutaraldehyde (v/v), 2.4% paraformaldehyde (v/v), 
0.1M MOPS [3-(N-morpholino) propane sulfonic acid], pH 7.4) (Karnovsky, 1965) onto the tissue 
pellet, letting stand overnight at 4°C. Specimens were then washed 3 times for 5 minutes each in 
0.1M cacodylate buffer, and post-fixed in 2% osmium tetroxide (w/v) in 0.1M cacodylate buffer for 2 
hours at room temperature. Specimens were rinsed in water, then dehydrated for 10 minutes each 
time in a series of increasing concentrations of ethanol (50%, 70%, 95%, 100% - v/v) in 0.1% NaCl 
(w/v), with a final transfer for 10 minutes into 100% acetone. They were then infiltrated with a 
50/50 mix of acetone and resin for 1 hour, and then 3 changes at 10 minutes each of 100% fresh 
resin at 70°C.The tissue blocks were then embedded in moulds, labelled with specimen 
identification, and the resin polymerised at 70°C for 10 hours. These blocks were then ready for 
cutting and imaging. 
 
2.2.13.2 TEM – spleen processing 
Spleen tissue specimens were washed 3 times for 5 minutes each in 0.1M cacodylate buffer, and 
post-fixed in 2% osmium tetroxide, dehydrated, infiltrated with resin, embedded in moulds, labelled 
with specimen identification, and the resin polymerised as per bone marrow specimens above. 
These blocks were then ready for cutting and imaging. 
 
 
2.2.13.3 TEM – cutting and imaging 
Bone marrow and spleen specimens were cut on a Leica EM UC6 ultramicrotome (Leica Biosystems, 
Mt Waverley, Australia) at a thickness of 90nm, and images recorded on a 120kV CM120 BioTWIN 
transmission electron microscope (Philips, Australia) using a Soft Image System (SIS) Morada side 
mount camera. 
 
2.2.14 Cell culture of megakaryocytic progenitor cells 
Harvested cells from bone marrow (femur) and from spleen that were collected separately into 
Iscove’s Modified Dulbecco’s Medium (IMDM) with 2% FCS (Gibco®, ThermoFisher Scientific, 
Australia) on ice were used to culture megakaryocytic progenitor cells in a semi-solid collagen-based 
matrix. This was carried out using the MegaCult™-C for Mouse CFU-Mk kit (#04960, Stemcell™ 
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Technologies Australia Pty Ltd, Tullamarine, Australia) in a level ll certified biological safety cabinet. 
MegaCult™-C serum-free medium (#04900, IMDM, BSA, recombinant human (rh) insulin, human 
transferrin, 2-mercaptoethanol, supplements) was prepared by the addition of cytokines rh 
thrombopoietin (50ng/mL final concentration (f.c.)), interleukin (IL)-6 (20ng/mL f.c.), and 
recombinant mouse (rm) IL-3 (10ng/mL f.c.) to a final volume of 2mL. Cell suspensions were 
resuspended in IMDM at approximately 2.2 x 106 /mL (33x required final cell concentration). A 
0.1mL of this cell suspension was then added to 2mL prepared medium, followed by 1.2mL of cold 
collagen solution (#04902) (final volume 3.3mL). A volume of 0.75mL of this final culture medium 
was then added to each of 2 wells of 2 labelled double chamber slides (#04963) and swirled gently 
to spread the mixture evenly over the slides. They were then placed in 100 mm Petri dishes, with 
uncovered 35mm culture dishes containing ~3mL of sterile water to maintain optimal humidity 
while incubating. The 100mm dishes were then covered with lids. These were then incubated at 
37°C with 5% CO2 and ~95% humidity for 6-7 days, after which they were assessed by microscopy for 
overall colony growth and morphology before being stained. Slides were then carefully blotted with 
kit-supplied filter paper, placed into ice-cold acetone fixative for 5 minutes, air-dried for 15 minutes, 
then allowed to come to room temperature before being stained. Staining mixture for the detection 
of acetylcholinesterase activity of megakaryocytes in the cultures (Jackson, 1973) was prepared 
according to kit instructions (0.05% acetylthiocholiniodide in 0.1M Na2HPO4, 5mM Na3 citrate, 3mM 
CuSO4, 0.5mM K3Fe(CN)6). Slides were then completely covered in staining solution and incubated 
for approximately 6 hours at 37°C. Staining solution was poured off, and slides were then fixed in 
95% ethanol for 10 minutes, rinsed with lukewarm water, and completely air-dried before being 
counterstained with Harris’ haematoxylin solution for 30 seconds. They were then rinsed with 
lukewarm water, air-dried, and stored in covered containers at room temperature. Megakaryocyte 
colonies were detected by light microscopy as being groups of large brown cells of 3 or more (Hogge 
et al., 1997) and distinguished from other cell colonies, which appeared pink (haematoxylin 
counterstain). Three independent observers counted the megakaryocyte colonies, and the mean 
values were calculated for each mouse. 
 
2.2.15 BSA gradient preparation of megakaryocytes from GFI1B TG and control mice 
In order to obtain purified and / or cultured megakaryocytes for the above procedures, it was 
necessary to isolate and attempt to purify the comparatively low population of megakaryocytes that 
is usually found in bone marrow. Megakaryocytes from harvested bone marrow and spleen cells 
collected in 2%FCS-IMDM (v/v) were filtered (100μm) then purified by application to a gradient of 
different concentrations of BSA in PBS (Nakeff and Floeh, 1976). A three-step density gradient was 
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prepared by the pipetting of 3mL of pre-warmed (37°C) sterile 3% BSA-PBS into a 15mL Falcon tube. 
This was then gently overlaid with 3mL of pre-warmed sterile 1.5% BSA-PBS, and finally 3mL of PBS 
as the top layer. Harvested cells were first centrifuged at 189xg (Heraeus Megafuge 1.0, 
ThermoFisher Scientific, Australia) at room temperature for 4 minutes, supernatant carefully 
aspirated, and cells resuspended in 3mL 2%FCS-IMDM. Cell suspension was then carefully layered 
over the prepared BSA gradient, and megakaryocytes left to sediment through it for 30-45 minutes 
at room temperature to pellet at the bottom. Upper layers of the gradient were pipetted off, leaving 
the bottom ~2mL containing megakaryocytes. This remaining volume of ~2mL was then centrifuged 
at 189xg for 5minutes at room temperature, the supernatant aspirated, and the cell pellet 
resuspended in either PBS or culture medium, such as DMEM, depending on the subsequent process 
or analysis. 
 
2.2.16 Nested PCR for DNA sequencing of cDNA from extracted RNA of megakaryocytes from 
GFI1B TG and control mice 
Harvested, filtered femoral bone marrow megakaryocytes from GFI1B knock-in and control mice 
were processed for DNA sequencing in order to confirm the transcription of FLAG-tagged TG human 
GFI1B after the excision by Pf4-Cre. Megakaryocytes that were separated and collected after 
application to a BSA gradient, were pelleted by centrifugation and had the supernatant aspirated. 
For sequencing studies, RNA was extracted from the resultant pellet of ~107 cells, according to 
manufacturer’s instructions (RNeasy® Plus Mini Kit, #74134, Qiagen Pty Ltd, Victoria, Australia), with 
the resultant RNA concentration being determined on the NanoDropTM 1000 spectrophotometer 
(Thermo Fisher Australia) on RNA-40 setting, with RNase-free water as blank. cDNA was synthesised 
from the resultant RNA, using random hexamers in Tetro cDNA Synthesis Kit, BIO65042, Bioline 
(Australia). cDNA concentration was also determined on the NanoDropTM 1000 spectrophotometer 
(Thermo Fisher Australia) on DNA-50 setting, with DNA Rehydration solution as blank. The first PCR 
run of the two-step nested PCR involved primers to target the entire FLAG-tagged inserted GFI1B 
cDNA. A 2% agarose gel was run to detect the target bands. The products from this PCR (GFI1B WT 
KI: 1039 bp; GFI1B Mut KI: 966 bp) were then used as DNA templates for the second step of the 
nested PCR, with primers targeting exon 7 of the GFI1B gene, where, in the mutant gene, a single 
nucleotide, C, had been inserted at base position 880 of cDNA. The PCR product from this second 
step was run on a 2% agarose gel, and the resultant bands cut out, cleaned up, and the DNA 
extracted with the Isolate II PCR and Gel Kit (#BIO-52060, Bioline (Australia) Pty Ltd). The DNA 
extracted from this was used as a template for DNA sequencing by AGRF (Australian Genome 
Research Facility), Sydney. All primers for nested PCR were purchased from Invitrogen™ Life 
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Technologies, Thermo Fisher Australia. Sequencing results were sent back as. ab1 chromatogram 
files, which were analysed with SnapGene Viewer software (GSL Biotech LLC, USA). 
 
Table 2. 5 Primers used for nested PCR of separated megakaryocytes of GFI1B knock-in mice. 
 
Nested 
PCR step 
Primer name Sequence 
Annealing 
temp (°C) 
Product size (bp) 
1st PCR FLAG tag (forward) 5'-GACTACAAGGACGACGATGACAAG-3' 62°C GFI1B WT KI: 1039 
product TgINS tail (reverse) 5'-CCATCGATGGCCCGTACGGC-3' GFI1B Mut KI: 966 
2nd PCR hGFI1B nested (forward) 5'-CTCAGACACGCGGCCCTACCC-3' 62°C GFI1B WT KI: 292 
product TgINS tail (reverse) 5'-CCATCGATGGCCCGTACGGC-3' GFI1B Mut KI: 221 
 
2.2.17 Transfection of FLAG vector in CHO cells for use as positive control for 
immunofluorescence (IF) microscopy and Western blot (WB) for GFI1B TG and control mice 
FLAG-positive control cells were required for studies on detection of FLAG-tag protein expression by 
immunofluorescence and by Western blot in harvested, cultured megakaryocytes from GFI1B knock- 
in and control mice. To this end, Chinese hamster ovary cells (CHO-K1, ATCC® CCL-61TM) were 
cultured, transfected with FLAG, harvested and tested for FLAG-tag protein expression as a positive 
control along with cultured murine megakaryocytes. 
 
2.2.17.1 Culture of CHO cells 
CHO cells were grown in RPMI 1640 medium with L-glutamine (Cat. No. 11875-085, Gibco®, Thermo 
Fisher Scientific, Australia) and 10% Foetal Bovine Serum (Cat. No. 26140-079, Gibco®, Thermo Fisher 
Scientific, Australia) (RPMI growth medium). Sub-confluent cultures (70-80% growth) were split 1:4 to 
1:10 i.e. seeded at 1-2 x 104 cells/mL using 0.25% (w/v) trypsin-0.53mM EDTA, with 5% CO2 at 37°C. For 
CHO transfection with FLAG, Promega ViaFectTM transfection reagent (#E498, Promega Corporation) 
was used, with the plasmid DNA, p3xFLAG-CMVTM-7.1 Expression vector (#E4026, Sigma-Aldrich Pty 
Ltd, Castle Hill, Australia). CHO cells were maintained in RPMI 1640 with L-glutamine, 10%FBS, and 
0.1mM MEM Non-Essential Amino Acids Solution (Cat. No. 11140-050, Gibco®, Thermo Fisher 
Scientific, Australia) (RPMI complete growth medium), and grown at 37°C with 5% CO2. On the day 
before transfection, medium was removed, and the cells treated with 0.25% (w/v) trypsin-0.53mM 
EDTA and counted. 2 x 106 cells per well were plated in a 6-well plate in 2mL per well of RPMI complete 
medium. Cells were grown to ~50-80% confluence, and underwent transfection. For each well of cells 
to be transfected, 3μg plasmid DNA was diluted into 200μL of RPMI medium without serum, as well as 
9μL of ViaFectTM transfection reagent. This was mixed gently and incubated for 20 minutes at room 
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temperature. RPMI growth medium was then removed from cells in 6-well plate, and replaced with 
2mL of RPMI complete growth medium. 200μL of the ViaFectTM transfection reagent / DNA plasmid / 
serum-free RPMI mixture was added directly to each well containing cells, and mixed gently by 
rocking the plate back and forth. Cells were then incubated at 37°C, 5% CO2, for 24 hours post- 
transfection. Transgene expression was determined after transfected cells were treated with 0.25% 
(w/v) trypsin-0.53mM EDTA and detached from wells. Cells were then counted and processed as for 
megakaryocytes for IF or for Western blot. 
 
2.2.18 Immunofluorescence microscopy of megakaryocytes from GFI1B TG and control mice 
2.2.18.1 Isolation and differentiation of megakaryocyte progenitors from murine bone marrow 
Harvesting of megakaryocytes 
Mouse bone marrow was flushed out from the 2 femurs with 21G needle and 1mL syringe 
containing DMEM medium supplemented with 10% FBS, 100IU/mL Penicillin / Streptomycin (Gibco®, 
Thermo Fisher Scientific, Australia), and 2mM L-glutamine (Gibco®, Thermo Fisher Scientific, 
Australia) (DMEM complete medium) into a final volume of 10mL. This was spun for 5 minutes at 
189xg at 4°C. After aspiration, cells were resuspended in 6mL ACK (ammonium-chloride-potassium) 
lysing buffer (0.15M NH4Cl, 1mMKHCO3, 0.1mM Na2EDTA), and incubated at room temperature for 5 
minutes. The cell mix was then filtered (70μm), spun at 189xg for 5 minutes at 4°C, aspirated and 
resuspended in 1mL DMEM complete medium. 
 
Isolation of megakaryocytes 
In order to isolate megakaryocyte progenitors for megakaryocyte cell culture differentiation, it was 
necessary to deplete the bone marrow cell suspension of other mature haematopoietic cells and 
their precursors. This was achieved by the incubation of the cells with 3μL each of rat antibodies 
against mouse lineage markers (Life Technologies, ThermoFisher Scientific, Australia). These 
included: Ly6G (myeloid differentiation antigen, Gr-1; clone RB6-8C5; #14-5931-82); CD11b 
(monocytes / macrophages, granulocytes, NK cells; clone M1/70; #14-0112-81); B220 / CD45R (B-cell 
lineage; clone RA3-6B2; biotin; #13-0452-82); CD16 / CD32 (low affinity receptors for mouse IgG Fc 
on B cells, monocytes / macrophages, NK cells and neutrophils; clone 93; #14-0161-82). The 
incubation was carried out on ice for 30 minutes. Depletion of the lineage cells was carried out by 
mixing the cells and rat anti-mouse antibodies with DynabeadsTM coated with sheep anti-rat IgG 
antibodies (#11035, ThermoFisher Scientific, Australia). First, 50μL of DynabeadsTM per mouse was 
washed 3 times in DMEM complete medium. The final bead resuspension was in 50μL of DMEM 
complete medium. Then, after incubation of cells with rat antibodies, 1mL of DMEM complete medium 
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was added to the cells, and spun at 189xg for 5 minutes at 4°C. After resuspension of cell / antibodies 
mix in 1mL of DMEM complete medium, 50μL of washed DynabeadsTM was added. This was then spun 
at 189xg for 5 minutes at 4°C and the mixture pipetted up and down for a total of 3 times. Tubes 
containing the mix were then placed in the Dynal MPCTM magnet for 1 minute to pull down the beads. 
The supernatant, which contained the megakaryocyte progenitors, was removed to a fresh tube. The 
beads were washed with 500μL of DMEM complete medium, vortexed, put in the magnet, and the 
second supernatant pooled with the first. Beads were discarded, and the pooled supernatant was spun 
at 189xg for 5 minutes at room temperature. 
 
Differentiation of megakaryocytes 
For the differentiation of megakaryocyte progenitors, the depleted bone marrow cells were 
resuspended in 4mL DMEM complete medium, supplemented with 20ng/mL SCF (stem cell factor; 
#PHC2116, Life Technologies, ThermoFisher Scientific, Australia) and 50ng/mL TPO (thrombopoietin; 
#SRP3236, Sigma-Aldrich Pty Ltd, Castle Hill, Australia). Cells were then incubated 1mL per well in a 
24-well plate for 4 days at 37°C, 5% CO2. Mature megakaryocytes were then isolated from the cell 
culture by application on to a BSA gradient (5mL 3%BSA-PBS, 5mL 1.5% BSA-PBS, %mL PBS, cell 
suspension) in a 50mL Falcon tube. This was allowed to sediment for ~45 minutes at room 
temperature, and the bottom 2mL collected into a separate tube, which was spun at 189xg for 3 
minutes, then resuspended in 300μL DMEM complete medium. Cells were counted and adjusted to get 
~5 x 104 cells per coverslip. 
 
 
2.2.18.2 Preparation of coverslips for immunofluorescence microscopy for megakaryocytes and for CHO 
cells 
Coverslips (14mm diameter, ThermoFisher Scientific, Australia) for binding megakaryocytes and CHO 
cells and carrying out antibody detection were placed in the wells of a 24-well plate and rinsed with 
PBS for 5 minutes. They were then each incubated with 500μL of fibronectin (20μg/mL in PBS) for 1 
hour at 37°C. They were washed 3 times with PBS for 5 minutes, saturated with 1%BSA-PBS for 30 
minutes at room temperature, and washed 3 times again for 5 minutes with PBS. Megakaryocyte or 
CHO cell suspensions containing ~5 x 104 cells were applied to the coverslips and incubated for 2 
hours at 37°C. DMEM medium was removed, and 300μL of fixative (2% sucrose 3% PFA-PBS) was 
applied to each coverslip for 30 minutes at 4°C. Coverslips were then washed 3 times for 5 minutes 
each with 300μL washing buffer (0.5% TritonTM-X-100 (CAS Number: 9002-93-1, Sigma-Aldrich Pty Ltd, 
Australia) in 0.5% BSA-PBS). 
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2.2.18.3 Immunofluorescence microscopy of megakaryocytes for FLAG protein and CHO cells for FLAG 
protein and for GFI1B 
Coverslips with either type of fixed, permeabilised cells were incubated with 100μL of primary 
antibody (mouse anti-FLAG, clone M2, #F3165, Sigma-Aldrich Pty Ltd, Castle Hill, Australia; mouse 
anti-GFI1B, clone B-7, #sc-28356, Santa Cruz Biotechnology, Inc.) at 0.5μg/mL for 1 hour at 37°C. These 
were then washed 3 times for 5 minutes each with 300μL washing buffer. Secondary antibody (goat 
anti-mouse Alexa Fluor 488, #A11001, InvitrogenTM, ThermoFisher Scientific, Australia) was diluted 
1/200 and 100μL incubated with each coverslip for 1 hour at room temperature in the dark. They 
were then washed 6 times for 5 minutes each with 300μL of washing buffer at room temperature. 
For mounting onto slides, each coverslip had 1 drop of mountant applied (InvitrogenTM Prolong® 
Diamond Antifade Mountant, #P36966, ThermoFisher Scientific, Australia) which included DAPI (4′,6- 
diamidino-2-phenylindole) a nuclear and chromosome counterstain, which emits blue fluorescence 
upon binding to AT regions of DNA. They were then incubated overnight at room temperature in the 
dark before being viewed on the Leica TCS SP5 LAS AF fluorescent microscope. For a negative 
control, secondary antibody was used alone to show non-specific binding. 
 
2.2.19 Western blot of FLAG-tagged GFI1B (nuclear) protein in GFI1B TG and control mice 
2.2.19.1 Extraction of nuclear proteins 
Megakaryocytes from GFI1B TG and control mice were harvested, isolated, and cultured as for those 
prepared for IF. After a BSA gradient, the megakaryocyte-rich bottom 2mL cell suspension was 
transferred to a 15mL Falcon tube, spun at 189xg for 5 minutes, and processed for the extraction of 
nuclear proteins (Schreiber et al., 1989, ThermoFisher Scientific, 2007, Abmayr et al., 2006). The cell 
pellet was washed twice in 10mL cold PBS and spun at 189xg for 5 minutes. The final cell suspension 
was in 1mL cold PBS in a 1.5mL Eppendorf tube. This was then spun at 189xg at 4°C for 10 minutes, 
and the supernatant removed. Cell pellet was then resuspended in 400μL of cold hypotonic 
cytoplasm extraction buffer (Buffer A, pH 7.9: 10mM Hepes, 10mM KCl, 0.1mM EDTA, 0.1mM EGTA, 
1mM DTT, 0.5mM PMSF, 1:20 dilution of protease inhibitor mix (#P2714, Sigma-Aldrich Pty Ltd, 
Castle Hill, Australia) on ice for 15 minutes.  25μL of the detergent 10% Nonidet-P40 was then 
added, mixture vortexed for 10 seconds to separate the nuclei from the cytoplasmic fraction, then 
centrifuged at 4°C for 10 minutes at 18,360xg. The supernatant, which contained the cytoplasmic 
fraction, was taken off into a separate tube and stored at -80°C. The remaining pellet was suspended 
in 50μL of cold nuclear extraction buffer (Buffer B, pH 7.9: 20mM Hepes, 0.4M NaCl, 1mM EDTA, 
1mM EGTA, 1mM DTT, 1mM PMSF, 1:20 dilution of protease inhibitor mix) on ice. The mixture was 
vortexed every 5 minutes for 10 seconds on ice for 30 minutes. This was then spun at 4°C for 30 
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minutes at 21,000g. The resultant supernatant was the nuclear fraction, which had protein 
concentration determined, before having 2% SDS added prior to being stored at -80°C or processed 
immediately for Western blot. 
 
2.2.19.2 Protein determination of nuclear proteins 
A modified version of the Lowry method was used to determine the protein concentration of the 
nuclear extraction samples (Markwell et al., 1978) which were diluted 1/100 and 1/200 in MilliQ 
water. A standard curve of BSA (0 - 100μg/mL) was set up, and a 3mL of a solution of 2% Na2CO3, 
0.4%NaOH, 0.16% Na tartrate and 1% SDS, with 0.04% CuSO4.5H2O was added to 1mL of standard / 
diluted sample, vortexed and incubated at room temperature for 30 minutes. 300μL of Folin- 
Ciocalteu’s phenol reagent (diluted ½) was added and incubated for 45 minutes at room 
temperature in the dark. 200μL of each solution was then pipetted into a 96-well plate, and the 
absorbance read at 660nm on a BioTek Instruments PowerWaveTM XS microplate reader, using 
Gen5TM software. Protein concentration for each sample was read against the standard curve. 
 
2.2.19.3 SDS-PAGE and Western blot of nuclear proteins 
The BoltTM system of reagents and apparatus (InvitrogenTM, ThermoFisher Scientific, Australia) was 
used to carry out SDS-PAGE on the extracted nuclear proteins. Samples were prepared by mixing 
50μg of sample into a reaction mix (reducing) of LDS (lithium dodecyl sulphate) sample buffer, 
reducing agent, blue dye, and deionised water in a total volume of 40μL. This mixture was heated at 
70°C for 10 minutes, then loaded onto a pre-cast 4-12% gel (BoltTM Bis-Tris Plus, #NW04120) in a 
mini-gel tank (#A25977) along with a protein standard (SeeBlue®Plus 2, #LC5925, 3- 200kDa) and run 
with 1x running buffer (BoltTM MES SDS running buffer, #B0002) at 165V for 30 minutes. 
 
The iBlot® Dry Blotting system (#IB1001, Gel Transfer Device, InvitrogenTM, ThermoFisher Scientific, 
Australia) was then used to transfer proteins from the gel to a nitrocellulose membrane (iBlot®Gel 
Transfer Stacks, #IB3010-01) for Western blotting. Transfer of proteins to the membrane was briefly 
checked by the immersion of the membrane into Ponceau reagent to detect protein bands, and 
rinsed off thoroughly with tap water. The membrane was blocked with 1% skim milk TBST (Tris- 
buffered saline with Tween®20: 0.15M NaCl, 0.05M Tris-HCl, 0.05% Tween®20, pH 7.6) for 1 hour, 
rocking, at room temperature. Blocking buffer was poured off, and the appropriate primary antibody 
at~1μg/mL in 1% skim milk TBST was applied to the membrane and incubated, rocking, overnight at 
room temperature. Membrane was washed 3 times with 1% TBST on the SNAP i.d.® 2.0 Protein 
Detection System (EMS Millipore, USA), and the secondary antibody, goat anti-mouse-HRP at 
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dilution of 1/5000 was made up in 1% skim milk TBST and incubated, rocking, for 1 hour at room 
temperature. Membrane was washed 3 times again in 1% TBST, and had ~4mL of imaging solution 
(10mL ECL buffer (0.1M Tris, pH 8.6), 22μL p-coumaric acid, 50μL luminol (#A8511, Sigma-Aldrich Pty 
Ltd, Castle Hill, Australia), 10μL 30% H2O2) (Mruk and Cheng, 2011) applied for ~90 seconds at room 
temperature. Membrane was then viewed on ChemiDoc™ Gel Imaging System (BioRad Laboratories, 
Australia) using Image Lab™ software (Gel imaging – Blots – Chem Hi resolution, no filter, first image 
5 sec, last image 200 sec, 40 images). Anti-lamin B1(a nuclear envelope protein; rabbit polyclonal, 
#PA5-19468, ThermoFisher Scientific, Australia) was used as a loading control. 
 
2.2.20 Data analysis 
Statistical analyses and data graphs were performed using GraphPad Prism 7.02 (GraphPad, La 
Jolla, CA, USA) and Microsoft® Excel (2013, 2016). Values were presented as mean ± standard 
deviation (SD). For K562 cell studies, statistical significance was determined using one-way analysis 
of variance (ANOVA), followed by the Student’s t-test, two-tailed, type 2 (two-sample, equal 
variance). For all mouse studies, Student’s t-test was also used to determine significance of results. p 
values less than 0.05 were considered statistically significant. 
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3. Effect of GFI1Bc.880-881insc on erythropoiesis in an erythroleukaemic 
cell culture model 
3.1 Introduction 
This chapter describes the establishment of an erythroleukaemic cell culture model to investigate 
the effects of the mutant transcription factor, GFI1Bc.880-881insC, on red cell development and 
differentiation. Rationales, materials, methods, results, and the final discussion and conclusions, are 
included under the different section headings for each of the research investigations carried out. 
 
3.1.1 Background 
The autosomal dominant bleeding disorder that has been investigated and characterised across four 
generations of an Australian family (Stevenson et al., 2013, Ardlie et al., 1976) is the basis for the 
research presented in this thesis. Our group confirmed that a mutant form of the gene for the 
transcription factor, GFI1B, was the cause of this bleeding disorder, with its presentation of 
thrombocytopenia, α-granule and signalling defects. As well as the distinctive haemostatic 
abnormalities and a tendency to bleed associated with an inherited platelet disorder, laboratory 
investigations also showed blood films with red blood cell anisopoikilocytosis (atypical cell size and 
cell shape) (Figure 3.1). Red cell distribution width was increased in the affected individuals (16.6% 
vs. 13.1%, p<0.001) (normal adult range (>12 years): 11.6% – 14.0%), and there was also an elevation 
of haemoglobin F: > 2%, compared to normal adult range (>12 years) of < 1%. 
 
The observation that red cell anomalies were also features of this transcription factor mutation in 
this family has led to this investigation into the causes of this phenomenon. GFI1B binds to the 
promoter of many genes considered important for erythroid and platelet maturation (Wilson et al., 
2010). Altered function of GFI1B can explain the platelet and red cell abnormalities. 
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Figure 3. 1 Photomicrographs of peripheral blood films from normal control and from affected 
family member III.12. 
(A) Normal blood film depicting normocellular red cells and granular platelets (black arrows). 
(B) Blood film from affected family member with large, hypogranular platelets (blue arrow) and 
abnormal red cell shape (red arrows) (Stevenson et al., 2013). 
 
3.1.2 Red cell membrane and cytoskeletal abnormalities 
Red cells normally show a defined morphology in the peripheral blood, with a narrow range of size 
and shape. Indications of abnormality are first seen in peripheral blood smears, where known red 
cell disorders can be provisionally diagnosed from the characteristic size, shape, colour, inclusions, 
and number of red cells seen (Ford, 2013). The causes and manifestations of many of these red cell 
membrane and cytoskeletal disorders have been studied and well-documented (Barcellini et al., 
2011, Gallagher, 2004, Ciccoli et al., 2013, Webb, 2005, Eber and Lux, 2004, An and Mohandas, 2008, 
Bruce, 2008, Tse and Lux, 1999). These have been attributed to deficiencies and / or defects in the 
various components that make up the cytoskeletal / membrane network: expression or function of 
any of the integral or peripheral proteins, the transport proteins, or lipids in the membrane bilayer. 
 
Diagnoses of these red cell membrane and cytoskeletal disorders have for many years been carried 
out based on those abnormalities described above. Despite biochemical and genetic links to specific 
red cell genes which code for many of the proteins and other molecules responsible for these 
abnormalities, it is estimated that mutations in these genes are found in the coding exons and 
promoter regions of only about 75% of cases studied (Steiner et al., 2009). This implies 
that about 25% of mutations causing red cell disorders are located in important regulatory regions 
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outside these promoters and exons. More recently, inherited defects in transcription factors and 
other elements that regulate the expression of genes that code for these components have been 
detected, introducing a molecular level of testing in the search for causes for these red cell 
disorders. 
 
Recent advances in technology, such as ChIP (chromatin immunoprecipitation) and Next-Generation 
DNA sequencing (Dore and Crispino, 2011, Kalfa et al., 2012), have allowed the quick identification  
of critical regions of gene regulation across an entire genome, identifying regions bound by 
transcription factors and other DNA-associated proteins (Steiner et al., 2009). Mutations are being 
found in the genes that code for these transcription factors and are being identified in various red 
cell membrane (and other components) disorders (Cantor and Orkin, 2002, Arnaud et al., 2010, Borg 
et al., 2011a, Ciovacco et al., 2008, Crispino and Weiss, 2014, Heruth et al., 2010, Nichols et al., 2000, 
Stevenson et al., 2013, Viprakasit et al., 2014, Ward et al., 2013). 
 
3.1.3 Experimental design: cell model system for studying the effect of GFI1Bc.880-881insC on 
erythropoiesis 
The association of observed red cell membrane abnormalities with the presence of a mutation in the 
gene for transcription factor, GFI1B, has led to this investigation into the effect of this mutant gene 
on red cell development and differentiation, focussing on expression of membrane and cytoskeletal 
proteins, and the production of haemoglobin F. This was addressed by the establishment of a red 
cell model system using an erythroleukaemic cell line, whereby the effects of the mutant GFI1B 
were examined. Various erythroid cell lines have been used in establishing model systems to 
investigate erythropoiesis (Lozzio and Lozzio, 1975, Martin and Papayannopoulou, 1982, Wong et 
al., 2010).The particular characteristics of K562 cells (Lozzio and Lozzio, 1975) of vigorous 
proliferation and the ability to be induced to differentiate along the erythroid line, confirmed their 
suitability to be adapted to this study, and so made the choice of cell line relatively straightforward.  
 
So K562 cells were stably transfected with wild type and with mutant GFI1B were cultured in the 
laboratory. Erythroid differentiation was induced by the addition of Ara-C and cells were cultured to 
terminal differentiation. During growth, cells were harvested and assayed for proliferation pattern 
of growth (DNA cell cycle) by flow cytometry, expression of erythroid cell markers, such as 
transferrin receptor (CD71) and glycophorin A (CD235a) also by flow cytometry, and expression of 
cytoskeletal proteins, such as band 3, ankyrin, and protein 4.1, and haemoglobin F by SDS-PAGE and 
Western blotting. Whole cell and nuclear lysates were assayed by Western blotting. Some initial 
studies also involved confocal microscopy. Characterisation of this cell system and the differences in 
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erythroid manifestations of transfected mutant GFI1B compared to transfected wild type, as well as 
untransfected K562 cells, were analysed. 
 
3.1.4 K562 erythroleukaemic cell line in human disease research 
Since the first human cell line was established there has been an increase in the use of human cell 
lines as models for human diseases (Reid et al., 2004). Cell line in vitro models have useful 
advantages over human primary cells for study, such as: having homogeneous genetic material 
which reduces the amount of variability in the cell phenotype; the ability to be stored indeﬁnitely in 
liquid nitrogen to generate sufﬁcient cells for studies on DNA, RNA and proteins; and better 
reproducibility of results obtained (D'Angelo et al., 2015). 
 
The human K562 cell line has been isolated from a patient with chronic myelogenous leukaemia 
(CML) in blast crisis (Lozzio and Lozzio, 1975) and characterised as erythroleukaemic (Andersson et 
al., 1979). K562 has been used as a model of common progenitor of erythroblasts and 
megakaryocytes (Koeffler and Golde, 1980), and can be differentiated into erythroid and 
megakaryocytic lineages (Benz et al., 1980, Rutherford et al., 1981, Bütler et al., 1990). It has 
therefore been used extensively as a model for the study of leukaemia, megakaryocyte, and 
erythroid differentiation (Tsiftsoglou et al., 2003, Huang et al., 2014, Huo et al., 2006), molecular 
mechanisms regulating the expression of genes (Addya et al., 2004), as well as investigation of the 
therapeutic potential of agents that induce differentiation (Gambari, 2003). 
 
Treatment of K562 cells with the cytidine analogue, 5-azacytidine (1-β-D-arabinofuranosylcytosine / 
AraC / cytarabine) has been found to cause the induction of erythroid differentiation, or at least 
expression of erythroid differentiated functions, by activating erythroid genes in K562 cells, and 
progressing towards terminally differentiating nucleate erythroid cells (Gambari et al., 1984, Luisi- 
DeLuca et al., 1984). AraC is an effective treatment for human acute myelogenous leukaemia, 
incorporating into DNA of human myeloblasts, and effectively inhibiting DNA synthesis (Luisi-DeLuca 
et al., 1984). Continuous exposure of AraC to human K562 erythroleukaemia cells induces terminal 
differentiation to erythrocytes and the induction of haemoglobin F (HbF) synthesis. No haemoglobin 
A is produced in this cell line. 
 
The characteristics of this cell line, and the action of AraC, have provided an appropriate model for 
the current investigation into the effects of the mutant transcription factor GFI1B c.880-881insC 
(with a single nucleotide insertion in exon 7 of GFI1B) - compared with wild type - on the growth 
rates, differentiation, and subsequent cell markers and associated proteins, of erythroid cells 
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produced in this line. In the clinical findings, manifestations of this mutant gene in the original 
family were observed in the abnormal morphology of affected members’ red cells. The proposed 
cell model was set up to measure and establish any differences between untransfected cells, cells 
transfected with normal (wild type) GFI1B and cells transfected with GFI1Bc.880-881insC. 
 
 
3.2 Establishment of cell culture 
3.2.1 Transfection 
Human erythroleukaemic K562 cells (ATCC® CCL-243TM) were stably transfected by Mr Walter Chen, 
Northern Blood Research, Centre, Kolling Institute, either with wild type GFI1B or the mutant c.880- 
881insC GFI1B plasmid pcDNA3, using Lipofectamine™ LTX Reagent and PLUS™ Reagent Mix 
(Invitrogen, Life Technologies,15338-100), as per the manufacturer’s protocol (Part No. 25-0941W). 
Untreated cells were used as controls. Transfected material was tested for expression by RNA 
extraction, cDNA synthesis and PCR with GFI1B primers, with the subsequent bands purified and 
sent off for sequencing by the Australian Genome Research Facility (AGRF). 
 
3.2.2 Cell culture 
K562 cells were cultured in RPMI complete medium (RPMI-CM): RPMI 1640 medium (Gibco, Life 
Technologies) supplemented with 10% foetal bovine serum (AusGenex) (previously heat-inactivated 
at 56°C), 2mM GlutaMAX (L-alanyl-L-glutamine) or L-glutamine (Gibco, Life Technologies), and 
100IU/mL penicillin–streptomycin (Gibco, Life Technologies), using 25 cm2, 75 cm2, or 175 cm2 flasks 
(Corning, Sigma-Aldrich) as required. The cell line was incubated at 37°C in a humidified environment 
with 5% CO2. Viability and cell counts were determined using 0.4% trypan blue stain (Invitrogen, Life 
Technologies) on the Countess™ automated cell counter (Invitrogen, Life Technologies). 
 
Stock cell cultures were maintained as well as those used for experiments, and stored in 1mL 10% 
DMSO / 90% foetal bovine serum at a concentration of 2 x 106/mL in liquid nitrogen. These were 
subsequently thawed, resuspended in 9mL RPMI-CM (total volume 10mL) in 15mL centrifuge tubes 
(Corning, CLS430055), centrifuged at 189xg (Heraeus Megafuge 1.0, ThermoFisher Scientific, 
Australia) for 5 minutes at room temperature, aspirated and resuspended in 10mL in 75 cm2 flasks. 
These were incubated as above, and used for ongoing experiments when required. 
 
3.3 Cell growth and proliferation 
Cell growth was determined by measuring the cell count of each group of cells allowed to multiply 
over the course of seven days. Six replicate assays per type of cell (untreated: “K562 only”; GFI1B 
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wild-type: “K562 GFI1B WT”; mutant GFI1B: “K562 GFI1B Mutant”) were set up initially in 24-well 
cell culture plates, with 6 wells per cell type. On Day 0 (0 hours), 0.5mL of each type of K562 cell 
suspension in culture medium containing 5 x 104 cells (i.e. 1 x 105/mL) were transferred to each of six 
wells and incubated at 37°C in 5%CO2. 
 
On Day 2 (48 hours), each set of cells was transferred to 15mL centrifuge tubes (corning, CLS430055) 
tubes, centrifuged at 189xg (Heraeus Megafuge 1.0) for 5 minutes, aspirated, resuspended in 1mL 
culture medium, 10µL aliquots counted in duplicate, and cells resuspended in a final volume of 2mL 
culture medium. Each set of six 2mL cell suspensions was then replated in a six-well cell culture 
plate, resulting in three separate plates for each cell type, and incubated at 37°C in 5%CO2. 
 
On Day 4 (96 hours), each set of cells was transferred to 15mL centrifuge tubes (corning, CLS430055) 
tubes, centrifuged at 189xg (Heraeus Megafuge 1.0) for 5 minutes, aspirated, resuspended in 1mL 
culture medium, 10µL aliquots counted in duplicate, and cells resuspended in a final volume of 5mL 
culture medium. Each 5mL cell suspension was then replated in a 25mL culture flask, and incubated 
at 37°C in 5%CO2. 
 
On the final day, Day 7 (168 hours), each set of cells was transferred to 15mL centrifuge tubes 
(corning, CLS430055) tubes, centrifuged at 189xg (Heraeus Megafuge 1.0) for 5 minutes, 
aspirated, resuspended in 1mL culture medium, and 10µL aliquots counted in duplicate. 
 
3.3.1 Statistical analysis 
For the analysis of cell proliferation and comparison of cell growth rate amongst the three cell types, 
the values shown represent the means ± SD for six replicate assays with duplicate counts. A one-way 
ANOVA was performed to determine any significant differences amongst the groups. The mean cell 
counts for each group of cells at each time point also were compared to each of the other two 
groups. Significance at each point was determined by the student’s t-test, with differences 
considered to be significant at p < 0.05. 
 
3.4 Cell viability after AraC 
In order to determine the optimal concentration of AraC to induce erythroid differentiation in the 
K562 cells at a level which would also minimise cell death, it was necessary to measure cell viability 
of the 3 groups of cells after a range of doses of AraC over several days. This was achieved by 
carrying out an MTT (3-[4,5-dimethylthiazol-2-yl]-2,5diphenyl tetrazolium bromide) cell viability 
assay (van Meerloo et al., 2011). 
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The principle of the MTT assay is that for most viable cells, mitochondrial activity is constant and 
therefore, an increase or decrease in the number of viable cells is linearly related to mitochondrial 
activity. This activity is measured by the conversion of MTT to purple intracellular formazan crystals, 
which are then dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich, D5879) and read at 570nm, 
with background readings at 630 nm. 
 
For this viability assay, all 3 types of K562 cells were grown to log phase (between 5 – 7 days). Then 
on Day 0, for each cell type, 100μL containing 2 x 104 cells in RPMI-CM was pipetted into each one of 
7 sets of 3 wells (i.e. in triplicate) in a 96-well microplate. Control wells consisted of 100μL of RPMI- 
CM only (no MTT), 100μL of untreated cells (no AraC), and 100μL of DMSO only, also in triplicate. 
 
Plated cells were allowed to grow for 6 hours at 37°C in 5% CO2. Then 100μL of AraC (#C1768, 
cytosine β-D-arabinofuranoside, Sigma-Aldrich) diluted in RPMI-CM at final concentrations of 0.05, 
0.1, 0.25, 0.5, 1.0, 2.5, and 5.0 μm AraC was added to the appropriate well. 100μL of RPMI-CM only 
was added to each of the control (no MTT) wells. The plated cells were then incubated from end of 
Day 0 to Day 3 at 37°C in 5% CO2, and checked regularly under the microscope for growth. 
 
On Day 3, MTT reagent (5mg/mL MTT powder, Sigma Ref M2128-5G, in phosphate-buffered saline 
(PBS), Dulbecco’s, no CaCl2, no MgCl2, pH 7.2, Gibco) 1/10 volume i.e.20μL for 200μL volume (100μL 
cells + 100μL AraC) was added to each well except control RPMI-CM only (no MTT), which had 20μL 
PBS added instead. The plates were then mixed on a plate mixer, and incubated at 37°C in 5% CO2. 
 
Control cells (no AraC) were checked every 10 minutes under the microscope for the formation of 
purple crystals in the cells, which reached a peak after an hour. Microplates were then centrifuged 
at 1704xg (Heraeus Megafuge 1.0) for 5 minutes, and supernatants from all wells aspirated with 
microtips. 100μL of DMSO was then added to each well (including DMSO only wells) and the plates 
covered in foil and incubated at room temperature. Plates were checked every 10 minutes for 
dissolution of the crystals, which occurred at 70 minutes. Plates were then read on a BioTek 
microplate reader, using Gen5 software, at 570nm, then 690nm which was deducted for 
background. 
 
3.4.1 Statistical analysis 
For the analysis of cell viability amongst the three cell types, the adjusted absorbance values for 
each group at each AraC concentration were calculated as a percentage of corresponding Day 0 
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control cells (no AraC). For the purpose of determining the optimal concentration of AraC to use for 
the differentiation studies of all 3 cell types, the means of these individual percentages were 
calculated. A one-way ANOVA was performed to determine any significant differences amongst the 
groups, with post hoc tests done to determine which groups were significantly different. Significance 
between groups was determined by the student’s t-test, with differences considered to be 
significant at p < 0.05. 
 
3.5 Cell differentiation with AraC 
After determination of the optimal concentration of AraC through the cell viability studies, erythroid 
differentiation experiments were set up to characterise each cell type and to determine the effect of 
the transfected mutant GFI1B compared with transfected wild-type GFI1B and untreated K562 cells. 
The 3 groups of cells were cultured to grow to log phase (5 – 7 days), then sub-cultured in 6-well cell 
culture plates (Corning, CLS3516, Sigma-Aldrich) over the course of 7 days (Days 0 – 6). Depending 
on the assays to be done on each day, up to 3 x 106 cells in 3mL of RPMI-CM with 0.5μM AraC (final 
concentration f.c. – 1.5μL of 1mM AraC in MilliQ H20) were set up. 
 
For each day’s experiments, the appropriate day’s volume of cells was taken from the corresponding 
well(s) and pipetted into 15mL centrifuge tubes (Corning, CLS430055), centrifuged at 189xg 
(Heraeus Megafuge 1.0) for 5 minutes at room temperature, aspirated, resuspended in 1mL RPMI-
CM, 10μL taken out for cell count on the Countess™ automated cell counter, and processed as per 
the scheme in Figure 3.2. In other experiments, cells were allowed to proliferate for longer, in some 
instances, for up to 10 days, with cell harvesting carried out, and experiments conducted, at various 
timepoints. 
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Figure 3. 2 Schedule for initial K562 differentiation experiments. 
Each of the 3 K562 cell types (K562 only, K562 transfected with GFI1BWT, K562 transfected 
with GFI1B c.880-881insC) was cultured in RPMI complete medium (RPMI-CM, with 10% foetal 
bovine serum, 2mM L-glutamine, and 100IU/mL penicillin / streptomycin). Day 0 cells were 
washed with PBS (Dulbecco’s) and allocated to each of 3 concurrent assays to measure 
different aspects of differentiation (see assays below). Cell suspensions for Days 1 – 6 were 
plated into 6-well culture plates, 3 x 106 cells in 3mL RPMI-CM with 0.5μM AraC and incubated 
at 37°C in 5% CO2. At each timepoint, the cell suspensions in the appropriate wells were 
processed (see text) for each of 3 concurrent assays for differentiation as per Day 0. Cells not 
due for processing were centrifuged at 189xg) for 5 minutes at room temperature, aspirated, 
resuspended in 3mL RPMI-CM per well with 0.5μM AraC f.c., and replated. 
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3.5.1 DNA cell cycle after AraC 
3.5.1.1 Introduction 
The measurement of DNA produces information about the distribution of cells across the cell cycle 
(Pozarowski and Darzynkiewicz, 2004). 
 
The principle of the detection method using flow cytometry is that DNA content differs in the 
different phases. The cells are stained with a fluorescent dye that binds to DNA, and its detection is 
directly proportional to the amount of DNA present (Ormerod, 2008). The protocol for this assay was 
taken from Encyclopedia of DNA Elements Consortium (ENCODE) cell culture guidelines for DNA 
FACS analysis for K562 cells, from the Farnham laboratory, University of Southern California, 2008 
(Consortium, 2011). 
 
However, in this study, the K562 cells are treated with 0.5μM AraC to induce differentiation. When 
cells continue to cycle, they do not differentiate, and when cells terminally differentiate, they no 
longer cycle. Differentiation, however, does not necessarily preclude progress through the cell cycle, 
which suggests that active maintenance of cell-cycle arrest is an important aspect of the cells 
differentiating (Myster and Duronio, 2000). The purpose of this DNA cell cycle study was to 
investigate the effects of AraC on the differentiation of these cells by monitoring the gradual arrest 
of the cell cycle. 
 
3.5.1.2 Preparation of cells 
For the investigation into the comparative effect of AraC on the DNA cell cycle in each cell group 
after differentiation with AraC, the appropriate calculated volume of cell suspension containing 1 x 
106 cells was removed from each day’s cell culture, centrifuged at 189xg (Heraeus Megafuge 1.0) for 
3 minutes at room temperature, and supernatant aspirated. Subsequent cell pellets were vortexed, 
resuspended in 0.5mL of ice-cold PBS, vortexed again, then had a further 5mL of ice-cold PBS added. 
This was then centrifuged at 189xg (Heraeus Megafuge 1.0) for 6 minutes at room temperature, and 
PBS aspirated. Cells were then resuspended in 0.5mL of ice-cold PBS to achieve a single-cell 
suspension. This cell suspension was then added slowly drop-wise into continuously vortexed 15mL 
centrifuge tubes containing 4.5mL of ice-cold 100% ethanol. These were then incubated at 4°C for at 
least 30 minutes, and then for up to 2 weeks before the DNA cell cycle flow cytometry assay was 
done. 
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3.5.1.3 DNA cell cycle flow cytometry assay with propidium iodide (PI) 
Stored cells at 4°C were warmed for 10 minutes in a 37°C water bath to prevent any formed crystals 
from tearing the cells. During this time, fresh propidium iodide (PI) staining solution was made up: 
200μL of 1mg/mL PI (P4170, Sigma-Aldrich Pty Ltd, Castle Hill, Australia) in MilliQ H2O, 200μL of 
10mg/mL RNase A (bovine; Sigma-Aldrich, R4875) in PBS, 9.6mL 0.1% (v/v) TritonTM-X-100 (CAS 
Number: 9002-93-1, Sigma-Aldrich Pty Ltd, Australia) in PBS. The warmed cell suspension in ethanol 
was centrifuged at 189xg (Heraeus Megafuge 1.0) for 5 minutes at room temperature, and the 
ethanol thoroughly decanted. The cell pellet was resuspended in 5mL of PBS, kept at room 
temperature for 5 minutes, then centrifuged at 189xg (Heraeus Megafuge 1.0) for 5 minutes at 
room temperature, and the supernatant aspirated. The cell pellet was then suspended in 1mL of the 
PI staining solution (PI / RNase / Triton-X-100), and kept in the dark at room temperature for 30 
minutes. Immediately before analysis, each sample was vortexed and filtered through a 5mL flow 
cytometry tube with cell-strainer cap (BD Biosciences, 352235, 35μm), then centrifuged at 189xg 
(Heraeus Megafuge 1.0) for 1 minute. Samples were then analysed on a FACSCalibur flow cytometer 
(BD Biosciences) with a 488-nm air-cooled laser, with CellQuestTM Pro software (BD Biosciences). 
 
3.5.1.4 Data acquisition and analysis 
A total of 10,000 events was acquired for each sample on a dot plot of forward scatter (FSC) versus 
side scatter (SSC) in linear mode. Parameters were set up for a designated propidium iodide channel, 
FL2, and DNA characteristics, FL2-A (Area – DNA mass: parameter for detecting DNA content) and 
FL2-W (Width – DNA TOF [time of flight]). In order to eliminate doublets and debris from the 
analysis, a doublet discrimination gate was set up by displaying DNA Width (W) versus DNA Area (A) 
for the DNA dye, PI (Figure 3.3 (A)). Gating was then carried out on the events that had one width of 
DNA content (R2) (Figure 3.3 (B)). Events from region R2 were then further gated onto a histogram 
with FL2-A on the x-axis. For the DNA / cell cycle analysis, the fluorescence detector voltages were 
adjusted so that the G0/G1 peak was centred over 200 on the FL-A axis, with the G2 / M peak being 
centred over 400. Markers were set to distinguish debris (M1), G0/G1 peak (M2), S-phase (M3), and 
G2 /M peak (M4) (Figure 3.3 (B)). Proportions were calculated for each marker as percentage of total 
events in R2. The software, ModFit LT, version 4.0 (Verity Software House, Inc, Maine, USA) was also 
used to analyse DNA cell cycle data, set on: “Fit”: diploid, debris, aggregates, no apoptosis. 
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Figure 3. 3 Acquisition and gating scheme for analysing DNA cell cycle phases in K562 cells. 
(A) After acquisition by FSC / SSC properties, cells are gated on a doublet discrimination gate set 
up by displaying DNA Width (W) versus DNA Area (A) for the DNA dye, PI. Region, R2, 
represents events that have one width of DNA content. This region is then gated in a histogram 
for DNA content (FL2-Area DNA MASS) versus count (B), and phases of the DNA cell cycle 
distinguished by markers M1 – M4). 
M1: debris, apoptotic cells; M: G0/G1 events; M3: S phase events; M4: G2/M phase events.
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3.5.2 Erythroid cell surface markers after AraC 
3.5.2.1 Introduction 
The maturation of human erythroblasts from adult haematopoietic stem/progenitor cells (HSPCs) 
through to mature erythrocytes can be assessed by tracing the expression of erythroid lineage 
markers (Mao et al., 2016). The transferrin receptor (CD71) is an integral membrane 
protein that mediates the uptake of transferrin-iron complexes (Marsee et al., 2010). The expression 
of this receptor is highest in early erythroid precursors through to the intermediate normoblast 
phase, after which expression decreases through to the reticulocyte phase. The maturation to 
erythrocytes results in the loss of transferrin receptor expression, along with the down-regulation of 
the process for haemoglobin synthesis. This high level of transferrin receptor within erythroid 
precursors proves to be one of the definitive markers for evaluating erythroid cell development and 
differentiation. 
 
Glycophorin A (CD235a) is a major sialo-glycoprotein present on the erythrocyte membrane. It is a 
dimeric complex, with its carboxyterminal ends extending into the cell cytoplasm. It forms part of 
the ankyrin-based macromolecular complex of membrane proteins (Mohandas and Gallagher, 2008), 
and is expressed on mature red blood cells and erythroid precursor cells in the later stages of 
erythroid development. CD235a appears at the erythroblast stage and reaches maximum expression 
by the normoblast stage (Loken et al., 1987). The expression of CD71 on erythroid cells precedes 
that of CD235a (Figure 3.3), with expression of the former almost at its maximum before the latter is 
detected. As erythroid cells mature, expression of CD235a continues through to mature cell stage, 
and is an integral part of erythrocyte membrane proteins, while CD71 diminishes. The measurement 
of these two erythroid markers by flow cytometry defines the basis of this investigation into the 
monitoring of erythroid development in these cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 4 Depiction of the stages in erythroid differentiation showing phases of detection of cell 
markers, CD71 (transferrin receptor) and glycophorin A (CD235a). 
Image adapted from (Dzierzak and Philipsen, 2013). 
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3.5.2.2 Flow cytometry assay for expression of erythroid cell surface markers, CD71 and CD235a 
The three groups of K562 cells (untransfected, transfected with GFI1BWT, transfected with GFI1B c.880- 
881insC) were cultured and harvested as per the schedule in Figure 3.2. For each day of differentiation 
after 0.5μM AraC, the appropriate calculated volume of cell suspension containing 4 x 105 cells was 
removed from each day’s cell culture, centrifuged at 189xg (Heraeus Megafuge 1.0) for 5 minutes at 
room temperature, and the supernatant aspirated. Cells were then suspended in 5mL PBS, 
centrifuged at 189xg (Heraeus Megafuge 1.0) for 5 minutes at room temperature, and the 
supernatant aspirated. This was done twice, with the final cell pellet being suspended in 50μL PBS. 
 
Two flow cytometry tubes were set up for cell type. The first tube was for the isotype controls, the 
second for the markers being investigated. Protein concentrations of antibodies were matched with 
isotype controls, and manufacturer ‘s recommendations followed for amount of antibody per 
number of cells: 0.5 antibody protein / 106 cells. So, for 2 x 105 cells, 0.1μg protein was used. All 
antibodies were from BD Biosciences. A volume of 2μL mouse IgG2a FITC (fluorescein isothiocyanate- 
conjugated) and one of 2μL mouse IgG2b PE (phycoerythrin-conjugated) were added to the first tube, 
while 1μL of mouse anti-human CD71 FITC and 4μL of mouse anti-human CD235a were added to the 
second tube. The volume of 25μL of cell suspension in PBS was added to each tube, vortexed, 
covered in aluminium foil, and incubated in the dark at room temperature. 450μL of 0.2% (w/v) 
paraformaldehyde in PBS was then added to each tube to fix the cells, vortexed and stored at 4°C 
overnight, until analysis. Samples were then analysed on a FACSCalibur flow cytometer (BD 
Biosciences) with a 488-nm air-cooled laser, with CellQuestTM Pro software (BD Biosciences). 
 
3.5.2.3 Data acquisition and analysis 
A total of 10,000 events was acquired for each sample on a dot plot of forward scatter (FSC) versus 
side scatter (SSC) in linear mode (Figure 3.4 (A)). Cells were gated to exclude debris (Figure 3.4 (B)) 
(R1). Photomultiplier tubes (PMT) voltages were adjusted for isotype controls so that the cells 
appeared in the first decade of the histogram and markers set up (Figure 3.4 (C), (D)). Cytometer 
compensation was adjusted for the two fluorochromes. Positive events for both fluorochromes were 
determined as those populations showing higher fluorescence that isotype controls (Figure 3.4 (E), 
(F)). The ratio was calculated of mean fluorescent intensity (MFI) for each cell surface marker to the 
MFI of its corresponding isotype control. 
78  
 
 
 
Figure 3. 5 Flow cytometry acquisition and analysis template for erythroid cell surface markers, CD71 
and CD235a. 
(A) A total of 10,000 events were acquired in linear mode of FSC versus SSC. Debris and smaller cell 
fragments were excluded by gating (R1). (B) Cells were displayed on a dot plot of CD71 FITC versus 
CD235a. (C), (D) Isotype controls were adjusted so that populations fell within the first decade. (E), 
(F) Positive cells for CD71 (green) or CD235a (pink) were deemed to be those with higher 
fluorescence than isotype controls. 
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3.5.3 Expression of haemoglobin F after AraC 
3.5.3.1 Introduction 
The observation that the level of haemoglobin F (HbF) was increased in affected members of the 
family under investigation (Stevenson et al., 2013) led to the analysis of the expression of HbF in 
K562 cells transfected with GFI1B c.880-881insC compared with those that were transfected with GFI1BWT 
or those that were untransfected. Initial research into this phenomenon by colleagues in the 
Northern Blood Research Centre, Kolling Institute, obtained promising preliminary results in 
lentiviral GFI1B-transfected K562 cells, with differences of HbF fluorescence seen in confocal 
microscopy from cytoplasmic extracts, and in expressed HbF protein on Western blots from whole 
cell lysates, before and after AraC. 
 
This research involved the continuation of this measurement of HbF expression in K562 cells after 
differentiation with AraC. Spectral analyses of HbF from supernatants of lysed cells and further 
Western blots of expressed HbF from cell cytoplasm extracts were carried out, and results compared 
and analysed amongst the three groups of cells. 
 
3.5.3.2 Confocal microscopy of HbF 
Preliminary confocal microscopy studies for HbF staining of transfected K562 cells (GFI1BWT and 
GFI1B c.880-881insC) after differentiation with 0.5μM AraC was carried out by Mr Walter Chen, Northern 
Blood Research, Centre, Kolling Institute. Briefly, coverslips with either type of fixed, permeabilised 
cells were incubated with HbF primary antibody (#G-134-C, polyclonal goat anti-human, Novus 
Biologicals, In Vitro Technologies, Victoria, Australia) washed, and incubated with secondary 
antibody (mouse anti-goat Alexa Fluor 488), and mounted onto slides with mountant (InvitrogenTM 
Prolong® Diamond Antifade Mountant, #P36966, ThermoFisher Scientific, Australia) which included 
DAPI (4′,6-diamidino-2-phenylindole) a nuclear and chromosome counterstain, which emits blue 
fluorescence upon binding to AT regions of DNA. Slides were viewed on a Leica TCS SP5 LAS AF 
fluorescent microscope. 
 
3.5.3.3 Spectral analysis of HbF 
Preparation of cells 
The three groups of cells were cultured as previously described with 0.5μM AraC (f.c.) added at Day 
0, and every second subsequent day (depending on number of days being tested) as per schedule in 
Figure 3.2. For each day of harvesting cells, cells were counted and approximately 107 cells taken out 
for HbF measurements. The protocol followed for this was that of (Smith et al., 2000). Cells were 
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washed two times: centrifuged at 189xg for 5 minutes (Heraeus Megafuge 1.0, ThermoFisher 
Scientific, Australia), aspirated and resuspended in 10mL ice-cold PBS. A third spin was done at 
1704xg, then cells resuspended in 2mL ice-cold PBS. This suspension was centrifuged at 4°C for 10 
minutes at 18,928xg, aspirated, and the pellet incubated in a 1.5mL Eppendorf tube in two volumes 
of MilliQ water on ice for 15 minutes with constant vortexing to lyse the cells. This suspension was 
finally centrifuged at 4°C for 10 minutes at 10,000xg, the supernatant carefully pipetted to a new 
Eppendorf tube, and stored at -80° until assayed. Approximately 20μL of this supernatant was set 
aside for protein determination, which was carried out on the NanoDropTM 1000 spectrophotometer 
(Thermo Fisher Australia) on the Protein A280 setting, which measures the protein’s absorbance at 
280 nm (A280) and calculates the concentration (mg/ml), with bovine serum albumin BSA) as the 
reference with mass extinction coefficient of 6.7 at 280 nm for a 1% (10 mg/ml) BSA solution. 
 
Control cells, FETALtrol™ (#FH101, Invitrogen™, ThermoFisher Scientific, Australia), comprised of D- 
antigen (Rho) negative adult human erythrocytes supplemented with D-antigen (Rho) positive 
human cord blood erythrocytes, were used for this assay. A volume of 107 cells was also processed 
as for K562 cells. 
 
Spectral analyses 
All spectral analyses were carried out on the BioTek Instruments PowerWaveTM XS microplate 
reader, using Gen5TM software. A volume of 200μL for each supernatant was added in triplicate to a 
96-well microplate and read by the reader at the designated wavelengths. Several different methods 
were attempted to measure HbF concentration in the supernatants of these cells. A multi- 
wavelength spectrum scan of wavelengths from 300nm to 600nm was performed on supernatants, 
and the change in absorbance at 415nm (absorbance for oxyhaemoglobin) for each supernatant was 
calculated as a function of protein concentration, to give a specific value for haemoglobin content: 
HbF absorbance / mg total protein (Smith et al., 2000). 
 
A second method, involving the Harboe direct spectrophotometric method (Harboe, 1959, Han et 
al., 2010, Cookson et al., 2004), with the Allen correction (Allen, 1950, Noe et al., 1984) was also 
attempted, which measured absorbance of haemoglobin at 415nm, with background corrections (at 
wavelengths 380nm, 450nm) for any confounding factors, such as lipid, in samples. The adjusted 
absorbance values for each group were calculated according to the Harboe direct 
spectrophotometric method: Hb g/L = 0.1672 x Abs415 (absorbance at 415nm) - 0.0836 x Abs380 
(absorbance at 380nm) - 0.0836 x Abs450 (absorbance at 450nm), where 415 is the absorbance for 
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haemoglobin, 380nm is the absorbance for non-specific plasma components, and 450nm is the 
absorbance for bilirubin/albumin complexes (Harboe, 1959). 
 
Statistical analysis 
For the analysis of differences in HbF concentration amongst the three cell types, statistical analyses 
were performed using GraphPad Prism version 7.02 (GraphPad Software, San Diego, USA), and 
Microsoft Excel (Excel 2016). A one-way ANOVA was performed to determine any significant 
differences amongst the groups, with post hoc tests done to determine which groups were 
significantly different. Significance between groups was determined by the student’s t-test, with 
differences considered to be significant at p < 0.05. 
 
3.5.3.4 SDS-PAGE and Western blot of HbF 
The cultured and AraC-treated cells were cultured, harvested, washed with PBS, and centrifuged to a 
pellet of cells as described for haemoglobin spectral analyses (before lysis). The initial cell count 
harvested was approximately 5 x 106 cells. Cell pellets were then processed for both cytoplasmic and 
nuclear protein extractions (a two-step protocol) (Schreiber et al., 1989, Abmayr et al., 2006, Abcam, 
2015, ThermoFisher Scientific, 2007), as subsequent investigations were carried out on nuclear 
proteins (see 2.2.19.1). Protein concentration for each fraction (nuclear and cytoplasmic) was 
determined (NanoDropTM 1000 spectrophotometer (Thermo Fisher Australia) on the Protein A280 
setting), Cytoplasmic fractions were then assayed for detection of HbF by SDS-PAGE and Western 
blot (see 2.2.19.3). For Western blot, the goat anti-human HbF primary antibody (Tables 3.1, 3.2) 
(at~1μg/mL in 1% skim milk TBST) was used. Secondary antibody (mouse anti-goat-HRP) (Table 3.2) 
was made up at a dilution of 1/5000 in 1% skim milk TBST. Mouse anti-β-actin (Tables 3.1, 3.2) was 
used as a loading control. 
 
3.5.4 Cell morphology after AraC 
3.5.4.1 Cytospin 
The harvested cell suspensions were counted, and the appropriate volume containing approximately 
2.5 x 105 cells (~5 x 104 cells in 200μL per glass slide) was made up to 1mL with 10% FCS phosphate- 
buffered saline (PBS), pH 7.4 (#09-9400-100, Medicago AB, Uppsala, Sweden from Astral Scientific, 
Gymea, Australia). The cytospin was then carried out in the Department of Haematology, Royal 
North Shore Hospital, on a Thermo Shandon Cytospin 3 (ThermoFisher Scientific, Australia). 200μL of 
this suspension was pipetted through the appropriate funnels onto microscope slides (Thermo 
SuperFrost® /Menzel-Glaser, ThermoFisher Scientific, Australia). These were spun at 300rpm for 4 
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minutes, then air-dried and stained with May-Grünwald-Giemsa stain on a Sysmex® SP-1000i 
automated staining system by staff in the Department of Haematology, Royal North Shore Hospital. 
Slides were then viewed on an Olympus CKX41_31 microscope with an Olympus DP21 digital 
camera. 
 
3.5.4.2 Photography 
Harvested cell pellets were photographed at each collection to record changes in colour as the K562 
cells differentiated into erythroid cells. 
 
3.5.5 Protein expression after AraC 
3.5.5.1 Confocal microscopy of cytoskeletal proteins 
Preliminary confocal microscopy studies for staining of transfected K562 cells (GFI1BWT and GFI1B 
c.880-881insC) for cytoskeletal proteins, ankyrin and band 3, on day 5 after differentiation with 0.5μM 
AraC was carried out by Mr Walter Chen, Northern Blood Research, Centre, Kolling Institute. Briefly, 
coverslips with either type of fixed, permeabilised cells were incubated with ankyrin and with band 3 
primary antibodies (Table 3.2) washed, and incubated with secondary antibody (goat anti-mouse 
Alexa Fluor 488), and mounted onto slides with mountant (InvitrogenTM Prolong® Diamond Antifade 
Mountant, #P36966, ThermoFisher Scientific, Australia) which included DAPI (4′,6-diamidino-2- 
phenylindole) a nuclear and chromosome counterstain, which emits blue fluorescence upon binding 
to AT regions of DNA. Slides were viewed on a Leica TCS SP5 LAS AF fluorescent microscope. 
 
3.5.5.2 Cytoplasm – cytoskeletal proteins 
Cells were harvested, and the extracted cytoplasmic cell fraction was processed as for Western blot 
of HbF. Cytoskeletal proteins β-actin, ankyrin, band 3, α-spectrin, α-tropomyosin, and cytoplasmic 
loading control, GAPDH (Tables 3.1, 3.2) were investigated. 
 
3.5.5.3 Nuclear fraction – nuclear proteins 
Similarly, the extracted nuclear cell fraction was processed as for Western blot of HbF. The 
transcription factor, GFI1B, a nuclear protein, and lysine-specific demethylase-1 (LSD-1), part of the 
co-factor complex, and nuclear loading control, lamin B1 (Tables 3.1, 3.2), were investigated. 
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Table 3. 1 Functions of erythroid cytoskeletal and nuclear proteins in K562 cells in Western blots. 
Protein Function 
Haemoglobin F Main oxygen transporter protein 
β-Actin Filaments in contractile apparatus in cell 
Ankyrin-1 Attaches integral membrane proteins to cytoskeleton in erythrocytes 
Band 3 Attachment site for cytoskeleton; binds ankyrin; Cl and HCO3 
exchange 
Spectrin-α Actin-binding protein; major component of erythrocyte cytoskeleton 
Tropomyosin-α Structural protein; binds actin filaments 
(Loading control – GAPDH) Glyceraldehyde 3-phosphate dehydrogenase; enzyme that catalyses 
the sixth step of glycolysis 
GFI1B Transcription factor – repressor; binds to DNA; in erythroid and 
megakaryocytic lineage 
LSD1 Lysine-specific histone demethylase – regulates chromatin structure 
and transcription; corepressor with GFI1B 
(Loading control – Lamin B1) Inner nuclear membrane 
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Table 3. 2 Antibodies used in confocal microscopy, Western blots for detection of cytoskeletal and 
nuclear proteins in K562 cells. 
Cell fraction Protein Ab Host / clone MW 
(kDa) 
Stock 
conc. 
/ mL 
Rec. 
dilution 
Cat. No. Company 
Cytoplasmic 
proteins 
 
Hb F Goat polyclonal 16 1mg 1/1000 G-134-C Novus 
Cytoskeletal 
proteins 
β-Actin 
Mouse 
monoclonal / C4 43/15 
200μg 1/200 sc-47778 Santa Cruz 
 Ankyrin-1 
Mouse 
monoclonal / H-4 
171 - 
206 
200μg 1/100 - 
1/1000 
sc-374240 Santa Cruz 
 Band 3 
Mouse 
monoclonal / A-6 95 
200μg 1/100 - 
1/1000 
sc-133190 Santa Cruz 
 Spectrin-α 
Mouse 
monoclonal / 
RG/26 
240 200μg 1/500 sc-53444 Santa Cruz 
 
Tropomyosin-
α 
Mouse 
monoclonal / F-6 35 - 45 
200μg 1/200 sc-376541 Santa Cruz 
 
(Loading 
control – 
GAPDH) 
Mouse 
monoclonal / 
0411 
37 200μg 1/2000 Sc-47724 Santa Cruz 
Nuclear 
proteins 
GFI1B 
Mouse 
monoclonal / B-7 41 
200μg 1/100 sc-28356 Santa Cruz 
 LSD1 
Mouse 
monoclonal / 2D6 107 
200μg 1/100 - 
1/1000 
sc-136174 Santa Cruz 
 
(Loading 
control – 
Lamin B1) 
Rabbit polyclonal 67 1mg 1/1000 PA5-19468 
ThermoFisher 
Scientific 
Secondary Ab N/A 
Mouse anti-goat-
HRP N/A 
0.8mg 1/5000 
205-035-108 
 
Jackson 
ImmunoResearch 
 N/A 
Goat anti-mouse -
HRP N/A 
0.8mg 1/5000 
115-035-003 
 
Jackson 
ImmunoResearch 
      N/A 
Goat anti-rabbit-
HRP      N/A 
0.8mg 1/5000 
111-035-003 
 
Jackson 
ImmunoResearch 
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3.6 Confirmatory DNA sequencing of transfected genes 
The presence of the transfected genes, GFI1BWT and GFI1Bc.880-881insC, in the K562 cells was checked 
periodically by the sequencing of the cDNA of these genes. For sequencing studies, cells were 
harvested after growth in culture to approximately 107 for RNA extraction. The washed, centrifuged 
and aspirated pellet of cells had RNA extracted according to manufacturer’s instructions (RNeasy® 
Plus Mini Kit, #74134, Qiagen Pty Ltd, Victoria, Australia), with the resultant RNA concentration 
being determined on the NanoDropTM 1000 spectrophotometer (Thermo Fisher Australia) on RNA-40 
setting, with RNase-free water as blank. cDNA was synthesised from the resultant RNA, using 
random hexamers in Tetro cDNA Synthesis Kit, BIO65042, Bioline (Australia). cDNA concentration 
was also determined on the NanoDropTM 1000 spectrophotometer (Thermo Fisher Australia) on 
DNA-50 setting, with DNA Rehydration solution as blank. PCR was performed on this cDNA, using the 
primers, GFI1B forward: 5’-CAGATGTTATTCAAAATTTCCAGCG-3’ and GFI1B reverse: 5’- 
GTGCTGGAGGATGCGTTTCTAC-3’. The PCR product from this step was run on a 2% (w/v) agarose gel 
in 1x TBE buffer (89 mM Tris, 89 mM boric acid, 2 mM EDTA, pH 8.3), and visualised on a ChemiDoc™ 
Gel Imaging System (BioRad Laboratories, Australia) using Image Lab™ software. The resultant bands 
were cut out, cleaned up, and the DNA extracted with the Isolate II PCR and Gel Kit (#BIO-52060, 
Bioline (Australia) Pty Ltd). The DNA extracted from this was used as a template for DNA sequencing 
by AGRF (Australian Genome Research Facility), Sydney. Results were returned from AGRF as files of 
chromatograms of the sequenced cDNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 6 Representative 2% agarose gel depicting cDNA bands for GFI1BWT and for GFI1B c.880- 
881insC. 
These bands were purified and sent to AGRF for DNA sequencing. 
Lane 1, GFI1BWT; Lane 2, GFI1Bc.880-881insC; Lane 3, negative control; Lane 4, HyperLadder 50kb. 
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3.7 Results 
3.7.1 Cell growth and proliferation 
A one-way ANOVA of cell count as indication of cell growth rate amongst the three differently 
treated cell groups (Figure 3.5) (Table 3.3) yielded significant differences amongst the three cell 
groups (F(2,102) = 3.95, p = 0.02). Two-sample t-tests (two-tailed, assuming unequal variances) were 
used to make post hoc comparisons between the different cell groups at different time points 
(Figure 3.6). 
 
 
Figure 3. 7 Cell growth of the three differently treated K562 cell groups. 
Cell growth was measured as mean cell count x 105/mL at different time points over the course of 
seven days. The outcomes of two-sample t-tests for the comparison of cell growth between each 
type of cell at the time points are show above each pair of groups. Data are presented as mean ± 
SD. 
 
 
 
The two-sample t-tests for Day 4 data showed statistically significant differences amongst the 
growth rates for all three groups of cells (p < 0.05 for all three groupings). The two transfected cell 
lines, K562 WT and K562 Mutant, showed similar mean values for cell counts (9.1±1.54, 10.4±1.08, 
respectively) compared to K562 only cells (4.1±0.46, p<0.05) (Table 3.3). The final two-sample t-tests 
for Day 7 data showed statistically significant differences between K562 GFI1B Mutant cells and each 
of the other two groups (p < 0.05 for each), with a mean two-fold increase in cell counts over both 
(Table 3.3). Cell numbers for K562 only cells and K562 WT showed similar mean values (22.8±2.80, 
24.9±3.46, respectively, p=0.07)., 
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Table 3. 3 Mean cell counts for each cell group at the different time points of sampling. 
 
Cell group Day 2 Day 4 Day 7 
K562 only 1.6 ± 0.42 4.1 ± 0.46 22.8 ± 2.80 
K562 GFI1B WT 2.4 ± 0.71 9.1 ± 1.54 24.9 ± 3.46 
K562 GFI1B Mutant 3.0 ± 0.88 10.4 ± 1.08 41.1 ± 2.72 
Data are presented as mean ± SD. For Days 2 and 4, n = 12 each; for Day 7, n = 10. 
The initial cell count for each group was 1.0 x 105/mL. 
 
3.7.2 Cell viability after AraC 
The cellular cytotoxicity of AraC, as measured in the MTT assay, was determined for all 3 cell groups. 
A one-way ANOVA of adjusted absorbance at 570nm compared to Day 0 control cells (no AraC) as 
indication of cell viability after varying doses of AraC amongst the three differently treated cell 
groups yielded significant differences amongst the three cell groups (F(2,60) = 20.05, p<0.0001). The 
determination of the optimal concentration of AraC to use for the subsequent differentiation 
experiments was taken from the mean percentage comparison values across all 3 cell groups (Table 
3.4). 
 
Two-sample t-tests (two-tailed, assuming unequal variances) were used to make post hoc 
comparisons between the different cell groups for the range of AraC concentrations (Figure 3.7). 
These indicated that there were significant differences in cell viability after varying concentrations of 
AraC between the untreated (K562 only) cells compared to both the wild-type GFI1B cells (K562 
GFI1B WT) (p < 0.001) and the mutant GFI1B cells (K562 GFI1B Mutant) (p < 0.01), as well as 
between K562 GFI1B WT cells and K562 GFI1B Mutant cells (p<0.0000001). 
 
The mean percentages of all 3 cell groups compared to Day 0 control cell (no AraC) (Table 3.4) 
(Figure 3.7(B)) showed that cell viability dropped below 90% at 1μM AraC (88.44%). A balance was 
needed to have a high enough concentration to provide differentiation with maximum cell viability 
(>90%). Accordingly, 0.5μM f.c. AraC (93.01% cell viability) was chosen as the AraC concentration to 
use for differentiation experiments. Of the 3 groups, the cells transfected with GFI1Bc.880-881insC 
appeared to show the least effect of AraC (minimum percentage cell viability 95.5±6.4 at 2.5μM 
f.c..AraC , while those transfected with GFI1BWT appeared to have maximum sensitivity to AraC 
compared to the other cell groups (minimum percentage cell viability of 74.6±5.2 at 1μM f.c. AraC 
(Figure 3.7(A)). 
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Figure 3. 8 The effect of AraC on the viability of untransfected (K562 Only) and transfected 
(K562 GFI1B WT; K562 GFI1B Mutant) cells. 
 
A total number of 2 x 104 cells / well of 96-well plates for each cell type were treated with 
AraC concentrations of 0 - 5μM (final concentration). At Day 3, cells were assessed by MTT 
cell viability assay. (A) Determination of viability was done by comparison of individual 
results to untreated cells for each cell type at Day 0, as a percentage. (B) Determination of 
optimal concentration of AraC to use for K562 cell differentiation studies was calculated 
from the average effect of AraC concentration on all three K562 cell types at Day 3 after 
AraC administration. Data are represented as mean ± SD (n=3). 
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Table 3. 4 Individual, and total, mean percentage viability, of K562 cells for each cell group (n=3) at 
Day 3 after AraC. 
 
AraC 
μM 
K562 Only K562 GFI1B WT K562 GFI1B Mutant 
Mean of all 3 
cell types 
0 100.0 ± 0.0 100.0 ±0.0 100.0 ± 0.0 100.0 ± 0.0 
0.05 99.6 ± 5.8 98.8 ± 3.7 101.2 ± 6.3 100.1 ± 1.5 
0.1 97.2 ± 7.9 92.8 ± 7.1 105.8 ± 12.2 98.6 ± 6.6 
0.25 93.3 ± 4.5 87.7 ± 3.8 106.1 ± 13.7 95.7 ± 9.5 
0.5 88.4 ± 17.2 82.5 ± 2.7 108.2 ± 11.9 93.0 ± 13.5 
1 94.4 ± 6.9 74.6 ± 5.2 96.3 ± 13.6 88.4 ± 12.0 
2.5 93.6 ± 9.4 74.9 ± 2.6 95.5 ± 6.4 88.0 ± 11.4 
5 91.6 ± 5.5 83.4 ± 6.6 107.1 ± 5.1 94.0 ± 12.1 
Cells were assessed for viability after administration of different concentrations of AraC, and 
compared to Day 0 untreated cells. The initial cell count for each group was 2 x 104 cells / well of 96- 
well plate. Data are represented as mean ± SD (n=3). 
 
 
3.7.3 Cell differentiation with AraC 
3.7.3.1 DNA cell cycle after AraC 
Stained cells were acquired and gated as per Figure 3.3. The software ModFit LT was applied to each 
resultant acquisition, with increasing difficulty as cells differentiated, and the DNA cell cycle 
histogram profile changed (Figure 3.8). Peaks became increasing indistinct, so that the software was 
unable to fit a model of cell cycle to the data. By day 6, in all 3 cell groups, the classic DNA cell cycle 
profile had changed to show cells arrested in the S phase. AraC (cytosine arabinoside) is similar 
enough to human cytosine deoxyribose (deoxycytidine) to be incorporated into human DNA, but is 
different enough to kill the cell. It interferes with the synthesis of DNA, by damaging it when the cell 
cycle holds in the S phase (synthesis of DNA). Rapidly dividing cells, which require DNA replication 
for mitosis, are therefore most affected (Perry, 2008). These results demonstrate the transition over 
the days of AraC treatment of the K562 cells from cell cycle progression to differentiation, with no 
discernible differences among the 3 groups of cells. 
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Figure 3. 9 Histogram profiles of DNA cell cycles of K562 cells at Days 0 – 6 after 0.5μM AraC. 
(A) : Untransfected cells; (B): cells transfected with GFI1BWT: (C): cells transfected with GFI1B c.880- 
881insC. Arrows indicate locations in histograms of cell cycle phases: blue arrow, G0/G1 cell 
population; red arrow, S phase population; green arrow, G2/M population. 
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3.7.3.2 Erythroid cell surface markers after AraC 
Results are expressed as the ratio of the mean fluorescent intensity (MFI) for a cell surface marker to 
the MFI of its isotype control. This method of presenting flow cytometry results was chosen as this 
ratio tells us how well separated a population of stained test cells is from the population of cells in 
the isotype control (Marquez et al., 2011, Herzenberg et al., 2006). The distance between these two 
populations is related to the percentage of cells above the isotype gate 
 
Dot plots of CD71 versus CD235a showed increasing numbers of cells expressing CD234aHigh and 
CD71Low as differentiation progressed after treatment with 0.5μM AraC (Figure 3.9) from day 0 to 
day 6. However, in both CD71 surface expression and in CD235a (glycophorin A) surface expression 
on K562 cells, there were no differences among any of the 3 cell groups: untreated; cells transfected 
with GFI1BWT; or cells transfected with GFI1B c.880- (Figure 3.10). One-way analysis of variance 
(ANOVA) found that mean expression of both surface markers among the 3 cell types was not 
significantly different (CD71: F(2,18)=1.66, p=0.22; CD235a: F(2,18)=1.13, p=0.35), and post hoc 
student’s t-test showed no significant differences between any two cell groups. For each population, 
comparison of this ratio to that acquired on day 0 as a percentage showed similar patterns of 
amongst the 3 cell groups (Figure 3.11). 
 
There was an inconsistency amongst the expression of these cell markers amongst the 3 groups, 
showing no particular pattern or definitive difference. Untransfected cells appeared to show the 
largest mean expression for both markers (Figure 3.10(A), (B)), while the K562 WT cells appeared to 
have the lowest mean values for CD235a amongst the three groups (Figure 3.10(B)). Large error bars 
and statistically insignificant results, however, meant that the results of this comparison of 
expression of both CD71 and CD235a amongst these three cell groups were inconclusive. 
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Figure 3. 10 Dot plots of K562 cells gated on surface markers CD71 vs CD235a. 
These images show the gradual increase in cells expressing CD235High as differentiation proceeds 
after 0.5μM AraC. (A): Untransfected cells; (B): cells transfected with GFI1BWT: (C): cells 
transfected with GFI1B c.880-881insC. 
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Figure 3. 11 CD71 and CD235a (Glycophorin A) surface expression on K562 cells after 0.5μM 
AraC. Results are expressed as the mean fluorescent intensity (MFI) ratio (MFI of CD71 (FITC-  
conjugated) stained cells/MFI of isotype negative control mouse anti-human IgG (FITC- 
conjugated) (A) or (MFI of CD235a (PE-conjugated) stained cells/MFI of isotype negative control 
mouse anti-human IgG (PE-conjugated) (B). Data are represented as mean ± SD (n=3). (K562 only: 
untransfected K562 cells (control); K562 WT: K562 cells transfected with GFI1B wild-type; K562 
Mutant: K562 cells transfected with GFI1B mutant c.880-881insC. 
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Figure 3. 12 Ratio of CD71 and CD235a (Glycophorin A) surface expression on K562 cells 0.5μM 
AraC. 
Results are expressed as the mean fluorescent intensity (MFI) ratio (MFI of CD71 (FITC- 
conjugated) stained cells/MFI of isotype negative control mouse anti-human IgG (FITC- 
conjugated) (A) or (MFI of CD235a (PE-conjugated) stained cells/MFI of isotype negative control 
mouse anti-human IgG (PE-conjugated) (B) compared to Day 0 values. Data are represented as 
mean ± SD (n=3). K562 only: untransfected K562 cells (control); K562 WT: K562 cells transfected 
with GFI1B wild-type; K562 Mutant: K562 cells transfected with GFI1B mutant c.880-881insC. 
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3.7.3.3 Expression of haemoglobin F (HbF) after AraC 
Confocal microscopy of HbF 
Preliminary experiments of confocal microscopic detection of haemoglobin F (HbF) in GFI1B- 
transfected K562 cells after treatment with AraC were carried out by Mr Walter Chen, Northern 
Blood Research, Centre, Kolling Institute. The results are included here as they appeared to show 
differences in green fluorescent intensity (expression of HbF) between those cells transfected with 
GFI1BWT and those transfected with GFI1Bc.880-881insC (Figure 3.12 (A) and (B), respectively). These 
initial images indicated that there may be some difference of HbF expression in the mutant cells 
after AraC, so further investigations into HbF expression were performed. 
 
Figure 3. 13 Confocal microscopy images of HbF expression in K562 cells after AraC. 
(A) : cells transfected with GFI1BWT; (B): cells transfected with GFI1B c.880-881insC. Red arrows indicate 
cytoplasmic areas with green fluorescence denoting HbF expression. Blue indicates DAPI staining 
for nucleus. 
Images provided by Mr Qiang (Walter) Chen, Northern Blood Research Centre, Kolling Institute. 
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Spectral analysis of HbF 
For the measurement of HbF by absorbance spectrum analysis (Figure 3.13), there were no 
statistically significant differences between group means as determined by one-way ANOVA (F(1.09, 
2.18) = 0.141, p = 0.7603). Expectations of increased HbF expression in the cells transfected with 
GFI1B c.880-881insC as found in preliminary confocal images did not occur here. Indeed, the 
untransfected cells appeared to have increased HbF expression at day 5 compared to both the 
transfected cell groups (untransfected: 0.093 ± 0.032; cells transfected with GFI1BWT: 0.074 ± 0.035; 
cells transfected with GFI1B c.880-881insC: 0.062 ± 0.015; data are expressed as mean ± SD change in 
absorbance at 415nm per mg of total protein in supernatant) (Figure 3.14) (Table 3.5). 
 
Similarly, measurement of HbF concentration by the Harboe direct spectrophotometric method 
showed a similar pattern. One-way ANOVA between the three group means for this method also 
showed no statistically significant differences (F(1.038, 2.076) = 0.2062, p = 0.7011). As for the 
absorbance spectrum method, this method also showed increased HbF expression of the 
untransfected cells at day 5 compared to both cells transfected with GFI1BWT and cells transfected 
with GFI1B c.880-881insC (0.0053 ± 0.0008; 0.0039 ± 0.0005; 0.0035 ± 0.0001, respectively; data are 
expressed as HbF g/L, mean ± SD) (Figure 3.15) (Table 3.6). 
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Figure 3. 14 Absorbance spectrum analyses (300nm – 600nm) of HbF expression. 
K562 cell supernatants days 0, 3, and 5 after 0.5μM AraC. 
(A) KO: Untransfected cells; (B) KWT: cells transfected with GFI1BWT; (C) KMU: cells 
transfected with GFI1B c.880-881insC. Sharp peak at wavelength 413nm in all 3 diagrams 
shows absorbance for HbF control cells. 
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Figure 3. 15 Determination by absorbance spectrum of HbF expression in K562 cell supernatant 
after AraC. 
Relative haemoglobin concentration is expressed as change in absorbance of supernatant at 
415nm per mg total protein. KO: Untransfected cells; KWT: cells transfected with GFI1BWT; KMU: 
cells transfected with GFI1B c.880-881insC. 
 
 
 
 
 
 
 
 
Table 3. 5. Relative HbF concentrations from supernatants of K562 cells from absorbance spectrum 
after AraC. 
 
Day after   Relative HbF concentration Δ Abs415/mg protein  
0.5μM AraC KO KWT KMU 
0 0.033 ± 0.013 0.027 ± 0.013 0.039 ± 0.009 
3 0.042 ± 0.014 0.087 ± 0.039 0.096 ± 0.021 
5 0.093 ± 0.032 0.074 ± 0.035 0.062 ± 0.015 
 
Data are presented as mean ± SD. Relative HbF concentration was calculated as change in 
absorbance at 415nm / mg total protein of supernatant. KO: Untransfected cells; KWT: cells 
transfected with GFI1BWT; KMU: cells transfected with GFI1B c.880-881insC. 
99  
 
 
 
Figure 3. 16 Spectrophotometric analysis by Harboe method of HbF expression in K562 cell 
supernatant after AraC. 
KO: Untransfected cells; KWT: cells transfected with GFI1BWT; KMU: cells transfected with GFI1B 
c.880-881insC. 
 
 
 
 
 
Table 3. 6 HbF concentrations from supernatants of K562 cells after AraC (Harboe method). 
 
Day after   HbF concentration g/L   
0.5μM AraC KO KWT KMU 
0 0.0005 ± 0.0003 0.0004 ± 0.0003 0.0007 ± 0.0002 
3 0.0014 ± 0.0004 0.0021 ± 0.0005 0.0021 ± 0.0007 
5 0.0053 ± 0.0008 0.0039 ± 0.0005 0.0035 ± 0.0001 
Data are presented as mean ± SD. HbF concentration was calculated according to the Harboe 
method: Hb g/L = 0.1672 x Abs415 (absorbance at 415nm) - 0.0836 x Abs380 (absorbance at 
380nm) - 0.0836 x Abs450 (absorbance at 450nm), where 415 is the absorbance for 
haemoglobin, 380nm is the absorbance for non-specific plasma components, and 450nm is the 
absorbance for bilirubin/albumin complexes (Harboe, 1959) KO: Untransfected cells; KWT: cells 
transfected with GFI1BWT; KMU: cells transfected with GFI1B c.880-881insC. 
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Western blot of HbF 
As for preliminary confocal studies, initial studies with expression of HbF on Western blots showed a 
28-fold increase in intensity of HbF band (cells transfected with GFI1BWT but no AraC used as 
reference band) of cells transfected with GFI1B c.880-881insC compared to reference before AraC, and 
203-fold increase after AraC (Figure 3.16). Quantitation of intensity of HbF bands was performed 
using Image Lab™ software on ChemiDoc™ Gel Imaging System (BioRad Laboratories, Australia) 
(Taylor et al., 2013). 
 
A replicated Western blot study appeared to show some indications of of higher intensity of HbF 
bands for cells transfected with GFI1B c.880-881insC by day 5 after AraC compared to the other cell 
groups but these were inconsistent (data not shown). However, further studies showed no 
discernible differences among the 3 groups after AraC at days 5, 8 and 10 (Figure 3.17 (A) and (B), 
respectively, with all three groups showing intensities between 6- and 7-fold at days 8 and 10. 
 
There appeared to be discrepancies amongst these result for the expression of HbF in these 
transfected cells after AraC, which were inconsistent with preliminary findings and expected results 
based on clinical investigations in the original studied family. 
 
 
Figure 3. 17 Western blot images of HbF expression in lentiviral transfected K562 cells from 
cytoplasmic extracts after AraC. 
WT: cells transfected with GFI1BWT; M: cells transfected with GFI1B c.880-881insC. Intensity fold 
increase was quantitated by comparison to WT band intensity with no AraC (lane 1). GFI1B c.880- 
881insC -transfected K562 cells show increased HbF expression compared to those transfected with 
GFI1BWT, showing further enhancement after AraC. β-actin was used as loading control. HbF: 
MW, 15 kDa; β-Actin: MW, 43 kDa. 
Images provided by Dr Marie-Christine Morel-Kopp, Northern Blood Research Centre, Kolling 
Institute. 
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Figure 3. 18 Relative quantitation of bands from Western blot images of HbF expression. 
HbF was measured at days 0, 8 and 10 after AraC in stably transfected K562 cells from cytoplasmic 
extracts. Quantitation of intensity of HbF bands of all 3 K562 cell groups from Western blot images 
(Image Lab™ software, BioRad Laboratories, Australia). HbF band from day 0 of untransfected cells 
was used as a reference band for all calculations. (A) Quantitation of band intensities from images 
from Western blots for days 0, 3 and 5 and (C) from days 0, 8 and 10. KO: Untransfected cells; KWT: 
cells transfected with GFI1BWT; KMU: cells transfected with GFI1B c.880-881insC. 
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3.7.3.4 Cell morphology after AraC 
Indications that the K562 cells were differentiating into erythroid cells after 0.5μM AraC were 
observed in the gradual transformation of pale, undifferentiated K562 cells (Figure 3.18, Day 0) to 
characteristic red cells (Figure 3.18, Day 10). Stained cytospin preparations also showed changing 
morphology of K562 cells through the erythroid stages of differentiation, with evidence of cell 
progression from proerythroblasts, through basophilic normoblasts, polychromatophilic 
normoblasts, orthochromatic normoblasts, to erythrocytes (Figure 3.20). 
 
Amongst the three group of images from the three cell groups (KO: untransfected cells; KWT: cells 
transfected with GFI1BWT; KMU: cells transfected with GFI1B c.880-881insC), there appears to be no 
discernible difference in the morphology of the different cell groups as they differentiate. Indicated 
erythroid cell types appear to be similar in all three sets of images, suggesting that there may be no 
effect of the transfected gene on cell differentiation, or that the transfection may not be present in 
these cells. 
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Figure 3. 19 Photographic images of harvested K562 cells after 0.5 μM AraC. 
Cells were harvested at days 0, 3, 5, 8, and 10 after 0.5 μM AraC, showing gradual changes in colour 
of cells towards the distinctive red of erythroid cells. From left to right in each image: KO, KWT, KMU. 
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Figure 3. 20 Representative MGG-stained cytospin preparations of harvested K562 cells. 
Images produced at days 0, 3, 5, 8, and 10 after 0.5 μM AraC, showing changing morphology of cells 
in the gradual process towards erythroid differentiation (magnification x 40). 
KO: Untransfected cells; KWT: cells transfected with GFI1BWT; KMU: cells transfected with GFI1B c.880- 
881insC. 
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3.7.3.5 Protein expression after AraC 
Confocal microscopy of cytoskeletal proteins 
Preliminary experiments of confocal microscopic detection of cytoskeletal proteins in GFI1B- 
transfected K562 cells on day 5 after treatment with 0.5μM AraC, were carried out by Mr Walter 
Chen, Northern Blood Research, Centre, Kolling Institute. As for HbF, the results are included here as 
they appeared to show some differences in green fluorescent intensity between those cells 
transfected with GFI1BWT (KWT) and those transfected with GFI1Bc.880-881insC (KMU) (Figure 3.21). 
These initial images indicated that there may be some increased ankyrin expression, although 
perhaps not band 3 expression, in the mutant cells (KMU) after AraC, so further investigations into 
the expression of these and other cytoskeletal proteins were carried out with Western blots. 
 
Western blot of cytoskeletal proteins 
In contrast to those preliminary results seen in confocal microscopy suggesting increased expression 
of cytoskeletal proteins, subsequent Western blot analyses showed no differences in band 
intensities of any proteins investigated (spectrin-α, band 3, β-actin, tropomyosin) across all cell 
groups on any day after AraC treatment (Figure 3.22). 
 
Western blot of nuclear proteins 
Similarly, the transcription factor protein, GFI1B and LSD-1, part of its co-factor complex, were 
visualised on Western blots for all three cell groups at days 0, 3, and 5 after 0.5μM AraC treatment 
(Figure 3.22). As for the cytoskeletal proteins, there were no discernible differences for either 
nuclear protein investigated for all three cell groups on any day after AraC. 
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Figure 3. 21 Confocal microscopy images of expression of cytoskeletal proteins. 
Images denote ankyrin and band 3 in K562 cells on day 5 after 0.5μM AraC. 
(A) KWT: cells transfected with GFI1BWT; (B) KMU: cells transfected with GFI1B c.880-881insC. 
Cytoplasmic areas with green fluorescence denote expression of cytoskeletal proteins. Blue 
indicates DAPI staining for nucleus. 
Images provided by Mr Qiang (Walter) Chen, Northern Blood Research Centre, Kolling Institute. 
107  
 
 
 
Figure 3. 22 Western blot images of expression of K562 cytoskeletal proteins. 
Protein bands at days 0, 3, and 5 after 0.5μM AraC in stably transfected K562 cells from 
cytoplasmic extracts. KO: Untransfected cells; KWT: cells transfected with GFI1BWT; KMU: cells 
transfected with GFI1B c.880-881insC. GAPDH was used as loading control. 
Spectrin-α: MW, 240 kDa; Band 3: MW, 95 kDa; β-actin: MW, 43 kDa; Tropomyosin: MW, 35-45 
kDa; GAPDH: MW, 37 kDa. 
 
 
 
 
 
Figure 3. 23 Western blot images of expression of K562 nuclear proteins. 
Protein bands at days 0, 3, and 5 after 0.5μM AraC in stably transfected K562 cells from nuclear 
extracts. KO: Untransfected cells; KWT: cells transfected with GFI1BWT; KMU: cells transfected 
with GFI1B c.880-881insC. Lamin B1 was used as loading control. 
GFI1B: MW, 41 kDa; LSD-1: MW, 107 kDa; Lamin B1: MW, 67 kDa. 
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3.7.4 Confirmatory DNA sequencing of transfected genes 
Throughout the investigations of these transfected cell lines, confirmatory DNA sequencing of the 
transfected genes in the K562 was performed three times, in particular when results were 
inconclusive and inconsistent. Unfortunately, the GFI1B c.880-881insC mutation was not detected in cells 
sent for sequencing after some months of experiments (Figure 3.24). Stock cells, stored in liquid 
nitrogen, were then re-cultured and cDNA being sent again for sequencing. This happened two more 
times, with the mutation being present to start with, but as cells were passaged, and experiments 
done, further inconclusive results suggested that once again, the transfected mutation may not have 
been present. These cells had a high turnover rate of proliferation, doubling cell numbers over a 24- 
hour period, and with an approximate rate of 50% transfection, it was clear that untransfected cells 
predominated in the cell population. 
 
On average, the number of passages in these experiments was about 5 – 6, which may have been 
too many times for these cells to retain the transfection. It may have been more effective to go back 
to the original stock after growing a culture for one month, and only passage the primary cells 3 - 4 
times (Consortium, 2011), as well as have the GFI1B mutation DNA sequence confirmed in the 
original stock before storage. 
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Figure 3. 24 Chromatograms of cDNA sequencing of GFI1BWT (K562 WT) cells and GFI1B 
c.880-881insC (K562 Mutant) cells. 
These chromatograms show the initial C insertion in the mutant cells, denoting an 
initially successful transfected mutation (A); and (B) no C insertion detected at site after 
more than six months, indicating the lost mutation. 
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3.8 Discussion 
The purpose of the establishment of this K562 erythroleukaemic cell culture model was, ultimately, 
to reproduce the red cell clinical findings in the bleeding disorder caused by a mutation, c.880- 
881insC, with a single nucleotide insertion in exon 7, in the gene for the transcription factor, GFI1B, 
in a four-generation Australian family (Stevenson et al., 2013). The redeeming characteristic of this 
particular cell line for this study is that it can be induced to differentiate to erythroid cells (Gambari 
et al., 1984, Andersson et al., 1979, Addya et al., 2004). To that end, the effects on growth rates, 
differentiation, and subsequent cell markers and associated proteins, of erythroid cells after 
transfection with the mutant GFI1B - compared with transfected wild type, and untransfected cells – 
were investigated and characterised. 
 
The findings in this study showed an array of some definitive, and some inconsistent and 
inconclusive, results. Positive differentiation of cells from basal level to haemoglobin-containing 
erythrocytes after AraC exposure was seen in the gradual change in colour of harvested cells from 
pale to red after treatment with AraC. Morphological changes showed distinct erythropoietic cell 
changes, from detection of proerythroblast populations in through to normoblasts but very few, if 
any, mature erythrocytes present. However, there did not appear to be any morphological 
differences among the three cell groups studied, especially the designated mutant cells, that 
resembled the morphological findings from the original family i.e. anisopoikilocytosis of cells. Cell 
growth appeared to be the most prolific in the mutant cell group, suggesting that this mutant form 
of GFI1B had an anti-apoptotic effect on the growth of these erythroid cells, as opposed to the 
apoptotic effect that normal GFI1B has on erythroblasts derived from Gfi1b-transduced CD34+ cells 
(Osawa et al., 2002). However, in this study, it is most probably the effect of a dominant mutant 
form of GFI1B. These cells also appeared to show a more robust tolerance of AraCThe arrest of the 
DNA cycle by AraC, as cells differentiated, showed no differences in the rates of differentiation 
among the three cell groups. 
 
Preliminary studies on the expression of haemoglobin F and cytoskeletal proteins showed 
indications of increased expression of these proteins in the mutant cells. However, replicate 
experiments for the detection of these proteins in other methods showed variations in regard to 
correlations with these findings, that were inconsistent with each other. No differences were seen 
across all three groups in the expression of cell surface markers, CD71 (transferrin receptor) or 
CD235a (glycophorin A) as differentiation progressed after exposure to AraC. 
 
The confirmation that the transfected GFI1B mutation had been lost from the cells accounted for 
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the anomalous results that were being generated. Despite re-confirmation that the mutation was 
present, and experiments repeated, the uncertainty that, at any time during the course of a study, 
the mutation could be lost again, severely impacted the objective of this research to successfully 
reproduce the original red cell attributes. The results for the cell proliferation studies were, 
however, presumed to be a representation of cell proliferation behaviour amongst the three groups, 
as cells tested for the transfected mutation were taken from stored cells from passages of cells used 
in these experiments. Nevertheless, as other results were inconclusive, these results were only 
indicative of differences in cell proliferation among the three cell groups. 
 
The effectiveness of the use of this particular cell model to reproduce the red cell anomalies in the 
original family has not been borne out by the results described in this chapter. The method by which 
these cells were transfected may have not been stable or permanent enough, and the proportion of 
transfected cells may not have been high enough to maintain an effective population for study. The 
characteristics of what is essentially an erythroleukaemic cancer cell line may not have been ideal to 
study the effects of this mutant gene, as there is a number of abnormal characteristics associated 
with this cell line, including the Philadelphia chromosome (BCR/ ABL fusion gene) (Lozzio and Lozzio, 
1975). However, the co-transfection of a selective gene, such as green fluorescent protein (GFP), red 
fluorescent protein (RFP) or enhanced GFP (EGFP) into the K562 cells, may have maintained the 
homogeneity of the cells, by enabling the detection of transfected cells by flow cytometry (Kaufman 
et al., 2008). The sorting and isolation of these would have allowed a more homogeneous cell line 
for this study. In any case, K562 remains one of the most common cell lines used for research into 
apoptosis (Duncan et al., 2016); tumour suppressor gene, p53 (Chylicki et al., 2000); cancer drugs 
(Wang et al., 2016); and other therapeutic methods. 
 
The establishment of a more robust, more relevant cell culture model to characterise the effects of 
GFI1B c.880-881insC on the formation of red cells in an attempt to reproduce family red cell indices 
would be more effective in investigating the mechanism of this mutant gene. Induced pluripotent 
stem cell (iPSC)-derived megakaryocytes have been successfully generated from affected members 
of this family to investigate the megakaryocyte differentiation and platelet formation that 
fundamentally characterise the bleeding disorder (Rabbolini et al., 2017a). A preliminary attempt to 
culture iPSCs from skin fibroblasts from affected and unaffected family members and induce 
differentiation to erythrocytes was undertaken as part of the research for this chapter, with minor 
success in the production of partially differentiated red cells, with some precursors. Unfortunately, 
due to time constraints, this was abandoned. However, it would be a better method to study the 
anisopoikilocytosis observed in these patients, enabling the characterisation of cellular proteins, 
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genetic studies, and other relevant investigations in this disorder. 
 
There is a number of variants in mutations in the GFI1B gene cited in the literature, with clinical 
phenotypes that are dependent on the site disrupted in the gene, and the nature of the mutation 
(Rabbolini et al., 2017b). Interestingly, those variants with red cell anomalies appear to have their 
mutations in the three zinc-finger domains in GFI1B that bind to DNA (Zn-f 3 to 5). A cell culture 
model sourced from the affected family members themselves would provide an excellent and highly 
specific vehicle with which to investigate the phenomena observed in this GFI1B mutation. 
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4. Characterisation of the role of Gfi1b in murine haematopoiesis - 
Gfi1b conditional knock-out (KO) mouse model – cell biology 
4.1 Introduction 
Inherited bleeding disorders caused by dysfunctional platelets can be attributed to failure of platelet 
adhesion, activation or adhesion during haemostasis (Alli et al., 2017, McDonald and Austin, 2017, 
Ramasamy, 2004) . Thrombocytopenia can also be a factor in these disorders, and there are many 
underlying mechanisms that contribute to this (Nurden and Nurden, 2007). Abnormal or reduced 
production of platelets from megakaryocytes can occur, amongst other determinants, when there 
are mutations in transcription factors involved in the differentiation of these cells (Tijssen and 
Ghevaert, 2013, Wijgaerts and Freson, 2014, Daly, 2017, Songdej and Rao, 2017). The confirmation 
of a mutant form of the gene for the transcription factor, GFI1B, as the cause of a human bleeding 
disorder with thrombocytopenia, α-granule and signalling defects (Stevenson et al., 2013) is the 
basis of this chapter. As complete ablation of this gene has been shown to be lethal due to severe 
disruption to both thrombopoiesis and erythropoiesis at approximately day 14.5 of embryonic 
development (Saleque et al., 2002, Vassen et al., 2007), a viable mouse model was developed during 
the course of these studies, whereby Gfi1b was conditionally knocked out through the 
megakaryocytic line. This chapter describes the investigation into the effect of loss of this gene on 
the cell biology aspects of haematopoiesis in this mouse model. 
 
 
4.2 Experimental design 
4.2.1 Mouse lines 
4.2.1.1 Gfi1b conditional knock-out mice (denoted Gfi1b KO) 
Embryonic stem (ES) cells (Pettitt et al., 2009) that carried the Gfi1btm1a (EUCOMM)Hmgu targeted allele 
(EUCOMM, European Conditional Mouse Mutagenesis Program, International Knock-out Consortium 
(KOMP)) (Skarnes et al., 2011) were used to generate conditional Gfi1b knockout mice. In brief, ES 
cells were generated using the L1L2_Bact_P cassette (Gossler et al., 1989) that targeted exon 4 of 
Gfi1b allele in Chromosome 2. Correct homologous recombination at the Gf1ib locus resulted in a 
“knock-out first” gene-trap allele (Gfi1bGT/+) with a 5’ Frt flanked region containing IRES-LacZ and 
beta-actin-driven neomycin cassettes and a splice acceptor site, and exon 4 flanked by two LoxP 
sites. In order to remove the FRT-flanked lacZ and neomycin cassette to generate a conditional 
floxed (fl) Gfi1b allele, Gfi1bGT/+ mice were crossed to the transgenic FLPe line (Rodríguez et al., 
2000). Gfi1bfl/fl mice were then shipped to the Kearns Facility. 
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The resultant mice with floxed Gfi1b alleles (Gfi1bfl/fl) were then crossed (in the Kearns Facility) with 
transgenic mice (from WEHI) that expressed Cre-recombinase exclusively in the megakaryocytic 
lineage under the platelet factor 4 (Pf4) promoter (Pf4-Cre) for conditional deletion of Gfi1b in the 
megakaryocyte lineage (Figure 4.1) (Tiedt et al., 2007). This EUCOMM strategy relied on the 
identification of a “critical” exon common to all transcript variants that, when deleted, created a 
frame-shift mutation, which, in turn, triggered nonsense-mediated decay of the mutant or modified 
transcript. This effectively created a null allele. 
 
4.2.1.2 Transgenic Pf4-Cre recombinase mice 
C57/BL6 mice were generated at WEHI with the transgenic expression of Cre-recombinase 
exclusively in the megakaryocytic lineage by the homologous recombination and replacement of the 
first exon of the platelet factor 4 (Pf4) (also called CXCL4) gene with a codon-improved Cre cDNA 
(Tiedt et al., 2007) These were transported to Kolling Institute for cross-breeding with mice with 
floxed Gfi1b alleles (Figure 4.2). 
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frameshifted Gfi1bCre 
 
 
Figure 4. 1 Schematic representation of generation of Gfi1b conditional knockout mice. 
C57/BL6 mice carrying the Gfi1btm1a (EUCOMM)Hmgu vector (Gfi1bGT/+) were crossed with 
transgenic FLPe mice, expressing FlpE recombinase which excises at FRT sites, to 
produce mice with floxed Gfi1b alleles (Gfi1bfl/fl). Further cross-breeding with transgenic 
Pf4-Cre mice (expressing Cre recombinase under the Pf4 promoter) caused the excision 
at the loxP sites either side of exon 4 in Gfi1b in the megakaryocyte line, producing a null 
allele (frameshifted Gfi1bCre). 
Numbered boxes, exons of Gfi1b; tm1a, vector, targeted mutation 1a, Helmholtz 
Zentrum Muenchen GmbH; FRT, flippase recognition target (34bp sequence); lacZ, gene 
for β-galactoside; loxP, locus of X-over P1, bacteriophage P1 (34bp sequence); neo, 
neomycin resistance gene; pA, SV40 polyA; FlpE, flippase recombinase; Pf4-Cre, Cre 
recombinase under the Pf4 promoter. 
 
 
 
 
 
4.2.2 Mouse breeding protocol 
4.1.2.1 Gfi1b conditional knock-out mice (denoted Gfi1b KO) 
Female mice with homozygous floxed Gfi1b (Gfi1bfl/fl) were bred to male mice with heterozygous 
Pf4-Cre (Pf4-Cre+/-) to produce a first generation of all heterozygous floxed Gfi1b (Gfi1bfl/-) and a fifty 
percent mix of heterozygous Pf4-Cre (Pf4-Cre+/-) or no Cre (-/-). Those offspring with genotype 
Gfi1bfl/- x Pf4-Cre+/- were then bred back to Gfi1bfl/fl-only mice to produce the required ultimate 
breeding mice of Gfi1bfl/fl x Pf4-Cre+/- and Gfi1bfl/fl x Pf4-Cre-/-. These then produced the final 
experimental mice of Gfi1bfl/fl x Pf4-Cre+/-, with littermates with Gfi1bfl/fl x Pf4-Cre-/- as controls 
(Figure 4.2). 
tm1a vector 
FRT loxP FRT loxP loxP Gfi1bGT/+ 
3 4 5 
pA 
FlpE 
neo lacZ 
Pf4-Cre 
3 4 5 Gfi1bfl/fl 
3 5 
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Figure 4. 2 Mouse breeding strategy for generation of PF4-Cre Gfi1b conditional knockout mice 
(see text). 
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4.3 Results 
4.3.1 The effect of the loss of Gfi1b on adult murine haematological indices 
The measurement of haematological indices between control and Gfi1b KO showed significant 
differences for all parameters except white blood cell counts (Table 4.1). Blood was collected retro- 
orbitally via heparinised capillary tubes into K2EDTA paediatric tubes. Each Gfi1b KO mouse was 
matched with a litter mate control (age and gender). Full blood count was performed on Beckman- 
Coulter AcT Diff cell counter in veterinary mode. Platelet counts were severely reduced in Gfi1b KO 
mice compared to controls (Figure 4.3), with mean Gfi1b KO counts of 15 ± 6.2 (x103/μL) and those 
of control mice, 1045 ± 192 (x103/μL) (p <0.0001); (data presented as mean ± SD). This reflects 
almost a 70-fold difference between the two groups. 
 
Table 4. 1 Haematological values for control and Gfi1b KO mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are presented as mean ± SD. Significant differences were found between control and Gfi1b KO 
mice for: platelet count, red blood cells count, haemoglobin, haematocrit, MCV, and MCHC. 
MCV, mean cell volume; MCH, mean cell haemoglobin; MCHC, mean cell haemoglobin 
concentration (student’s t-test). 
+Source: (Everds, 2007). 
Peripheral blood 
(retro-orbital) 
 
Control 
 
Gfi1b KO 
n 
(pairs) 
Normal 
range+ 
p value 
Platelets (x103/μL) 1045 ± 192 15 ± 6.2 18 1000 - 2000 <0.0001 
White blood cells (x102/μL) 42.1 ± 32.3 40.1 ± 22.6 8 20 - 90 NS 
Red blood cells (x104/μL) 916.0 ± 36.1 723.6 ± 121.2 10 700 - 1100 0.0001 
Haemoglobin (g/L) 136.9 ± 4.9 109.0 ± 15.6 10 130 - 180 <0.0001 
Haematocrit 0.42 ± 0.01 0.35 ± 0.04 10 0.4 – 0.5 <0.0001 
MCV (fL) 45.5 ± 1.0 48.4 ± 3.0 10 40 - 55 0.004 
MCH (pg/cell) 15.0 ± 0.5 15.2 ± 0.8 10 13 - 17 NS 
MCHC (g/L) 329.3 ± 6.8 314.6 ± 12.5 10 260 - 320 0.01 
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Figure 4. 3 Gfi1b conditionally knocked out along the megakaryocyte lineage via Pf4-Cre 
severely reduces the production of platelets. 
Platelet counts from control mice (n=18) and Gfi1b KO mice (n=18) show a significant 
difference between the 2 groups (p<0.0001). 
 
In contrast, there was no effect on white blood cell counts (NS, Figure 4.4) but loss of Gfi1b 
appeared to have an effect on red blood cell indices. Red blood cell count (RBC), haemoglobin 
concentration (Hb), haematocrit (Hct), and the red blood cell indices of mean volume (MCV), 
haemoglobin (MCH), and haemoglobin concentration (MCHC) all showed significant differences 
between control mice and the Gfi1b KO mice (Figure 4.4). 
 
Gfi1b is known to be an essential transcriptional regulator of megakaryocyte and erythroid 
development, with no effect on myelopoiesis (Saleque et al., 2002), so one would expect that white 
blood cell count would not be affected. The effects of very low platelet count are manifested in the 
Gfi1b KO mice’s inability to stop bleeding. This subsequent blood loss is a possible cause of the 
relative anaemia seen in the Gfi1b KO compared to control mice. 
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Figure 4. 4 Gfi1b conditionally knocked out along the megakaryocyte lineage via Pf4-Cre also 
affects red blood cell indices but has no effect on white blood cell counts. 
Significant differences were found in all red blood cell indices (except mean cell haemoglobin) 
between control (Gfi1bfl/fl) mice (n=10) and Gfi1b KO (Pf4-Cre Gfi1bfl/fl) mice (n=10). No significant 
difference was found in white blood count from both groups (n=8). (A) RBC – red blood cell count 
x 104/μL, (B) haemoglobin g/L, (C) haematocrit L/L, (D) mean cell volume fL, (E) mean cell 
haemoglobin pg/cell, (F) mean cell haemoglobin concentration, g/L. (G) WBC – white blood cell 
count x 102/ μL. NS, not significant. 
A B C 
D E F 
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4.3.2 Mouse bleeding time is increased in Gfi1b KO mice 
Excessive blood loss in Gfi1b KO mice compared to control mice was effectively demonstrated in the 
measurement of tail bleeding times (Figure 4.5). Control mice and Gfi1b KO mice (n=3 pairs) were 
anaesthetised with 2% isoflurane, and an approximate 2-10mm segment of the tail tip was removed 
with a scalpel. Tail bleeding time was monitored by allowing blood to drip onto the Whatman filter 
paper at 20-second intervals, without touching the wound site (Bender et al., 2013) (Haining et al., 
2017). There was a significant difference in bleeding time (seconds) between the two groups (control 
mice 287 ± 170, Gfi1b KO mice 1200 ± 0, p<0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 5 Prolonged tail bleeding times in Gfi1b KO mice compared to control mice. 
(A) Filter papers show rows of consecutive bleeding spots, spaced at 20-second intervals. Tail 
bleeding time was determined as that time when no more blood was seen on the filter paper. 
Otherwise, measurements were stopped at 20 minutes. (B) There was a significant difference in 
bleeding time (seconds) between the two groups (mean ± SD: control mice 287 ± 170 (s); Gfi1b 
KO mice 1200 ± 0 (s); p<0.001). 
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4.3.3 The effect of the loss of Gfi1b on adult murine body organs 
The body organs - spleen, kidneys, heart, lungs, thymus and liver - were harvested from control mice 
and Gfi1b KO mice and weighed. Each Gfi1b KO mouse was matched with a litter mate control (age 
and gender). Relative size of each organ was calculated as percentage (%) of total body weight for 
each mouse (Table 4.2). For kidneys, heart, lungs, thymus and liver there were no significant 
differences (NS) in weight as % of total body weight between the two groups (Figure 4.6). 
 
 
 
 
 
 
Figure 4. 6 Body organs harvested from control and Gfi1b KO mice. 
Body organs were harvested from control mice (n=6) and Gfi1b KO mice (n=6), weighed, 
and their relative sizes calculated and expressed as a percentage of mouse total body 
weight. There were no significant differences between any of the shown organs. (A) 
Kidneys, (B) heart, (C) lungs, (D) thymus, (E) liver. NS, not significant. 
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Figure 4. 7 Spleens in Gfi1b KO mice are significantly larger than those in control mice. 
Spleens were harvested from control mice (n=9) and Gfi1b KO mice (n=9) and weighed. (A) 
Representative picture of comparison of whole spleens of control mouse (upper organ) and 
Gfi1b KO mouse (lower organ). Ruler indicates length (cm). (B) Dot plot of spleen size relative 
to body weight as a percentage. There was a significant difference between the 2 groups 
(p=0.0004). 
A 
B 
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However, there was a significant difference in the weight as % of total body weight of the spleens 
(control mice 0.36 ± 0.16, Gfi1b KO mice 1.23 ± 0.56, p=0.0004). Spleens from Gfi1b mice were 
greatly enlarged (Figure 4.7), suggesting haematopoietic expansion (Vassen et al., 2014). 
 
 
Table 4. 2 Body organs for control and Gfi1b KO mice as percentage of total body weight for each 
mouse. 
 
 
Body organ 
%Total body 
Control 
weight 
Gfi1b KO 
n 
(per group in pair) 
p 
value 
Spleen 0.36 ± 0.16 1.23 ± 0.56* 9 0.0004 
Kidneys 1.24 ± 0.18 1.31 ± 0.05 6 NS 
Heart 0.60 ± 0.11 0.81 ± 0.46 6 NS 
Lungs 0.69 ± 0.36 0.77 ± 0.08 6 NS 
Thymus 0.22 ± 0.14 0.24 ± 0.14 6 NS 
Liver 5.46 ± 0.70 5.14 ± 0.51 6 NS 
Data are presented as mean ± SD. Significant difference was observed in the relative sizes of the 
spleens of the Gfi1b KO mice compared to those of the control mice (*p=0.0004). For all other 
organs, there was no statistically significant difference (NS, no significance) (student’s t-test). 
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4.3.4 The loss of Gfi1b increases erythropoiesis in spleen but not in bone marrow 
The finding of increased spleen size in Gfi1b KO mice compared to control mice, and the suggestion 
of splenic haematopoietic expansion, were borne out by the measurement by flow cytometry of 
erythroid precursor groups in spleen cells (Figure 4.8). Cell surface markers CD71 (transferrin 
receptor), an effective erythroid cell marker (Marsee et al., 2010), and TER119 (murine glycophorin 
A), expressed on erythroid cells towards the later stages of erythroid development (Kina et al., 
2000), were used in conjunction with the forward scatter parameter(FSC), which denotes cell size. 
 
This combination of markers was used to distinguish the subsets of erythroblast cells into a 
developmental sequence (Liu et al., 2006) (Koulnis et al., 2011). These TER119-positive subsets of 
cells corresponded, respectively, to morphological subsets of erythroblasts, namely: ProE, 
proerythroblasts; EryA, basophilic erythroblasts; EryB, poly-chromatic erythroblasts; EryC, 
orthochromatic erythroblasts (Socolovsky, 2007). Cells were harvested from femoral bone marrow 
and from the spleens of control mice and Gfi1b KO mice. Gfi1b KO mice were matched with litter 
mate controls (age and gender). Cells were stained with erythroid cell surface markers, CD71 and 
TER119, and gated accordingly. High TER119 cells in this gate were further gated on cell size 
(forward scatter, FSC) as outlined above (Figures 4.8, 4.9), and the proportions of the erythroid 
precursor groups (denoting developmental stages) were calculated as percentages (%) of total 
erythroid (high CD71 + high TER119) cells (Table 4.3). 
 
In the harvested bone marrow cells, there were no significant differences (NS) between control mice 
and Gfi1b KO mice in any of the erythroblast precursor groups (Table 4.3, Figure 4.9 (B)). In contrast, 
in the spleen cells, there were significant differences in 3 of the 4 the erythroblast precursor groups 
between the control mice and the Gfi1b KO mice. An increase in the numbers of the more immature 
cells (ProE, EryA, EryB), with a comparative reduction in numbers in the more mature cells (EryC) in 
the splenic erythroid cell populations of the Gfi1b KO mice may indicate an erythropoietic response 
to haemorrhage (stress erythropoiesis), which occurs in the murine spleen (Kim et al., 2015, Paulson 
et al., 2011). 
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Figure 4. 8 Increased populations of immature erythroid precursor cells in spleens of Gfi1b KO mice 
compared to those of control mice. 
(A) Representative flow cytometry dot plots of gating strategy (for both groups of mice) to produce 
erythroblast populations. Gated single cells (top right panel) are expressed according to erythroid cell 
surface markers, CD71 and TER119 (lower left panel). High TER119 cells are redefined as subsets 
according to their CD71 expression and cell size (forward scatter, FSC) (bottom right panel). 
Proerythroblasts are defined as the population CD71High TER119Low (bottom left panel). (B) Comparison 
of subset distributions showed significant differences between control mice and Gfi1b KO mice of 2 of 
the 4 subsets (ProE, p=0.02; EryB, p=0.03) with EryC, p=0.09 (n=5 pairs). ProE, proerythroblasts; EryA, 
basophilic erythroblasts; EryB, poly-chromatic erythroblasts; EryC, orthochromatic erythroblasts. 
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Figure 4. 9 No difference in populations of immature erythroid precursor cells in femoral bone marrow of 
Gfi1b KO mice compared to those of control mice. 
(A) Representative flow cytometry dot plots of gating strategy (for both groups of mice) to produce 
erythroblast populations. Gated single cells (top right panel) are expressed according to erythroid cell 
surface markers, CD71 and TER119 (lower left panel). High TER119 cells are redefined as subsets 
according to their CD71 expression and cell size (forward scatter, FSC) (bottom right panel). 
Proerythroblasts are defined as the population CD71High TER119Low (bottom left panel). (B) Comparison of 
subset distributions showed no differences (NS) between control mice and Gfi1b KO mice in any of the 4 
subsets (n=5 pairs). 
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Table 4. 3 Proportion of erythroid precursor cell groups in femoral bone marrow and in spleen for 
control and Gfi1b KO mice as percentage of total erythroid population. 
 
Body organ 
Erythroblast 
group 
% Total  
Control 
erythroid cells 
Gfi1b KO 
n  
(per group 
in pair) 
p  
value 
Bone marrow ProE 1.5 ± 1.0 1.1 ± 1.0 5 NS 
 EryA 15.0 ± 12.9 21.0 ± 19.4 5 NS 
 EryB 45.9 ± 23.3 49.0 ± 24.2 5 NS 
 EryC 31.3 ± 10.8 24.9 ± 7.8 5 NS 
Spleen ProE 1.1 ± 1.19 3.3 ± 1.2 5 0.02 
 EryA 9.5 ± 10.9 27.2 ± 23.4 5 NS  
 EryB 9.4 ± 6.7 30.9 ± 16.5 5 0.03 
 EryC 55.0 ± 29.2 26.8 ± 15.1 5 0.09 
Data are presented as mean ± SD. No significant differences (NS) were observed in bone marrow in 
the percentage of any of the erythroid subsets in the Gfi1b KO mice compared to those of the 
control mice. In the spleen, there were significant differences in 3 of the 4 subsets between control 
mice and the Gfi1b KO mice (ProE, p=0.02; EryB, p=0.03; EryC, p=0.09) (student’s t-test). 
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4.3.5 The effect of Gfi1b on ploidy of megakaryocytes in femoral bone marrow 
Cells from murine femoral bone marrow were harvested from control mice and Gfi1b KO mice, and 
stained for megakaryocytes (CD41) and DNA ploidy (propidium iodide, PI). Flow cytometric 
measurement of megakaryocytes in femoral bone marrow was based on the gating strategy of 
CD41-positive cells (denoting megakaryocytes) showing propidium iodide (PI) staining (indicating 
DNA content – ploidy - of cells) (Figure 4.10 (A), left panels). Positive cells for both were further 
defined in a PI histogram, showing the range of PI fluorescence for those CD41-positive cells (Figure 
4.10 (A), right panels). The resultant peaks denoted the distribution of DNA ploidy in the 
megakaryocyte population in the bone marrow. 
 
Individual ploidy values for each peak were calculated as a percentage of the total numbers of CD41- 
positive, PI-stained cells. Starting at ploidy 2N, the peaks were then grouped in 2 sets of ploidy 
values:  2N – 8N vs ≥ 16N (Table 4.4). Significant differences were seen between the control mice 
and the Gfi1b KO mice in both these ploidy groups (2N-8N: p < 0.001; ≥16N: p < 0.001), with the 
Gfi1b KO mice showing increased numbers of megakaryocytes with DNA ploidy 16N or more, and 
fewer with DNA ploidy 8N or less (Figure 4.10 (B)). This suggests that Gfi1b deficiency along the 
megakaryocyte lineage in the Gfi1b KO mice increases megakaryocyte proliferation and has an effect 
on the distribution of DNA ploidy in the population compared to control mice (Vassen and Moroy, 
2011) (Beauchemin et al., 2017). 
 
 
Table 4. 4 Comparison of distribution of megakaryocyte DNA ploidy in femoral bone marrow for 
control and Gfi1b KO mice as percentage of total megakaryocyte population. 
Ploidy %MK in mouse group n p 
class Control Gfi1b KO (per group in pair) value 
2N – 8N 79.9 ± 2.9 61.3 ± 8.2 6 <0.001 
16N – 256N 19.8 ± 3.0 38.6 ± 8.2 6 <0.001 
 
Distribution of megakaryocyte ploidy for each group was calculated as percentage of total 
megakaryocyte population and grouped as 2N-8N and ≥16N. Data are presented as mean ± SD. 
Significant differences were observed in both DNA ploidy groups between control mice and Gfi1b 
KO mice, with Gfi1b KO mice showing increased numbers of megakaryocytes with DNA ploidy ≥16N, 
and fewer with DNA ploidy ≤8N compared to control mice (2N-8N: p < 0.001; ≥16N: p < 0.001) (n=6 
pairs) (student’s t-test). 
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4.3.6 Quantitation of clonal growth of megakaryocyte progenitor cells from both femoral 
bone marrow (BM) and from spleen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 10 Increased populations of megakaryocytes with higher ploidy in bone marrow of Gfi1b KO mice 
compared to control mice. 
(A) Representative flow cytometry dot plots of gated populations (rectangle) of megakaryocytes (left 
panels) in bone marrow, redefined as histograms (right panels) showing distribution of cell ploidy (upper 
panels, control mouse; lower panels, Gfi1b KO mouse). (B) Comparison of distribution of megakaryocyte 
ploidy (2N-8N vs ≥ 16N) between control mice (n=6) and Gfi1b KO mice (n=6) showed significant 
difference between the 2 groups (2N-8N: p < 0.001; ≥16N: p < 0.001). Data are expressed as mean ± SD. 
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Megakaryopoiesis in both control and Gfi1b KO mice was examined by the establishment of colony 
assays using cells harvested from both bone marrow and from spleen. Suspensions of approximately 
5 x 104 cells harvested from bone marrow (femur) and from spleen of control mice (n=5) and Gfi1b 
knockout (KO) mice (n=5) were grown in a collagen-based, semi-solid CFU-MK assay (Stem CellTM 
Technologies) with cytokines: thrombopoietin (TPO), interleukin 3 (IL-3), and interleukin 6 (IL-6). 
Cells were plated onto chamber slides and allowed to grow for 6 -7 days. Colonies were then stained 
for acetylcholinesterase activity, and counter-stained with haematoxylin. Megakaryocyte colonies 
were detected by their acetylcholinesterase activity (appearing brown) and distinguished from other 
cell colonies by the use of the counterstain, haematoxylin (pink stain). 
 
 
Figure 4. 11 The loss of Gfi1b increases the number of megakaryocyte (MK) colonies cultured from 
both femoral bone marrow (BM) and from spleen. 
Each point represents mean count per mouse. Significant differences in numbers of MK colonies 
were found between control and Gfi1b KO mice in both tissues: bone marrow, p=0.03; spleen, 
p=0.005. CFU, colony-forming unit. 
 
Three independent observers counted the megakaryocyte colonies, which were defined as 
consisting of 3 or more megakaryocytes, and the mean values were calculated for each mouse 
(Figure 4.11). Increased numbers of megakaryocyte colonies were found from cells harvested both 
from bone marrow and from spleen for Gfi1b KO mice compared to those from control mice (bone 
marrow, p=0.03; spleen, p=0.005; n=5) (Table 4.5). 
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Table 4. 5 Numbers of megakaryocyte colonies grown from bone marrow and from spleen from 
control and Gfi1b KO mice. 
 
Body Mouse Megakaryocyte n p 
organ group colonies (per group in pair) value 
Bone marrow Control 14.4 ± 4.2 5 0.03 
 Gfi1bKO 20.6 ± 3.1 5  
Spleen Control 1.0 ± 0.8 5 0.005 
 Gfi1bKO 12.4 ± 6.5 5  
Mean values for numbers of megakaryocyte colonies grown from bone marrow and from spleens of 
control and of Gfi1b KO mice. Increased numbers were seen in colonies from both bone marrow 
and from spleen in the Gfi1b KO mice compared to the control mice (bone marrow, p=0.03; spleen, 
p=0.005; n=5 (pairs) (student’s t-test). Data are expressed as mean ± SD. 
 
4.3.7 Thrombopoietin (TPO) in plasma is increased when Gfi1b is knocked out from the 
megakaryocyte lineage 
Plasma levels of thrombopoietin (TPO) from blood collected in EDTA from control and GFi1b KO mice 
and centrifuged 6832xg for 3 minutes were determined by ELISA (Mouse TPO (THPO) ELISA kit, 
#EMTHPO, ThermoFisher Scientific, Australia). TPO is a major regulator of megakaryocytopoiesis and 
thrombopoiesis, stimulating the proliferation and maturation of megakaryocytes, and regulating the 
level of circulating platelets in vivo (Hitchcock and Kaushansky, 2014). Values for TPO levels of 
control mice vs Gfi1b KO mice showed a significant increase for Gfi1b KO mice (457 ±238 pg/mL) 
compared to controls (190 ± 109 pg/mL) (mean ± SD, p<0.02). 
 
 
Figure 4. 12 Plasma TPO levels are increased in Gfi1b KO mice compared to controls. 
Measurement of TPO levels in control mice (n=8) compared to Gfi1b KO mice (n=7) showed a 
significant increase in the latter (control: 190 ± 109 pg/mL vs Gfi1b KO: 457± 238pg/mL, 
p<0.02. Data are shown as mean ± SD. 
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4.3.8 The loss of Gfi1b has no effect on lymphoid and myeloid cell populations in bone marrow 
and spleen 
As part of the investigation into the effects of the loss of Gfi1b on all blood cells, subpopulations of 
lymphoid and of myeloid cells were examined by flow cytometry for any differences in cell surface 
markers and proportions. As was done for erythroid studies, cells were harvested from femoral bone 
marrow and from the spleens of matched litter mate control (age and gender) mice and Gfi1b KO 
mice. 
 
4.3.8.1 Lymphoid cell populations 
Bone marrow 
Harvested, filtered (100μm) bone marrow cell suspensions, with no erythrocyte lysis performed 
(Allan et al., 2008, Arnoulet et al., 2010) were incubated with antibodies tested against T-cells - CD3 
(T-cell marker), CD4 (T-helper cell), CD8a (cytotoxic T-cell),as well as the leucocyte common antigen, 
CD45. Single cells were initially gated on FSC-A vs FSC-H. Cell subpopulations – nucleated erythroid 
precursors, E; precursor B-lymphoid cells, B-Ly; myeloid cells, My; blasts, Bl; and lymphocytes, Ly - 
were then defined, based on side scatter height (SSC-H) vs FSC-H, and on SSC vs CD45 characteristics 
(Stelzer et al., 1993, Borowitz et al., 1993) (Figure 4.13 (A)). 
 
The lymphocyte population was analysed for total T-cells (CD3- positive), which were further 
subdivided into T-helper cells (CD4) and cytotoxic T-cells (CD8a), and the ratios of these determined. 
B-cells were detected in all sub-populations by the murine pan B-cell marker, CD45R/B220 (Kantor 
and A., 1993). Proportions of each sub-population of lymphocytes (T-cells and B-cells) were then 
calculated as percentages of total number of cells for each population. No significant differences 
were seen between both groups of mice in terms of proportion of CD3-positive, CD4- and CD8- 
positive cells (Figure 4.13(B)), CD4/CD8 ratios (Figure 4.14 (B)) (Table 4.6), and B-cell CD45/B220 
surface expression in bone marrow populations (Figure 4.14 (D)) (Table 4.7). 
 
Spleen 
Harvested, filtered (100μm) spleen cell suspensions were incubated with antibodies against T-cell 
and B-cell markers as per bone marrow cells (4.3.8.1). A similar gating strategy for spleen cells 
showed subpopulations of erythroid precursors, E; myeloid cells, My; and lymphocytes, Ly (Figure 
4.15(D)) (Bayne and Vonderheide, 2013, Colovai et al., 2004). T-cell and B-cell flow cytometry assays, 
and subsequent ratios and calculations were carried out as for bone marrow cells. 
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Figure 4. 13 Representative flow cytometry gating strategy for investigation of cell populations in 
bone marrows of control and Gfi1b KO mice for lymphoid and myeloid markers. 
This gating strategy consists of cells being acquired in (A) Forward scatter (FSC) vs side scatter (SSC) 
which is then converted to single cell gating (B), based on FSC-height vs FSC-area. These single cells 
are then gated according to their SSC and CD45 (leucocyte common antigen, LCA) expression (C), 
resulting in scatter characteristics of the different populations of cells (D) (Stelzer et al., 1993). E, 
nucleated erythroid precursors; B-Ly, precursor B-lymphoid cells; My, myeloid cells; Bl, blasts; Ly, 
lymphocytes. (B) CD3-positive cells in lymphocyte populations analysed for expression of CD4 and of 
CD8 showed no differences between cell numbers for either marker in either of the two mouse 
groups (CD8: control, 66.23 ±5.65% vs Gfi1b KO, 57.23 ±3.75%, NS, n=3 pairs; CD4: control, 27.77 
±10.54% vs Gfi1b KO, 28.90 ±6.48%, NS, n=3 pairs (student’s t-test). Data are expressed as mean ± 
SD. 
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Figure 4. 14 Lymphoid populations in bone marrow. 
T cells: comparison of CD4+/CD8+ ratio (proportion of CD4 helper T cells compared to CD8 
cytotoxic T cells) in bone marrow of control and Gfi1b KO mice; B-cells: detection in 
subpopulations 
(A) Lymphoid T-cell populations in the bone marrow (Ly, Figure 4.13 (A)) were gated on dot 
plots of CD4/ CD3 and CD8 / CD3 as proportions of total T cells (CD3). (B) CD3+ cells were then 
plotted on a dot plot of CD4 vs CD8 (A) and the CD4 / CD8 ratio was calculated as number of 
CD3+ CD4+ cells / CD3+ CD8+ cells (B) (n= 3 pairs). Data were expressed as mean ± SD, and 
student’s t-test was performed. No significant difference (NS) was found in CD4 / CD8 ratio 
between the 2 groups of mice. 
Lymphoid B-cell cells, distinguished by cell surface marker, CD45/B220, were determined for 
all gated populations (as defined in Figure 4.13 (D)). (C) shows histogram of lymphocyte (Ly) 
subpopulation. (D) No significant differences (NS) for numbers of CD45/B220-positive cells 
were seen in each subpopulation between controls and Gfi1b mice (D) (n= 3 pairs). E, 
nucleated erythroid precursors; B-Ly, precursor B-lymphoid cells; My, myeloid cells; Bl, blasts; 
Ly, lymphocytes. 
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No significant differences were seen between both groups of mice in terms of CD4/CD8 ratios 
(Figure 4.16 (B)) (Table 4.6), and B-cell CD45/B220 surface expression in spleen populations (Figure 
4.16 (C)) (Table 4.8). 
 
 
 
Figure 4. 15 Representative flow cytometry gating strategy for investigation of cell 
populations in spleens of control and Gfi1b KO mice for lymphoid and myeloid 
markers. 
This gating strategy consists of cells being acquired in (A) Forward scatter (FSC) vs side 
scatter (SSC) which is converted to single cell gating (B), based on FSC-height vs FSC-area. 
These single cells are then gated according to their SSC and CD45 (leucocyte common 
antigen, LCA) expression (C), resulting in scatter characteristics of the different populations 
of cells (D)(Colovai et al., 2004) . 
E, nucleated erythroid precursors; My, myeloid cells; Ly, lymphocytes. 
A B 
C D 
My 
  Gating  
E Ly 
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Figure 4. 16 Lymphoid populations in spleen. 
T cells: comparison of CD4+/CD8+ ratio (proportion of CD4 helper T cells compared to CD8 
cytotoxic T cells) in spleens of control and Gfi1b KO mice; B-cells: detection in subpopulations 
Lymphoid cell populations (Ly) in the spleen (Figure 4.11 (D)) were gated on dot plots of CD4/ 
CD3 and CD8 / CD3 as proportions of total T cells (CD3). CD3+ cells were then plotted on a dot 
plot of CD4 vs CD8 (A) and the CD4 / CD8 ratio was calculated as number of CD3+ CD4+ cells / 
CD3+ CD8+ cells (B) (n= 3 pairs). Student’s t-test was performed, and no significant difference 
(NS) was found in CD4 / CD8 ratio between the 2 groups of mice. 
Lymphoid B-cell cells, distinguished by cell surface marker, CD45/B220, were determined for 
all gated populations (as defined in Figure 4.15 (D)). (C) No significant differences (NS) for 
numbers of CD45/B220-positive cells were seen in each subpopulation between controls and 
Gfi1b mice (D) (n= 3 pairs). (D) shows histogram of lymphocyte (Ly) subpopulation. 
E, nucleated erythroid precursors; My, myeloid cells; Ly, lymphocytes. 
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Table 4. 6 Comparison of CD4 / CD8 ratios in lymphocyte populations of bone marrow and of 
spleen in control and in Gfi1b KO mice. 
Body Mouse CD4 / CD8 Ratio n p Normal 
organ group Lymphocytes (per group in pair) value range 
Bone marrow Control 0.43 ± 0.20 3 NS 0.50* 
 Gfi1bKO 0.51 ± 0.14 3   
Spleen Control 1.31 ± 0.13 3 NS 1.0 - 1.5^ 
 Gfi1bKO 1.24 ± 0.28 3   
Mean ratios of CD3+ CD4 / CD8 cells in lymphocyte populations of bone marrow and of spleens of 
control and of Gfi1b KO mice. No significant differences were seen in either pair of ratios between the 
two tissues in the two groups (bone marrow, NS; spleen, NS; n=3 (pairs) (student’s t-test). Data are 
expressed as mean ± SD. 
*(Zhao et al., 2012) 
^(Pinchuk and Filipov, 2008) 
 
 
Table 4. 7 Percentage of B-lymphoid cells expressing CD45/B220 in populations of bone marrow in 
control and in Gfi1b KO mice. 
Bone marrow   % CD45/B220  n p 
population Control Gfi1b KO (pairs) value 
Myeloid 5.01 ± 2.00 7.05 ± 3.42 3 NS 
Blasts 26.33 ± 5.86 21.14 ± 5.34 3 NS 
Lymphocytes 64.93 ± 5.77 62.53 ± 6.69 3 NS 
B-lymphoid 52.66 ± 38.25 45.94 ± 33.38 3 NS 
Erythroid 1.12 ± 1.56 1.54 ± 2.31 3 NS 
 
Proportion of cells expressing B-lymphoid marker CD45 / B220 in populations of bone marrow in control 
and in Gfi1b KO mice. No significant differences (NS) were seen in expression in any of the populations 
in the two groups (student’s t-test). Data are expressed as mean ± SD; n=3 (pairs). 
 
 
 
Table 4. 8 Percentage of B-lymphoid cells expressing CD45/B220 in populations of spleen in 
control and in Gfi1b KO mice. 
Spleen   % CD45/B220  n p 
population Control Gfi1b KO (pairs) value 
Myeloid 11.94 ± 5.02 5.88 ± 0.40 3 NS 
Lymphocytes 49.07 ± 6.03 17.34 ± 20.15 3 NS 
Erythroid 2.72 ± 0.39 1.59 ± 0.58 3 NS 
Proportion of cells expressing B-lymphoid marker CD45 / B220 in populations of spleen in control and in 
Gfi1b KO mice. No significant differences (NS) were seen in any of the populations in the two groups 
(student’s t-test). Data are expressed as mean ± SD; n=3 (pairs). 
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4.3.8.2 Myeloid cell populations 
Bone marrow 
In conjunction with the analyses of lymphoid cell surface markers, flow cytometric analyses of 
myeloid cell surface markers were also carried out on bone marrow cells. Harvested, filtered cell 
suspensions were incubated with antibodies tested against myeloid markers, LyG6 – neutrophils 
(granulocytes), F4/80 – mature macrophages, and the leucocyte common antigen, CD45. Cells were 
gated as for lymphoid studies (Figure 4.13 (A)), and proportions of LyG6-positive cells and F4/80- 
positive cells were calculated for each subpopulation (Table 4.9). No significant differences were 
seen between the two mouse groups for either marker in any of the subpopulations (Figure 4.17 (B) 
and (D), respectively). 
 
Spleen 
Similarly, harvested, filtered spleen cells were incubated with the same myeloid markers, and 
subpopulations gated (Figure 4.15 (D)) as was done for spleen subpopulations for lymphoid markers 
(4.3.8.1). Proportions of LyG6-positive cells and F4/80-positive cells were analysed (Rose et al., 
2012) and calculated for each subpopulation (Table 4.10). No significant differences were seen 
between the two mouse groups for either marker in any of the subpopulations (Figure 4.18 (A) and 
(D), respectively). 
. 
140  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 17 Subpopulations in bone marrow show no differences between control mice and 
Gfi1b mice for myeloid markers. 
(A) Histogram plot of granulocyte subpopulation showing majority of cells expressing myeloid 
marker, LyG6. (B) Histogram of control and Gfi1b KO subpopulations showing no differences of 
expression of LyG6. (C) Histogram plot of blast cell subpopulation showing expression of 
macrophage marker, F4/80. (D) Histogram of control and Gfi1b KO subpopulations showing no 
differences of expression of F4/80. 
E, nucleated erythroid precursors; B-Ly, precursor B-lymphoid cells; My, myeloid cells; Bl, 
blasts; Ly, lymphocytes. 
141  
 
 
 
 
 
Figure 4. 18 Subpopulations in spleen show no differences between control mice and Gfi1b mice 
for myeloid markers. 
 
(A) Histogram of control and Gfi1b KO subpopulations showing no differences of expression of 
LyG6. (B) Histogram plot of granulocyte subpopulation showing majority of cells expressing 
myeloid marker, LyG6. (C) Histogram plot of erythroid cell subpopulation showing no expression 
of macrophage marker, F4/80. (D) Histogram of control and Gfi1b KO subpopulations showing 
no differences of expression of F4/80. 
E, nucleated erythroid precursors; My, myeloid cells; Ly, lymphocytes. 
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Table 4. 9 Percentage of cells in bone marrow populations expressing myeloid marker and 
macrophage markers in control and in Gfi1b KO mice. 
 
Bone marrow % Ly6G n p % F4/80 n p 
population Control Gfi1b KO (pairs) value Control Gfi1b KO (pairs) value 
Myeloid 87.97 ± 1.23 84.18 ± 3.32 3 NS 10.91 ± 2.54 13.45 ± 5.67 3 NS 
Blasts 7.69 ± 2.97 8.95 ± 8.45 3 NS 32.64 ± 15.46 32.63 ± 5.84 3 NS 
Lymphocytes 0.64 ± 0.33 0.73 ± 0.07 3 NS 12.34 ± 7.06 17.05 ± 1.29 3 NS 
B-lymphoid 0.49 ± 0.28 0.72 ± 0.27 3 NS 10.82 ± 7.27 15.43 ± 5.14 3 NS 
Erythroid 0.45 ± 0.38 0.37 ± 0.09 3 NS 0.05 ± 0.03 0.09 ± 0.02 3 NS 
Proportion of cells expressing myeloid marker, Ly6G, and macrophage marker, F4/80, in populations of 
bone marrow in control and in Gfi1b KO mice. No significant differences (NS) were seen in either marker 
in any of the populations in the two groups (student’s t-test). Data are expressed as mean ± SD; n=3 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. 10 Percentage of cells in spleen populations expressing myeloid marker and macrophage 
markers in control and in Gfi1b KO mice. 
 
Spleen % Ly6G n p % F4/80 n p 
population Control Gfi1b KO (pairs) value Control Gfi1b KO (pairs) value 
Myeloid 64.50 ± 25.41 78.85 ± 12.41 3 NS 26.28 ± 17.28 8.61 ± 7.99 3 NS 
Lymphocytes 1.94 ± 0.61 1.39 ± 0.35 3 NS 8.70 ± 7.11 11.21± 10.27 3 NS 
Erythroid 2.09 ± 0.84 1.12 ± 0.72 3 NS 2.82 ± 0.75 0.51 ± 0.16 3 0.01 
Proportion of cells expressing myeloid marker, Ly6G, and macrophage marker, F4/80, in populations of 
spleen in control and in Gfi1b KO mice. No significant differences (NS) were seen in either marker in all 
populations in the two groups, except for percent expression of F4/80 in erythroid populations only (p=0.01) 
(student’s t-test). Data are expressed as mean ± SD; n=3 (pairs). 
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4.4 Discussion 
This chapter shows the results from the investigation into the effects of this conditional knock-out of 
Gfi1b through the megakaryocytic cell line on the cell biology of platelets and megakaryocytes, with 
the corresponding differences in cell and tissue morphology being presented and discussed in 
Chapter 5. The process by which circulating platelets are produced from megakaryocytes involves 
the commitment of haematopoietic stem cells to the megakaryocyte lineage, proliferation of 
progenitors, and the maturation of megakaryocytes to terminal differentiation which culminates in 
the production of platelets (Deutsch and Tomer, 2006, Guo et al., 2015, Geddis, 2010, Tozawa et al., 
2014, Wijgaerts and Freson, 2014). The purpose of the establishment of this conditional knockout 
mouse model was to study the function of the Gfi1b gene in the formation of platelets from 
megakaryocytes in these mice and its effects on the various stages of cell maturation and 
termination. 
 
The findings in this study showed that the major effects of the conditionally knocked out 
transcription factor Gfi1b in these mice were a 60-fold reduction in platelet counts and 4-fold 
prolonged tail bleeding times. There was significant reduction in blood haematological indices for 
erythrocytes observed for all parameters investigated, while there was no change in any white cell 
indices. In the investigation into the effects of on megakaryocyte formation and function, there was 
a significantly increased range of populations of megakaryocytes with higher DNA ploidy (replication 
of DNA content) observed in the bone marrow of Gfi1b KO mice. This may be in response to 
corresponding decreased platelet counts in these mice, which event would be likely to raise the rate 
of endomitosis, creating higher ploidy megakaryocytes in a feedback loop (Patel et al., 2005). 
Investigation into formation of megakaryocytes from progenitor cells also showed significantly 
increased numbers of colonies of megakaryocytes, from both bone marrow and especially from 
spleen (10-fold), grown in cell cultures. 
 
Measurement of thrombopoietin (TPO), the key regulatory cytokine involved in the production of 
platelets from megakaryocytes (Hitchcock and Kaushansky, 2014, Matsumura and Kanakura, 2002, 
Kuter, 2014, Mattia et al., 2002) showed plasma levels to be over two-fold higher in Gfi1b KO mice 
than in controls. This may be due to the effect of the reduced platelet mass in these mice on the 
production of TPO, which can increase in response to low platelet numbers (Machlus et al., 2014). 
TPO also is a major regulator of endomitosis, i.e. the replication of DNA content without cell division, 
and through binding to the cell surface receptor, c-Mpl, which is found both on megakaryocytes and 
on platelets, activates intracellular signal transduction pathways (Guo et al., 2015). 
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Spleens as percentage of total body weight were found to be enlarged 3-fold compared to controls, 
while all other body organs studied were unaffected. Investigation into erythroid precursor 
populations both in bone marrow and in spleen found that, in the spleen, there were significantly 
increased numbers and proportions in the more immature cells (ProE, EryA, EryB), with a 
comparative reduction in numbers in the more mature cells (EryC) of Gfi1b KO mice compared to 
controls. In contrast, in the bone marrow, there were no differences in any of the erythroid 
precursor population groups between the control mice and the Gfi1b KO mice. Examination of 
lymphoid and myeloid populations in both bone marrow and in spleen showed no differences in 
proportions or numbers between control and Gfi1b KO mice. This latter finding attests to the 
compartmentalisation of Gfi1b during haematopoiesis and its specific involvement with erythroid 
and megakaryocytic lineages only, with no contribution to the differentiation of lymphoid and 
myeloid blood cell lines (Anguita et al., 2017, van der Meer et al., 2010). 
 
These research findings are indications of the importance of this gene in maintaining normal platelet 
production in the mouse. In the process of assembling and releasing platelets, megakaryocytes 
become polyploid by endomitosis, and then undergo a maturation process in most of the cell 
cytoplasm which is transformed into many long processes (proplatelets), and the nucleus is expelled. 
The paucity of platelet numbers and the corresponding accumulation of megakaryocyte populations 
with increased DNA ploidy in the bone marrow suggest that this megakaryocytic production of 
platelets in these Gfi1b KO mice has been disrupted (Foudi et al., 2014). The almost complete 
absence of platelets in these mice indicates that the normal process of thrombopoiesis is arrested. 
The accumulation of high ploidy megakaryocytes, in the normal process, is required to support the 
large amounts of mRNA and proteins needed to form granules, and hence platelets, while still able 
to generate the demarcation system (DMS) which forms proplatelets (Machlus et al., 2014). 
However, in these Gfi1b KO mice, this process is being arrested at the point of polyploidisation, with 
megakaryocytes being unable to mobilise DMS to package granules, form proplatelets, and thence 
platelets. 
 
Increased levels of plasma TPO in Gfi1b KO mice in conjunction with this severe thrombocytopenia 
indicate a response to the markedly reduced number of circulating platelets (Singh et al., 2015). TPO 
binds to the c-Mpl receptors on the platelet cell surface and is thus removed from plasma. In the 
case of very few or no platelets, TPO is not removed from plasma and maintains a high circulating 
level. Consequently, this high level of TPO is able to act continuously on megakaryocytes, 
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overstimulating endomitosis, without, however, the continuation to mature platelet production, 
which is inhibited by the loss of Gfi1b. 
 
The bleeding diathesis in the Gfi1b KO mice was found to be quite marked as exemplified by the 
prolonged tail bleeding times and very low platelet counts. Indeed, these bleeding time 
measurements were actually only discontinued at 20 minutes’ duration due to time constraints, 
while indications at the time suggested a tendency of the mice to continue to bleed freely. The 
splenomegaly observed in the Gfi1b KO mice and the detection of expanded populations of 
erythroid precursors in the spleen may indicate an erythropoietic response to haemorrhage which is 
termed stress erythropoiesis. This is characterised by the rapid expansion of erythroblast precursors, 
which was observed in this mouse model (Paulson et al., 2011) (Kim et al., 2015). In contrast to 
humans, where this response occurs mainly in the bone marrow, murine stress erythropoiesis 
occurs primarily in extramedullary sites such as the spleen (producing splenomegaly) and liver, in 
preference to the bone marrow, which is more concerned with steady-state (homeostatic) 
erythropoiesis. Stress erythropoiesis involves progenitor cells and signals that are distinct from 
bone marrow steady-state erythropoiesis (Bennett et al., 2018, Lenox et al., 2009). This may also 
account for the unchanged proportions in the murine bone marrow erythroid cell populations of 
control mice compared to Gfi1b mice. 
 
The establishment of this mouse model to examine the effect of the transcription factor, Gfi1b, on 
the murine haematopoietic system, has given rise to a distinctive phenotype of defective platelet 
formation and subsequent effects on murine haemostasis (Khandanpour et al., 2010, Foudi et al., 
2014, Beauchemin et al., 2017, Vassen and Moroy, 2011). Our C57BL/6J mouse model was set up as 
a conditional knockout of the Gfi1b gene by the crossing of mice with homozygous floxed Gfi1b 
alleles with mice carrying a Pf4-Cre transgene (Tiedt et al., 2007). This has allowed the deletion of 
the Gfi1b gene along the megakaryocyte line only, thus avoiding the effects of lethality arising from 
deletion of Gfi1b in other cell types (Saleque et al., 2002). Control mice carried homozygous floxed 
Gfi1b alleles only (Gfi1bfl/fl), and were thus able to express normal Gfi1b function. 
 
Similar mouse models have been studied by others with results corroborating some of the findings of 
this study (Beauchemin et al., 2013, Beauchemin et al., 2017, Foudi et al., 2014). The 2017 study of 
Beauchemin et al was published after our group had started our Gfi1b KO project in 2014, so it was 
of interest to us to compare our findings. In their study, Gfi1bfl/fl mice were crossed with mice either 
expressing a Pf4-Cre transgene or a Rosa-Cre-ERT transgene, enabling a tamoxifen-inducible 
deletion. In the Gfi1bfl/fl Pf4-Cre mice, Beauchemin found that these mice were viable, but showed 
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internal bleeding and a 1,000-fold reduction of platelets owing to a failure of platelet production 
rather than a clearance of circulating platelets. Investigations into DNA ploidy of megakaryocytes 
from these mice, however, were carried out on lineage-depleted megakaryocyte cell cultures, rather 
than from fresh bone marrow cells, with a resultant differing pattern of ploidy populations. In this 
case, in contrast to our study, the 32N population was not affected by Gfi1b loss, the 16N fraction 
was notably decreased, and the 2N, 4N and 8N fractions were slightly increased compared to 
controls, whereas in our study, DNA ploidy fractions 2N – 8N were decreased, and those 16N and 
above were increased. Control mice in this case were heterozygous floxed Gfi1b (Gfi1bwt/fl) rather 
than homozygous, as in our study. The author’s reasoning was that Pf4-Cre deleted Gfi1b only in 
mature Gfi1bwt/fl megakaryocytes (>70%) but in Gfi1bfl/fl mice, megakaryocyte deletion started earlier 
and with higher efficiency (>99%). This meant that their controls did experience some deletion of 
Gfi1b, whereas our control mice showed completely normal megakaryocyte development and 
function. However, their cell culture studies did provide some pertinent insights into the possible 
mechanism for the failure of Gfi1b-deficient megakaryocytes to mobilise the DMS into forming 
proplatelets. This is discussed in Chapter 5. 
 
In the design of our mouse model, the premise for this study was that the gene for the transcription 
factor, Gfi1b, is conditionally deleted along the megakaryocytic line under the promoter of Pf4 (Tiedt 
et al., 2007). While the results that we achieved for this model were definitive, limitations for the 
construct of this model can be mentioned. Although the Pf4-Cre transgene is deemed to be active 
only from late megakaryocyte progenitors to mature megakaryocytes (Mathur et al., 2004), there 
have been other investigations into the possibility that Pf4 is expressed in cells outside of the 
megakaryocyte lineage (Pertuy et al., 2015, Schaffner et al., 2005, Calaminus et al., 2012). These 
authors found that Pf4 expression in mice was not restricted to the megakaryocytic/platelet lineage 
and was also present in foetal liver and bone marrow haematopoietic stem cells and their primitive 
progeny. Pf4-Cre mediated recombination, as well as being detected in all CD42-positive 
megakaryocytes, had also been found in cells of monocyte / macrophage origin, which had the 
potential of modifying the tissues involved with these cells.  Also, PF4 synthesis in humans had also 
been found to be constitutionally produced in monocytes. Their recommendations were that 
phenotypes observed in conditional knockout mouse models using the Pf4-Cre deleter system were 
to be interpreted in light of the possibility of Pf4-Cre activation outside the megakaryocyte lineage in 
order to be able to fully interpret results obtained from the use of the Pf4-Cre mouse model system. 
However, in this study, there was no evidence of changes in the lymphoid or myeloid cell lines 
investigated (Figures 4.17, 4.18). 
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Consequently, in order to create a more platelet / megakaryocyte-specific mouse model, with 
minimal expression  and recombination of a Cre transgene  in other cell populations  as has been 
noted, where there is the potential of producing phenotypes unrelated to  the deletion of proteins 
in platelets, there have been studies carried out to generate  Gb1bα-Cre transgenic mice  (Nagy et 
al., 2019).   Gp1bα is a platelet surface  membrane glycoprotein, which functions as a receptor for 
von Willebrand factor, and is highly specific for both platelets and megakaryocytes. The use of this  
transgene has been found to have highly specific recombination in the megakaryocytic lineage with 
no corresponding expression in other cell types,  thus removing the interference of other potential 
phenotypes in platelet and megakaryocyte studies.
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CHAPTER 5: 
CHARACTERISATION OF THE ROLE OF 
Gfi1b IN MURINE HAEMATOPOIESIS - 
Gfi1b CONDITIONAL KNOCK-OUT 
MOUSE MODEL – CELL MORPHOLOGY 
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5. Characterisation of the role of Gfi1b in murine haematopoiesis - 
Gfi1b conditional knock-out (KO) mouse model – cell morphology 
5.1 Introduction 
This chapter presents the corresponding morphological investigations into the characteristics of 
haematological tissue and cells (megakaryocytes and platelets) of mice with conditional knock-out of 
the transcription factor, Gfi1b, compared to control mice, as described in Chapter 4. All of these 
investigations, and the specimens required to conduct them, were carried out concurrently with the 
previous chapter’s accounts of the cell biology investigations. Aspects of megakaryopoiesis and the 
analyses of Gfi1b-deficient megakaryocytes were determined by the visual representation in 
haematological tissue of the effects of the loss of this transcription factor. 
 
5.2 Experimental design 
Morphological investigation into this mouse model involved the microscopic examination and the 
analyses of a number of cytological and tissue preparations. Blood films stained with May-Grünwald- 
Giemsa (MGG) stain were examined for platelet counts and blood cell anomalies. Stained cytospin 
preparations of bone marrow cells and of spleen cells were also visualised with MGG stain. 
Histological specimens for bone marrow and for spleen were assessed by the contrasting actions of 
haematoxylin and eosin staining. Bone marrow and spleen tissue were processed for transmission 
electron microscopy (TEM), and the resultant images observed and analysed. Immunohistochemical 
studies were carried out on bone marrow and spleen tissue with key markers for haematopoiesis 
and megakaryopoiesis. Statistical analyses were carried out on observed numbers of cells in blood 
and tissues by Student’s t test, two-tailed, type 2 (two-sample equal variance). 
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5.3 Results 
5.3.1 The loss of Gfi1b reduces the number of platelets seen in MGG-stained blood films 
Microscopical examination of MGG-stained blood films showed severely reduced numbers of 
platelets in those films from Gfi1b KO mice compared to those from control mice (Figure 5.1). 
Control platelets exhibited normal morphology, size, distribution, and granularity (Figure 5.1 (A), (C)) 
while those that could be seen on Gfi1b KO films were slightly larger with irregular granularity 
(Figure 5.1 (B), (D)). Gfi1b KO films also showed a number of Howell-Jolly bodies in red blood cells, as 
well as increased numbers of polychromatophilic red blood cells, neither of which featured on any 
control films. Observed platelets were counted per random field, confirming significantly reduced 
numbers of platelets in Gfi1b KO blood films compared to those in controls (5.2 ± 2.6 vs 130.0 ± 14.5, 
respectively, (mean ± SD); p=0.014; Student’s t test, two-tailed, type 2) (Table 5.1, Figure 5.2). 
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Figure 5. 1 Representative blood films stained with MGG stain from control mice and 
Gfi1b KO mice. 
Images show decreased number of platelets in Gfi1b KO mice compared to control 
mice. (A), (B): Magnification x 100. (A): Control mice. Black arrows denote platelets; (B): 
Gfi1b KO mice. Black arrow: single platelet observed in field; red arrow: Howell-Jolly 
body in red blood cell; blue arrows: polychromatophilic red blood cells. Inset images (C) 
and (D) show higher magnification (x 140) of platelets in (A) and (B), respectively. 
MGG, May-Grünwald-Giemsa. 
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Figure 5. 2 Confirmatory count of numbers of platelets observed in MGG-stained blood films 
in control mice compared with Gfi1b KO mice (Table 5.1). 
Platelets were observed in stained blood films, and counted per high power field, confirming 
a statistically significant difference between the two groups (in this case, p=0.014) of the 
previous platelet results obtained from full blood count. 
MGG, May- Grünwald-Giemsa. 
 
 
Table 5. 1 Increased numbers of platelets observed in blood films of Gfi1b KO mice compared to 
controls. 
 
   Mouse group  Number of platelets  Number of mice  Number of random fields  p value  
Control 130.0 ± 14.5 2 5 0.014 
Gfi1b KO 5.2 ± 2.6 4 6  
Data are expressed as mean counts ± SD. Statistical analysis used was Student’s t-test, unequal 
sample size, equal variances, two-tailed, type 2. 
 
 
5.3.2 Megakaryocytes from harvested bone marrow cells show morphological differences in 
cytospin preparations 
Filtered bone marrow cell suspensions were processed for cytospin slides (~5 x 104 cells per slide) 
and stained with MGG. Megakaryocytes of control mice showed normal morphology (Figure 5.3 (A, 
C, E)), with a centrally located, multi-lobed nucleus and pale cytoplasm, while those of Gfi1b KO mice 
showed more eccentric nuclei, with peripherally placed lobes (Figure 5.3 (B, D, F)). 
In the cell suspensions processed from spleen, there were insufficient numbers of cells for the 
detection of any megakaryocytes for analysis, both in controls and in Gfi1b KO mice. 
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Figure 5. 3 Representative MGG-stained cytospin preparations of harvested filtered bone marrow 
cells from the femurs of control mice and Gfi1b KO mice. 
(A), (C), (E) control mice; (B), (D), (F) Gfi1b KO mice; magnification x 40. Red arrows denote 
megakaryocytes. 
MGG, May-Grünwald-Giemsa 
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5.3.3 Morphological differences are seen in megakaryocytes in tissue 
5.3.3.1 Increased numbers of atypical megakaryocytes are seen in bone marrow of Gfi1b KO mice 
compared to controls 
Stained sections of bone marrow from murine sternum showed significantly more megakaryocytes 
observed per field in Gfi1b KO mice than in control mice (25.5 ± 6.7 vs 11.2 ± 3.1, respectively (mean 
± SD); p<0.005; Student’s t-test) (Table 5.2) (Figure 5.6). The higher magnification showed clearly the 
morphological differences between the two groups of megakaryocytes, namely the centrally located, 
multi-lobed nucleus and pale cytoplasm of controls while those of the Gfi1b KO mice showed 
characteristic eccentric horseshoe-shaped lobulated nuclei. 
 
Figure 5. 4 Representative H&E stained histological sections of bone marrow (sternum) from 
control mice and Gfi1b KO mice. 
(A) Control mice; (B) Gfi1b KO mice; Magnification x 40. (A), (B): Black arrows indicate 
megakaryocytes. Inset(C), (D): magnified images (x 100) of control and Gfi1b KO 
megakaryocytes (A) and (B), respectively. H&E, haematoxylin and eosin. 
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5.3.3.2 Loss of Gfi1b in the megakaryocytic line produces a ten-fold increase in the spleen of numbers 
of megakaryocytes with abnormal morphology 
Spleens from Gfi1b KO mice stained with H&E showed an approximate ten-fold increase in the 
number of megakaryocytes compared with those of control mice (19.8 ± 5.7 vs 1.7 ± 1.1, respectively 
(mean ± SD); p<0.0001; Student’s t-test) (Table 5.2) (Figure 5.6). As observed in other morphological 
examinations, these megakaryocytes were distinctly different from control megakaryocytes, having 
eccentric nuclei with peripheral lobes (Figure 5.5 (C) and (D), respectively). 
 
 
Figure 5. 5 Representative H&E stained histological sections of spleen from control mice 
and Gfi1b KO mice. 
(A) Control mice; (B) Gfi1b KO mice; magnification x 20. (A), (B): Black arrows indicate 
megakaryocytes. Inset (C), (D): magnified images (x 60) of control and Gfi1b KO 
megakaryocytes (A) and (B), respectively. H&E, haematoxylin and eosin. 
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Figure 5. 6 Numbers of megakaryocytes observed per field of *bone marrow (sternum) and 
spleen (2 independent observers) in control mice compared with Gfi1b KO mice (Table 
5.2). 
*More usable images for spleen were able to be viewed, compared to those for bone marrow. 
 
 
 
 
Table 5. 2 Increased numbers of megakaryocytes are observed in H&E-stained sections of bone 
marrow and of spleen of Gfi1b KO mice compared to controls. 
 
Body Mouse Number of Number of Number of p 
organ group megakaryocytes Mice* random fields value 
Bone marrow Control 11.2 ± 3.1 3 12 <0.005 
 Gfi1bKO 25.5 ± 6.7 2 11  
Spleen Control 1.7 ± 1.1 5 13 <0.0001 
 Gfi1bKO 19.8 ± 5.7 5 14  
Mean values for numbers of megakaryocytes counted per random field (magnification 20x) in H&E- 
stained sections of bone marrow and of spleens of control and of Gfi1b KO mice. Significantly 
increased numbers were seen in sections from both bone marrow and from spleens in the Gfi1b KO 
mice (n=2, 5 pairs, respectively) compared to the control mice (n=3, 5 pairs, respectively) (bone 
marrow, p<0.005; spleen, p<0.0001; Student’s t-test, unequal sample, equal variance, two-tailed, 
type 2). Data are expressed as mean ± SD. 
*Only serviceable images for bone marrow were used for analysis. 
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5.3.4 Abnormal ultrastructure observed in megakaryocytes of Gfi1b KO mice compared to 
those of control mice in both bone marrow and spleen tissue by transmission electron 
microscopy (TEM) 
Processed tissue from the bone marrow (Figure 5.7) and spleens (Figure 5.8) of two control and two 
Gfi1b KO mice was examined by TEM, with a total of 36 megakaryocytes (8, control bone marrow; 
13, Gfi1b KO bone marrow; 7, control spleen; 8, Gfi1b KO spleen) being analysed. In all instances, 
control mice tissue showed prominent α-granules (g), structured demarcation membrane systems 
(DMS) extending concentrically around the nucleus, and well-defined platelet territories (pt) in the 
cytoplasm of the megakaryocytes in both bone marrow (Figure 5.7 (A), (C)) and spleen (Figure 5.8 
(A), (C)). In contrast, all Gfi1b KO mice tissue displayed no α-granules, poorly defined or no platelet 
territories, and immature DMS, concentrated at one end of the megakaryocyte, in both bone 
marrow (Figure 5.7 (B), (D)) and spleen (Figure 5.8 (B), (D)). Evidence of normal platelet formation in 
the Gfi1b KO murine megakaryocytes was not seen. 
 
In normal megakaryocytes, the DMS separates the cell cytoplasm into smaller connected platelet 
territories and becomes the plasma membranes of proplatelets (Ru et al., 2016). Several models of 
the transformation mechanism of DMS have been proposed, that it is either transformed from 
invaginated megakaryocyte plasma membrane (and hence is known as IMS, invaginated membrane 
system, in some reports) or that it is transformed directly from endoplasmic reticulum (ER) and Golgi 
apparatus in the cytoplasm, or that it is a combination of both (Eckly et al., 2014). In any case, the 
megakaryocyte tissue from the Gfi1b KO mice showed the accumulation of amorphous DMS mass, 
with no distinctive territories. This suggested that the loss of Gfi1b arrested the thrombopoietic 
process at DMS production and was unable to progress to produce proplatelets (Figures 5.7 (D), 5.8 
(D)). The lack of any granules seen in these cells implied that the production and packaging of 
granules were also blocked, while in control megakaryocytes, definitive platelet territories with 
accompanying granules were clearly seen, indicating progress toward the formation of proplatelets 
(Figures 5.7 (C), 5.8 (C)). 
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Figure 5. 7 Representative transmission electron micrographs of megakaryocytes in bone marrow 
from control mice and Gfi1b KO mice. 
(A) Control mice; (B) Gfi1b KO mice; Magnification x 2500. (C), (D): Magnification of boxed 
regions from (A) and (B) respectively (magnification x 13500). 
e, emperipolesis (2 cells contained within the cytoplasm); n, nucleus; dms, demarcation 
membrane system; pt, platelet territories; g, α-granules, m, mitochondria. 
158  
 
 
Figure 5. 8 Representative images of transmission electron micrographs of megakaryocytes in spleen 
from control mice and Gfi1b KO mice. 
(A) Control mice; (B) Gfi1b KO mice; Magnification x 2500. (C), (D): Magnification of boxed regions 
from (A) and (B) respectively (magnification x 13500). 
e, emperipolesis (2 cells contained within the cytoplasm); n, nucleus; dms, demarcation membrane 
system; pt, platelet territories; g, α-granules, m, mitochondria. 
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5.3.5 Immunohistochemistry (IHC) 
Immunohistochemical analyses of bone marrow and spleen tissue from 2 controls and 2 Gfi1b KO 
mice were carried out for three different epitopes: von Willebrand factor (vWf), CD34, and 
myeloperoxidase (MPO). Interpretation and quantification of IHC for these epitopes in these tissues 
were evaluated according to the phenomena that were being investigated (Fedchenko and 
Reifenrath, 2014, de Matos et al., 2010, Meyerholz and Beck, 2018). vWf was used as a tool to 
quantify the numbers of megakaryocytes in each tissue (Tomer, 2004); CD34 was used as it has been 
seen to be an aberrant marker in GFI1B-related disorders, as well as myelodysplastic syndromes 
(Tang et al., 2011, Insuasti-Beltran et al., 2012, Rabbolini et al., 2017a); and MPO was used as an 
indication of myeloid activity and stress haematopoiesis in bone marrow and spleen (Pulli et al., 
2013). Positive control tissue was processed with each epitope tested. 
 
5.3.5.1 vWf staining shows increased numbers of megakaryocytes in both bone marrow and spleen of 
Gfi1b KO mice compared to controls. 
In order to highlight the incidence of megakaryocytic numbers in both bone marrow and spleen, vWf 
staining was applied to these tissues. vWf is a highly specific and the most useful marker for 
identifying megakaryocytes (Chuang et al., 2000, Rehg et al., 2012), being expressed in the 
cytoplasm of these cells in α-granules. Megakaryocytes were identified in these tissues by the 
intensity of the staining and the recognisable morphological characteristics of the megakaryocytes, 
namely large, multilobulated cells (Figure 5.9, 5.10). The numbers of megakaryocytes were counted 
in 6 random high-powered fields per tissue and expressed as mean ± SD (Table 5.3, Figure 5.11). 
 
For bone marrow, numbers of megakaryocytes in control tissue vs those of Gfi1b KO were 21.2 ± 3.0 
vs 36.0 ± 7.3, respectively (p<0.001), showing a significant increase in the knock-out mice. In spleen 
tissue, however, there was a much greater increase in megakaryocyte numbers in Gfi1b KO mice 
compared to controls (74.2 ± 18.8 vs 3.5 ± 2.1, p<0.00001). In both types of tissue, the morphological 
aspects of megakaryocytes of the Gfi1b KO mice correlated with those seen in histological and TEM 
analyses: namely, the peripherally-localised, ring-shaped lobulated nuclei (Figure 5.9 (F), Figure 5.10 
(F)) compared to the control megakaryocytes of centrally-located, multi-lobulated nuclei (Figure 5.9 
(E), Figure 5.10 (E)). Intensity of vWf staining in control megakaryocytes appeared darker compared 
to that in the Gfi1b KO megakaryocytes (Figures 5.9 (E), 5.10 (E); 5.9 (F), 5.10 (F), respectively), 
suggesting that there was less intense staining in these latter cells due to marked reduction, or 
absence, of granules expressing vWf. 
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Figure 5. 9 Representative images of immunohistochemistry staining for von Willebrand factor (vWf) 
in bone marrow (sternums) of control mice and Gfi1b KO mice. 
(A) Control mice: Magnification x 10.23. Boxed area of control mouse bone marrow (C, 
magnification x 48.65) shows megakaryocytes (blue arrows) with intense staining of vWf in the 
cytoplasm, with clearly defined central multi-lobulated nuclei (inset (E), magnification x 69.3). (B) 
Gfi1b KO mice: Magnification x 10.79. Boxed area of Gfi1b KO mouse bone marrow (D, 
magnification x 43.18) shows megakaryocytes (red arrows) with lighter staining of vWf in the 
cytoplasm, with peripherally-localised, ring-shaped lobulated nuclei (inset (F), magnification x 
61.06). 
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Figure 5. 10 Representative images of immunohistochemistry staining for von Willebrand factor 
(vWf) in spleens of control mice and Gfi1b KO mice. 
(A) Control mice: Magnification x 5. Boxed area of control mouse spleen (C, magnification x 40) 
shows megakaryocytes (blue arrows) with intense staining of vWf in the cytoplasm, with clearly 
defined central multi-lobulated nuclei (inset (E), magnification x 61.06). Very few megakaryocytes 
can be seen. (B) Gfi1b KO mice: Magnification x 5. Boxed area of Gfi1b KO mouse bone marrow (D, 
magnification x 40) shows megakaryocytes (red arrows) with lighter staining of vWf in the 
cytoplasm, with peripherally localised, ring-shaped lobulated nuclei (inset (F), magnification x 
61.06). Many stained megakaryocytes can be seen throughout the Gfi1b KO spleen tissue. 
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Figure 5. 11 Numbers of vWf-positive megakaryocytes observed in bone marrow (sternum) 
and spleen. 
Cells in 6 random high-power fields each were counted in tissues from control mice and 
compared with those tissues from Gfi1b KO mice (Table 5.3) 
 
 
 
 
 
 
Table 5. 3 Increased numbers of vWf-positive megakaryocytes are observed in Gfi1b KO mice 
compared to those of controls. 
 
Body Mouse Number of Number of p 
organ group megakaryocytes random fields value 
Bone marrow Control 21.2 ± 3.0 6 <0.001 
 Gfi1bKO 36.0 ± 7.3 6  
Spleen Control 3.5 ± 2.1 6 <0.00001 
 Gfi1bKO 74.2 ± 18.8 6  
Data are expressed as mean counts ± SD from 6 random high-powered fields per tissue. Statistical 
analysis used was Student’s t test, two-tailed, type 2. 
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5.3.5.2 CD34 is expressed in the megakaryocytes of Gfi1b KO mice in both bone marrow and spleen but 
not in those of control mice 
CD34 is a membrane antigen and is used as a marker for identifying pluripotent haematopoietic 
stem or progenitor cells (Rehg et al., 2012). Its expression in the megakaryocytic lineage is found on 
early progenitor cells, such as promegakaryoblasts and megakaryoblasts, and is gradually lost as cells 
differentiate and mature (Insuasti-Beltran et al., 2012, Tang et al., 2011). Immunohistochemical 
staining for CD34 in the bone marrow and the spleen of control mice showed no evidence of it in 
mature megakaryocytes (Figure 5.12 (C) (E), Figure 5.13 (C), (E), respectively), with some cell 
membrane expression of CD34 in other progenitor cells. In contrast, megakaryocytes in the bone 
marrow and the spleen tissue of Gfi1b KO mice, stained positively for CD34 (Figure 5.12 (D) (F), 
Figure 5.13 (D), (F), respectively). 
 
Normally, CD34 is not expressed on terminally differentiated haematopoietic cells. However, its 
presence on the megakaryocytes in the Gfi1b KO mice tissue indicates an atypical expression of this 
transmembrane protein in these cells. Mature megakaryocytes with high-level CD34 expression are 
seen to be prognostically important in myelodysplastic syndromes (Tang et al., 2011), and platelet 
CD34 expression has been seen as a common feature in patients with dysfunctional GFI1B (Rabbolini 
et al., 2017a). These reports suggest that the CD34 expression in the Gfi1b KO mice indicates 
perturbation in megakaryocyte development as an effect of the loss of Gfi1b function. 
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Figure 5. 12 Immunohistochemistry staining for CD34 in bone marrow (sternums) of control 
mice and Gfi1b KO mice. 
 
(A) Control mice: Magnification x 5.95. Boxed area of control mouse bone marrow (C, magnification 
x 40) shows megakaryocytes (black arrows) with no staining for CD34, with normal central multi- 
lobulated nuclei and pale cytoplasm (inset (E), magnification x 61.06) Brown arrows indicate cell 
membrane expression of CD34 in a few progenitor bone marrow cells. (B) Gfi1b KO mice: 
Magnification x 10. Boxed area of Gfi1b KO mouse bone marrow (D, magnification x 40) shows 
megakaryocytes (red arrows) with distinct staining for CD34, with the Gfi1b KO characteristically 
defined ring-shaped lobulated nuclei (inset (F), magnification x 61.06). Blue arrow denotes 
unstained but abnormal megakaryocyte. 
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Figure 5. 13 Immunohistochemistry staining for CD34 in spleens of control mice and Gfi1b 
KO mice. 
(A) Control mice: Magnification x 5. Boxed area of control mouse spleen (C, magnification x 
40) shows megakaryocytes (black arrows) with no staining for CD34, with normal central 
multi-lobulated nuclei and pale cytoplasm (inset (E), magnification x 61.06) Red arrows 
indicate cell membrane expression of CD34 in a few progenitor cells. (B) Gfi1b KO mice: 
Magnification x 5. Boxed area of Gfi1b KO mouse spleen (D, magnification x 40) shows 
megakaryocytes (red arrows) with distinct staining for CD34 in the centrally located 
cytoplasm, and with the Gfi1b KO characteristically defined ring-shaped lobulated nuclei 
(inset (F), magnification x 61.06). 
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5.3.5.3 Increased MPO activity is observed in both bone marrow and spleen tissue of Gfi1b KO mice 
compared to that of control mice 
Myeloperoxidase (MPO) is a major enzyme in inflammatory and degenerative or oxidative processes, 
synthesised in early myeloid cells (Hachiya et al., 2000). It is stored in neutrophil primary granules 
and is detected in myeloblasts and immature myeloid cells (Pinkus and Pinkus, 1991). The expression 
of MPO peaks with late myeloblasts and promyelocytes, and is greatly reduced at later stages of 
differentiation. Increased expression of this enzyme can be a marker of stress in tissue and is 
associated with a number of haematological disorders (Pulli et al., 2013). 
 
Immunohistochemical staining of bone marrow tissue for MPO showed an increase in areas of cells 
with intensely stained cytoplasm in Gfi1b KO mice (Figure 5.14 (B), (D)) compared to that of control 
mice (Figure 5.14 (A), (C)). Positively-stained cells were denoted as those whose cytoplasm was 
intensely stained which were deemed to be granulocytes, as only faint, non-specific staining could 
be seen in the cytoplasm of megakaryocytes from both control and Gfi1b KO groups (Figure 5.14 (E), 
(F), respectively). These megakaryocytes also showed the morphological characteristics of controls 
(Figure 5.14 (C), (E)) and Gfi1b KO mice (Figure 5.14 (D), (F)), respectively as observed in other 
analyses in this chapter. 
 
In spleen tissue of Gfi1b KO mice, there was an indication of increased numbers of cells positive for 
MPO staining as denoted by intense cytoplasmic staining (Figure 5.15 (B), (D)) compared with that of 
control mice (Figure 5.15 (A), (C)). Unspecified lighter staining was also seen in control tissue. 
However, megakaryocytes from both types of tissue showed no staining, as would be expected, and 
once, again, showed morphological characteristics pertaining to each group as described previously 
(control: Figure 5.15 (E); Gfi1b KO: Figure 5.15 (F)). 
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Figure 5. 14 Immunohistochemistry staining for myeloperoxidase (MPO) in bone marrow (sternums) 
of control mice and Gfi1b KO mice. 
(A) Control mice: Magnification x 5.4. Boxed area of control mouse bone marrow (C, magnification x 
40) shows megakaryocytes (black arrows) with indications of pale staining for MPO in the 
cytoplasm, with normal nuclei (inset (E), magnification x 61.06) Dark pink arrows indicate 
cytoplasmic expression of MPO in myeloid bone marrow cells. (B) Gfi1b KO mice: Magnification x 
8.41. Gfi1b KO tissue shows increased areas of highly stained cells compared to control. Boxed area 
of Gfi1b KO mouse bone marrow (D, magnification x 40) shows megakaryocytes (red arrows) also 
with indications of pale staining for MPO in the abnormally centrally located cytoplasm, and the 
Gfi1b KO characteristically defined ring-shaped lobulated nuclei (inset (F), magnification x 61.06). 
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Figure 5. 15 Immunohistochemistry staining for MPO in spleens of control mice and Gfi1b 
conditional knockout mice. 
(A) Control mice: Magnification x 5. Boxed area of control mouse spleen (C, magnification x 40) 
shows megakaryocytes (black arrows) with no staining for MPO in the cytoplasm, with normal 
nuclei (inset (E), magnification x 61.06) Dark pink arrows indicate cytoplasmic expression of 
MPO in myeloid cells. (B) Gfi1b KO mice: Magnification x 5. Gfi1b KO tissue shows more areas of 
intense staining of MPO compared to control. Boxed area of Gfi1b KO mouse bone marrow (D, 
magnification x 40) shows megakaryocytes (red arrows) also with no staining for MPO in the 
abnormally centrally located cytoplasm, and with the Gfi1b KO characteristically defined ring- 
shaped lobulated nuclei (inset (F), magnification x 61.06). Expression of MPO can be seen in the 
cytoplasm of myeloid cells. 
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5.4 Discussion 
This chapter deals with results from the morphological investigation, examination and analyses of 
haematological cells and tissue from C57BL/6J mice with the conditional knockout (KO) of the 
transcription factor Gfi1b down the megakaryocyte line under the Pf4 promoter. These studies are in 
conjunction with the cell biology aspects of this mouse model system as described in Chapter 4. In 
comparison to control mice with floxed Gfi1b and normal Gfi1b expression, the major results from 
these Gfi1b KO mice showed marked morphological differences, and significantly different 
frequencies of platelet and of megakaryocyte numbers, in the tissues studied. In blood films of Gfi1b 
KO mice, an average of 5 or fewer platelets were seen per high-powered field, compared to an 
average of 130 platelets seen in films of control mice. Those of Gfi1b KO mice that were observed 
were of a comparative larger size and irregular granularity. Blood films of these mice also showed 
evidence of Howell-Jolly bodies in red blood cells, and the frequent appearance of 
polychromatophilic red blood cells that were not seen in the blood films of the control mice. 
 
The most definitive result was the confirmation, in all the approaches attempted, of the atypical 
morphology of megakaryocytes of Gfi1b KO mice compared to those of control mice. In images from 
stained cytospin preparations, stained histological tissue, and immunohistochemical staining in both 
bone marrow and spleen tissue, these abnormal megakaryocytes showed characteristic eccentric 
nuclei with peripherally placed lobes. This was in contrast to control megakaryocytes which 
displayed normal morphological characteristics of centrally located, multi-lobed nuclei and pale 
concentric cytoplasm. Under more magnified examination of these cells by transmission electron 
microscopy (TEM), it could be seen that megakaryocytes of control mice, in both bone marrow and 
spleen, showed the formation of defined platelet islands, with accompanying production of α- 
granules, in the demarcation system (DMS) arranged concentrically around a multi-lobed nucleus. In 
contrast, the megakaryocytes of Gfi1b KO mice displayed eccentrically or peripherally placed nuclei, 
rare α-granules, poorly defined or no platelet territories, and immature DMS, concentrated at one 
end of the megakaryocyte, in both bone marrow and in spleen. 
 
The numbers of megakaryocytes seen in both bone marrow and spleen tissue of Gfi1b KO mice were 
significantly increased compared to those of control mice. Quantitation of megakaryocytes observed 
in high-powered fields of stained histology sections of bone marrow showed a twofold increase in 
Gfi1b KO mouse tissue compared to that of controls. In spleen sections of Gfi1b KO mice, however, 
there was an even more marked increase of megakaryocytes, being 10-fold higher than those in 
control tissue. As an adjunct to these investigations, immunohistochemical staining of formalin-fixed 
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paraffin-embedded (FFPE) bone marrow (sternum) and spleen tissue for von Willebrand factor (vWf) 
was employed to highlight and confirm numbers of megakaryocytes in these tissues. vWf is 
produced constitutively in megakaryocytes and is a highly specific and the most useful marker for 
identifying megakaryocytes (Chuang et al., 2000, Tomer, 2004). Identification and quantitation of 
megakaryocytes in these tissues by this method showed approximately 1.5-fold increase in numbers 
of megakaryocytes in bone marrow, and 20-fold increase in spleen tissue of Gfi1b KO mice compared 
to controls. 
 
In the megakaryocytic lineage, normal expression of CD34, an important regulator of cell trafficking 
and cellular adhesion in the haematopoietic system, has been detected only in early 
progenitors, promegakaryoblasts and megakaryoblasts, and progressively decreasing in expression 
as megakaryocytes mature (Insuasti-Beltran et al., 2012, Tomer, 2004). Immunohistochemical 
staining carried out to detect the presence of CD34 in both bone marrow and spleen tissue of both 
groups of mice showed that, while there was no evidence of CD34 staining seen in mature 
megakaryocytes of control mice in either tissue, there was distinct positive staining for CD34 seen in 
the atypical megakaryocytes in both types of tissue of Gfi1b KO mice. Expression of CD34 on mature 
megakaryocytes has been associated with severe cytopenia, increased myeloblasts, cytogenetic 
abnormalities, and shorter survival (Tang et al., 2011). This has been observed in the investigation of 
myelodysplastic syndromes, in both normal and abnormal megakaryocytes, with the pattern of CD34 
staining including the cytoplasm, the membrane, as well as the Golgi apparatus. However, most 
pertinent to our findings is the association of CD34 expression in the platelets and megakaryocytes 
of different families with mutations or variants of GFI1B (Rabbolini et al., 2017a, Monteferrario et 
al., 2014, Kitamura et al., 2016, Uchiyama et al., 2017, Schulze et al., 2017). GFI1B in its function as a 
transcriptional repressor, normally represses the CD34 promoter, but this is weakened in zinc-finger 
(ZnF) mutations of GFI1B, leading to increased CD34 expression in these afflicted families (Rabbolini 
et al., 2017a). With the loss of Gfi1b in these KO mice down the megakaryocytic lineage, the usual 
repression of CD34 appears to be diminished, as demonstrated by its persistent expression in 
megakaryocytes in bone marrow and spleen tissue. 
 
An indicator of stress in tissues, myeloperoxidase (MPO) is a major enzyme in inflammatory and 
degenerative or oxidative processes, synthesised in early myeloid cells (Hachiya et al., 2000). An 
assessment of the level of inflammatory processes in bone marrow and spleen by 
immunohistochemical staining for MPO, showed that, while megakaryocytes from both mouse 
groups showed no detection of this enzyme, as would be expected, there were areas of increased 
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numbers of cells positive for MPO, as denoted by intense cytoplasmic staining, in bone marrow, and 
especially in spleen tissue, of Gfi1b KO mice, compared to control tissue. However, both types of 
tissue showed megakaryocytes with morphological characteristics pertaining to each group as 
described previously. 
 
These research findings are indications that the loss of the transcription factor, Gfi1b, down the 
megakaryocyte line in these mice, has a disruptive effect on the development and differentiation of 
megakaryocytes through to maturity. The demarcation membrane system (DMS) in the 
megakaryocyte develops to provide additional membrane for the formation of platelets. During the 
various stages of normal megakaryocyte development, the DMS becomes dispersed throughout the 
cytoplasm, dividing it into similarly-sized small regions which form platelet precursors or “islands” 
(Ru et al., 2015). Current explanations for DMS formation and development in megakaryocytes 
include the proposition that the DMS is contiguous with the cell-surface plasma membrane which 
invaginates into the cytoplasm (Mahaut-Smith et al., 2003, Schulze et al., 2006); that DMS is derived 
from the plasma membrane, while Golgi bodies and rough endoplasmic reticulum (rER) in the 
cytoplasm contribute membrane to the growing DMS (Eckly et al., 2014); or that Golgi bodies and 
rER are in continuity with, and are transforming into, DMS, with the latter phenomenon being more 
prevalent that the infolding of the plasma membrane (Ru et al., 2015). Regardless of the disputed 
source of membrane for the DMS, our findings were that the megakaryocytes of the Gfi1b KO mice 
appear to be arrested at a premature stage of development, with primitive forms of the 
demarcation membrane system present in the cytoplasm, with no advancement to the formation of 
any platelet islands, and hence proplatelets, and no production at all of α-granules, or indeed any 
other type of granule. 
 
The findings of severe thrombocytopenia and abnormal platelet morphology, coupled with the 
appearance of lack of platelet formation in these abnormal megakaryocytes, indicate that the effect 
of the knocked-out Gfi1b has stunted the ability of these megakaryocytes to produce platelets. The 
indications of increased MPO in Gfi1b KO mouse tissue, and the appearance of Howell-Jolly bodies 
in red blood cells and numbers of polychromatophilic red blood cells in blood films from these mice 
point to manifestations of stress-induced haematopoiesis (Zhao and Baltimore, 2015). Howell-Jolly 
bodies are basophilic nuclear remnants found in red cells, indicating incomplete enucleation of 
these cells. Their presence usually indicates a damaged or poorly functioning spleen, as these 
inclusions would be removed by a normally functioning spleen (Sears and Udden, 2012). With the 
evidence of splenomegaly in the Gfi1b KO mice, it would suggest that this may also indicate 
hyposplenic function, which would account for the appearance of these inclusions. The appearance 
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of polychromatophilic (blue-grey) erythrocytes in the blood films of Gfi1b KO mice indicates 
immature red blood cells with residual RNA. Normally, these cells remain in bone marrow before 
their designated release, but when bone marrow is stressed due to blood loss or other conditions, 
erythropoiesis is increased, and these cells are released prematurely into the bloodstream. In the 
mouse, this can also occur from extramedullary haematopoiesis in the spleen (Iseki et al., 2008, 
Johns and Christopher, 2012, O'Connell et al., 2015). Their presence in these blood films suggests an 
erythropoietic response in these mice to anaemia or blood loss. 
 
Various mouse models have been developed recently in order to determine the effects of the loss of 
Gfi1b on megakaryopoiesis and erythropoiesis (Saleque et al., 2002, Foudi et al., 2014, Vassen and 
Moroy, 2011, Vassen et al., 2014, Beauchemin et al., 2013, Beauchemin et al., 2017). Comparisons of 
differing methods to induce conditional deletion of the Gfi1b gene were employed, depending on 
the stage of cell development. These included the use of an interferon-inducible deletion, or the 
cross-breeding of Gfi1bfl/fl with Mx-Cre mice, which efficiently excised floxed alleles in the bone 
marrow upon injection of polyinosinic: polycytidylic acid (an immunostimulant), or a doxycycline- 
inducible Cre transgene, TetO-Cre, as conditional knockout. In most of these studies, these 
approaches also included a similar design to our research i.e. Gfi1bfl/fl or Gfi1bwt/fl mice were also 
cross-bred with Pf4-Cre transgenic mice. In all accounts of the Pf4-Cre conditional knockout mice, 
findings similar to own were observed. Numbers of megakaryocyte were found to be increased in 
these mice by 5- to 10-fold, with high ploidy, and highly disturbed morphology. Gfi1bfl/fl PF4-Cre 
megakaryocytes contained less cytoplasm, fewer dense granules, and a multi-lobulated, ring-shaped 
nucleus localised peripherally, giving an almost “inside-out” appearance, and indicating a disturbed 
cytoskeletal organisation. These mice showed a stress-induced splenic erythropoiesis, which was 
postulated as a probable consequence of their substantial bleeding due to the severe 
thrombocytopenia. MGG-stained blood films showed reduced numbers of platelets and red cells 
displaying Howell-Jolly bodies. TEM images showed poorly defined DMS and other cellular 
structures, also with very few granules. However, whereas in our model, no α-granules were 
detected at all in TEM images of Gfi1b KO mice, a similar study found the presence of a few granules 
restricted to a single zone in the cytoplasm – the “pocket” formed by the nucleus (Beauchemin et al., 
2017). Interestingly, despite increased numbers of megakaryocytes seen in bone marrow in each of 
these reported studies no fibrosis has been observed in the tissue. Normally, fibrosis is linked with 
megakaryocyte proliferation and differentiation, whereby secretion of the contents of α-granules 
within the bone marrow contribute to the progression of fibrosis (Malara et al., 2018). As 
megakaryocytes in these Gf1ib KO mice lack α-granules, bone marrow fibrosis would be predicted to 
be less prominent in these mice. 
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Our research has been able to suitably replicate these findings from these previous studies, and 
contributes significantly to understanding the essential role that Gfi1b plays in megakaryopoiesis in 
the mouse. However, these findings do not cover the full functionality of Gfi1b, which is also 
essential for erythropoiesis, and indeed, proves lethal in embryonic mice if is deleted (Saleque et al., 
2002). Conditional knockout studies of Gfi1bfl/fl mice crossbred with erythroid-specific 
(erythropoietin receptor, EpoR) Cre transgenic mice have shown that erythroid-specific ablation of 
Gfi1b allows full gestation of mice, but very few have survived to adulthood (Vassen et al., 2014). It 
appears that the loss of Gfi1b has a profound effect on thrombopoiesis at the point between 
generation of DMS and formation of proplatelets and granule production. Further research could 
involve a more thorough investigation into the expression of proteins involved in endocytic 
pathways and DMS formation, such as dynamin 2 and rubicon; the assessment of fibrinogen uptake 
by these megakaryocytes; and the ability, or lack thereof, of these megakaryocytes to form 
proplatelets, and the differences in mechanism between these and control cells. 
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6. Gfi1b in foetal murine haematopoiesis - Gfi1b conditional knock- 
out (KO) mouse model 
6.1 Introduction 
During the course of the breeding program for investigations into the characteristics of 
haematological tissue and cells (megakaryocytes and platelets) of mice with conditional knock-out of 
the transcription factor, Gfi1b, (as described in chapters 4 and 5), there were, at times, indications 
that fewer than expected Gfi1b KO offspring were being generated. Genotyping for weaned litters 
occasionally revealed that Pf4-Cre-positive mice being not being produced in the expected 
Mendelian proportions. From 65 genotyped offspring, there were four expected genotypes: 
Gfi1bfl/fl/ Pf4-Cre negative; Gfi1bfl/fl / Pf4-Cre positive; Gfi1bfl/-/ Pf4-Cre negative; and Gfi1bfl/- / Pf4-
Cre positive. The proportions of these genotypes were found to be: 36.9%, 10.8%, 46.2%, and 6.2%, 
respectively. This gave a proportion of Pf4-Cre negative pups of 83.1% compared to 16.9% Pf4- Cre 
positive pups, compared to the expected Mendelian ratio of 50%:50%. While there were indications 
from regular checks of the pre-weaned pup numbers that some were being lost from stillbirth or 
failure to thrive, and were being consumed by the mother (Weber et al., 2013), there was still the 
question of whether they were not surviving full- term gestation by dying In utero. Speculation arose 
that the deletion of the Gfi1b gene down through the megakaryocytic line in these particular mice 
was proving to be lethal, as total disruption of the Gfi1b gene has been found to be embryonically 
lethal (Saleque et al., 2002). The null hypothesis for this investigation was that the Mendelian mode 
of inheritance would not be seen in the genotyping of the in utero foetuses of late gestational age. In 
order to resolve this issue, pregnancy trials were set up to investigate mouse foetuses for genotype 
and any histological evidence of altered haematopoiesis. 
 
6.2 Experimental design 
Female mice, homozygous for Gfi1bfl/fl (floxed Gfi1b) but Pf4-Cre-negative, were mated to male 
Gfi1bfl/fl, Pf4-Cre-positive mice, and pregnancies confirmed by staff in the Kearns Facility, Kolling 
Institute, University of Sydney, Royal North Shore Hospital, Sydney. At gestational age E16-E17 
approximately, pregnant mice were prepared for surgery by being culled after exposure to CO2 for at 
least 15 minutes until all breathing had stopped and there was no toe-pinch reflex. Subsequently, 
the abdomen was surgically opened and uterine horns with foetuses removed. All foetuses were 
then counted, photographed, weighed, stored for histological analysis, and tails removed for DNA 
extraction and genotyping. 
 
The expected Mendelian proportions for this trial were 50% Pf4-Cre-negative vs 50% Pf4-Cre- 
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positive. Proportions were determined by the application of the chi-square test of independence on 
observed vs expected values. Probability, p, of less than 0.05 was considered statistically significant. 
All other data were analysed with the student’s t-test. 
6.3 Results 
6.3.1 Genotyping of foetal mice shows expected Mendelian proportions for numbers of Gfi1b 
KO pups compared to control pups 
Genotyping for Gfi1bfl/fl and for Pf4-Cre was carried out on DNA extracted from the tails of all mouse 
foetuses as well the cell mass from a resorbed pup. All 18 foetuses were homozygous (fl/fl) for 
floxed Gfi1b, with 10 of the 18 pups showing the presence of Pf4-Cre. A chi-square (χ2) goodness-of- 
fit test was performed on the results to determine the difference between the observed and the 
expected proportions of Pf4-Cre-positive and Pf4-Cre-negative mice, according to Mendelian 
proportions, which, in this case, would be 50% for each of the two groups. There was no significant 
2 
difference found between proportions of the two groups (χ   (1, n = 18) = 0.11, p=0.74) (Figure 6.1). 
Genotype for the resorbed embryo was Pf4-Cre-negative. 
 
 
 
Figure 6. 1 Genotyping of foetal mice (E16 - E17 – day 17) of Gfi1b
fl/fl 
x (Gfi1b
fl/fl
x Pf4-Cre
+/-
) 
parents shows no difference between observed and expected values. 
Pregnancy trials to investigate suspected loss of Pf4-Cre positive mice in utero were 
carried out at late gestation (E16, E17). A chi-square test was performed on the results of 
genotyping which showed no significant difference between observed and expected 
frequencies, as per Mendelian inheritance (χ 
2 
(1, n = 18) = 0.11, p=0.74). 
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6.3.2 Mouse foetuses show no differences in weight, size or in appearance between control 
and Gfi1b KO at gestational age E16 – E17 
Mouse foetuses excised from uterine horns were weighed, observed, and photographed (Figure 6.2 
(A)). Embryonic or foetal mortality was defined as pale, undeveloped embryonic foetuses, or the 
appearance of bags of cells or clots (resorption) included in the amniotic sac (McKelvey et al., 2016). 
Viability was deemed if foetuses were observed as being pink or perfused. The numbers of viable 
foetuses and resorbed cells were recorded. Of the 18 foetuses recorded, 17 were defined as viable, 
while there was evidence of one resorbed pup. Placentas appeared to be healthy and well-perfused 
for all viable foetuses. 
 
Mean values for weight between the two groups (control: 0.460 ± 0.106 g; Gfi1b KO: 0.504 ± 0.113 g; 
mean ± SD) showed no significant difference (NS) (Table 6.1) (Figure 6.2 (B)), indicating that at this 
stage of gestation, at least, the Gfi1b KO genotype did not have an effect on foetal growth. 
 
6.3.3 Morphological differences seen in haematoxylin and eosin (H & E)-stained histological 
tissue in foetal liver of Gfi1b KO mice compared to controls 
Mouse foetuses were processed for histological staining by collection of whole bodies and placentas 
into 10% neutral buffered formalin, and thence 70% ethanol. Bodies and placentas were sliced 
sagittally and placed in cassettes for paraffin embedding, slicing, and haematoxylin-eosin staining. 
Livers were examined under light microscope, frequency of megakaryocytes observed, and images 
captured. Although there were not enough samples processed to get quantitative data on the 
numbers of megakaryocytes seen in the images, there were indications of increased proliferation of 
megakaryocytes in the foetal liver tissue from the Gfi1b KO mice (Figure 6.3 (B)) compared to that of 
control mice, where there appeared to be fewer present (Figure 6.3 (A)). 
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Figure 6. 2 Mouse foetuses at days E16 – E18 of gestation. 
(A) Representative photograph of mouse pup foetuses and corresponding placentas at 
gestation E16. Rulers indicate sizes in mm. (B) Weight in grams of each mouse pup foetus in 
study. Mean values in the two groups, controls and Gfi1b KO, showed no significant 
difference (NS). 
 
 
 
 
Table 6. 1 Weights of mouse pup foetuses at gestation age E16 – E18 
 
Genotype of pups Weight (g) n p value 
Control 0.460 ± 0.106 7 NS 
Gfi1b KO 0.504 ± 0.113 10  
Mean values for weights in grams of mouse pup foetuses at days E16 – 
E18 of gestation of control and of Gfi1b KO mice. No significant difference 
(NS) in weight was between the two groups (student’s t-test, unequal 
sample size, equal variance). Controls: n=7; Gfi1b KO: n=10. Data are 
expressed as mean ± SD. 
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Figure 6. 3 Representative H&E stained histological sections of foetal liver of E16 – E17 
foetuses from control mice and Gfi1b KO mice. 
(A) Control mice; (B) Gfi1b KO mice; Magnification x 40. (A), (B): Black arrows indicate 
megakaryocytes. Inset(C), (D): magnified images (x 100) of control and Gfi1b KO 
megakaryocytes (A) and (B), respectively. H&E, haematoxylin and eosin. 
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6.3.4 Immunohistochemical analyses 
Immunohistochemistry (IHC) was carried out on formalin-fixed, paraffin-embedded sagittally-sliced 
foetuses. Duplicate slides of one control mouse and of one Gfi1b KO mouse were processed for 
three different epitopes - von Willebrand factor (vWf), CD34, and myeloperoxidase (MPO) – with 
image analysis focussed on liver tissue as the primary organ at this stage for haematopoiesis (Ayres- 
Silva Jde et al., 2011). vWf was used as an alternative method to quantify the numbers of 
megakaryocytes in each tissue (Tomer, 2004); CD34 was an indicator of the presence of 
megakaryocytic precursor cells (Insuasti-Beltran et al., 2012); and MPO was used as an indication of 
myeloid activity and stress in the tissue (Pulli et al., 2013). Positive control tissue was processed with 
each epitope tested. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. 4 Representative image of sagittal section of Gfi1b KO mouse foetus and placenta 
stained for CD34. 
Magnification x 0.48. Stained control tissue shown bottom right. 
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6.3.4.1 vWf staining shows indications of increased numbers of megakaryocytes in foetal liver of Gfi1b 
KO mouse compared to control mouse 
vWf, is highly specific marker for identifying megakaryocytes (Chuang et al., 2000, Rehg et al., 2012), 
as it is expressed in the cytoplasm of these cells. In the foetal liver tissue under examination, 
megakaryocytic cells were identified by the intense vWf staining and the recognisable morphological 
characteristics of large, multilobulate, nucleated cells (Figure 6.5). While only one set of duplicate 
slides for each foetus was available for study, the quantitation of the numbers of megakaryocytes 
showed marked differences between the two foetuses. Total numbers of megakaryocytes were 
counted across the whole of the liver tissue for all slides, and mean values calculated. There was a 
significant difference in megakaryocyte numbers even in this small population sample: control, 17.5 
± 0.7; Gfi1b KO, 82.5 ± 3.5; p=0.002; mean ± SD; student’s t-test. 
 
 
Morphological aspects of the megakaryocytes showed differences even at this age in the liver tissues 
of the two mice. Control megakaryocytes showed normal centrally-located, multi-lobulated nuclei 
(Figure 6.5 (C)), while the Gfi1b KO megakaryocytes had the appearance of peripherally-located, 
ring- or horseshoe-shaped lobulated nuclei around centralised cytoplasm (Figure 6.5 (D)). 
 
 
6.3.4.2 CD34 staining is seen in megakaryocytes in foetal liver of Gfi1b KO mouse but not in those of 
control mouse 
CD34 is expressed in the megakaryocytic lineage on early progenitor cells, such as 
promegakaryoblasts and megakaryoblasts, and is gradually lost as cells differentiate and mature 
(Insuasti-Beltran et al., 2012, Tang et al., 2011). In these foetal mice, the megakaryocytes in the liver 
tissue of the Gfi1b KO mouse showed distinct staining of CD34 (Figure 6.6 (B)) compared to those of 
the control mouse, which showed no megakaryocytic staining of CD34 (Figure 6.6 (A)). CD34 staining 
was also seen in other progenitor cells in both livers. 
 
Differences in megakaryocytic morphology, as noted in the vWf-stained slides, were seen again in 
these slides i.e. the control foetal megakaryocytes showed normal morphology (Figure 6.6 (C)) while 
those of the Gfi1b KO foetus exhibited ring-shaped, peripheral nuclei and central cytoplasm (Figure 
6.6 (D)). 
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Figure 6. 5 Representative images of immunohistochemistry staining for von Willebrand factor 
(vWf) in foetal liver (E16 – E17) of control mice and Gfi1b KO mice. 
(A) Control mice: Magnification x 18.15. Control mouse foetal liver shows megakaryocytes (red 
arrows) with intense staining of vWf in the cytoplasm, with clearly defined central multi- 
lobulated nuclei (inset (C), magnification x 67.2). (B) GFi1b KO mice: Magnification x 18.15. Gfi1b 
KO mouse foetal liver shows megakaryocytes (red arrows) with staining of vWf in the 
cytoplasm, with peripherally-localised, ring-shaped lobulated nuclei (inset (F), magnification x 
67.2). 
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Figure 6. 6 Representative images of immunohistochemistry staining for CD34 in foetal 
liver (E16 – E17) of control mice and Gfi1b KO mice. 
(A) Control mice: Magnification x 22.86. Control mouse foetal liver shows single megakaryocyte 
(red arrow) with no staining for CD34, with normal central multi-lobulated nuclei and pale 
cytoplasm (inset (C), magnification x 64.67) (B) GFi1b KO mice: Magnification x 21.59. Gfi1b KO 
mouse foetal liver shows numerous megakaryocytes (red arrows) with distinct staining for 
CD34, with the Gfi1b KO characteristically defined ring-shaped lobulated nuclei (inset (D), 
magnification x 61.06). 
Blue arrows indicate cell membrane expression of CD34 in haematopoietic progenitor cells. 
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6.3.4.3 MPO staining is not markedly different between control and Gfi1b KO foetal liver tissue 
MPO is a major enzyme in inflammatory processes, synthesised in early myeloid cells (Hachiya et al., 
2000), stored in neutrophils, and is detected in myeloblasts and immature myeloid cells (Pinkus and 
Pinkus, 1991). It is a marker of stress in tissue, and is implicated in some haematological disorders 
(Pulli et al., 2013). Its expression is greatest in late myeloblasts and promyelocytes, and is reduced 
at later stages of differentiation. Accordingly, there was no MPO staining seen in megakaryocytes of 
either foetal liver (Figure 6.7 (A), (B)), although the marked differences in morphology could be seen 
(Figure 6.7 (C), (D): control mouse and Gfi1b KO mouse, respectively). Areas of cells with intensely 
stained cytoplasm were seen in the liver tissue of both mice, with no apparent marked difference in 
the extent of these areas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. 7 Representative images of immunohistochemistry staining for MPO in foetal liver 
(E16 – E17) of control mice and Gfi1b KO mice. 
(A) Control mice: Magnification x 25.67. Control mouse foetal liver shows single unstained 
megakaryocyte (red arrow), with normal central multi-lobulated nuclei and pale cytoplasm (inset 
(C), magnification x 51.35) (B) Gfi1b KO mice: Magnification x 25.67. Gfi1b KO mouse foetal liver 
shows numerous unstained megakaryocytes (red arrows), with the Gfi1b KO characteristically 
defined ring-shaped lobulated nuclei (inset (D), magnification x 51.35). Blue arrows indicate cell 
membrane expression of MPO in haematopoietic myeloid cells. 
185  
6.4 Discussion 
The investigations into the fate of foetal Gfi1b KO mice to determine whether pups with any 
bleeding disorders from this genotype were surviving through to late gestation (up to E18), showed 
that foetuses at gestational age E16 – E17 with the Gfi1b KO genotype were indeed thriving, were 
viable, well-perfused, and showed no differences in weight, size, and appearance compared to 
control foetuses. The expectation that the genotypes of the surviving foetuses would not reflect 
Mendelian proportions, however, was confounded by the finding that these proportions in the 
genotyping of all foetuses studied were actually observed, with no significant difference between 
expected and observed outcomes. This finding indicated that the discrepancy in the expected 
Mendelian proportions in live offspring was due to postpartum / neonatal losses. 
 
Histological examination of foetal liver tissue showed indications of increased haematopoiesis and 
proliferation of megakaryocytes in Gfi1b KO mice compared to control mice. This was also borne out 
by immunohistochemical (IHC) staining for vWf, a megakaryocyte marker, in foetal liver tissue of 
Gfi1b KO mice. The foetal liver is the primary foetal haematopoietic organ, the main site of 
differentiation of haematopoietic stem cells (HSC) (Mikkola and Orkin, 2006). These first appear in 
the foetal liver at about E11.5, reaching a maximum by about E16.5. As gestation progresses, 
haematopoietic populations proliferate and differentiate, ultimately migrating to the bone marrow 
perinatally. Megakaryocytes viewed in all IHC liver tissue in this investigation showed abnormal 
morphology in Gfi1b KO mice compared to those normal megakaryocytes seen in control tissue. 
CD34 was also expressed in these abnormal megakaryocytes, compared to no expression at all in 
control cells. Staining for MPO as a marker of stress activity in liver tissue showed no remarkable 
difference between the two groups. 
 
These findings suggested that Gfi1b knocked out along the megakaryocyte line may not result in 
embryonic lethality in these foetuses. Foetal resorption, as observed for one embryo in one litter in 
this study, can be due to other factors other than genetic mutations, such as maternal age, 
overcrowding of one uterine horn, and intrauterine growth retardation (IUGR) (McKelvey et al., 
2016). Interestingly, the sole resorbed pup in our study was genotyped as a control mouse i.e. 
Gfi1bfl/fl-Pf4-Cre-negative , suggesting that death was due to causes other than the loss of Gfi1b.The 
average gestational period for these mice is 18 – 21 days (Murray et al., 2010), and the average size 
of a litter for C57BL/6J mice is eight pups. The average foetal litter size in this study was 8.5 pups, 
inferring that no obvious reduction in sizes of litters pre-birth was observed. 
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Haematopoiesis from mouse gestational age E10.5 to E18.0 occurs primarily in the foetal liver 
(Figure 6.8) (Al-Drees et al., 2015). Evidence of disturbed megakaryopoiesis is seen in liver tissue of 
foetal Gfi1b KO mice at E17 in our investigation, which suggests that the effects of this loss of Gfi1b 
are not manifested until after birth. 
 
 
 
 
 
Figure 6. 8 Timeline of murine haematopoiesis from early development to postnatal development. 
Haematopoiesis from gestational age E10.5 to E18.0 occurs primarily in the foetal liver. 
Figure adapted and summarised from (Al-Drees et al., 2015). 
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CHAPTER 7: 
GFI1B TRANSGENIC MOUSE MODEL 
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7. GFI1B transgenic mouse model 
7.1 Introduction 
The establishment of the use of gene transfer technology in mice in recent decades has allowed the 
generation of genetically altered mice to test hypothesis-driven studies of genetic pathways in 
disease (Doyle et al., 2012). In these cases, a gene of interest is identified as being associated with a 
human disease or disorder, and is investigated with a mouse model designed to mimic the effects of 
that gene. 
 
In this study, the confirmation of a single nucleotide insertion into the human GFI1B (GFI1Bc.880-881insC) 
as the mutation causing a novel bleeding disorder with autosomal negative dominance in a studied 
family (Ardlie et al., 1976, Stevenson et al., 2013) has led to the attempt to establish a transgenic 
mouse model of this mutation. Affected family members were found to have platelet changes 
consistent with aberrant platelet formation from the bone marrow, consisting of thrombocytopenia, 
α-granule defects, and signalling defects. 
 
This study has been designed to investigate the function of the human mutant GFI1B gene on 
megakaryocyte, and hence platelet, formation in the haematopoietic tissue of genetically altered 
adult mice, at a time when the haematological system is mature (6-12 weeks). Analyses with respect 
to changes in megakaryocyte and platelet number and function between mutant and litter mate 
controls have been carried out. 
 
This mouse model was used in order to better understand how GFI1B controls platelet formation, so 
as to provide this family with a better understanding of their disease, and potentially offer better 
treatments of their bleeding disorder. 
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7.2 Experimental design 
7.2.1 Mouse lines 
7.2.1.1 Transgenic human wild-type (WT) GFI1B / human mutant (Mut) GFI1Bc.880-881insC mice 
C57/BL6 mice with transgenic expression of the mutant (GFI1Bc880-881insC) (Stevenson et al., 2013) and 
wild-type human GFI1B were generated at WEHI. Transgenic constructs of pCAGGS-loxP-STOP-loxP- 
FLAG-hGFI1BWT and of pCAGGS-loxP-STOP-loxP-FLAG- GFI1Bc880-881insC were targeted to the Col1a1 
locus of 5B3 embryonic stem (ES) cell lines using FRT/FlpE recombinase-mediated site-specific 
integration, and clones selected by hygromycin resistance (Beard et al., 2006). The Col1a1 locus has 
been shown to support high transgene expression even in cell types that do not normally express 
the type I collagen gene (McCreath et al., 2000). 
 
In brief, 5B3 ES cells were generated using a frt-hygroR-pA ‘‘homing’’ cassette (Col1a-frt-hygro-pA – 
plasmid 20730 (Addgene)) targeting 500 base pairs (bp) downstream of the 3’ untranslated region 
UTR of the Col1a1 locus. This left the coding portion and 3’ UTR transcriptional control region of the 
Col1a1 gene intact (Figure 7.1(A)). 5B3 ES cells were then targeted for conditional transgenic 
expression of hGFI1B wild-type (WT) or hGFI1Bc.880-881insC (Mut) by co-electroporation of the pgk-ATG- 
frt vector (plasmid 20734, Addgene), the flp-in vector carrying the lox-STOP-lox cassette with hGFI1B 
WT or MUT allele (pCAGGS-losSTOPlox-Cla1 flp-in, plasmid 21548 Addgene), and a FlpE transient 
expression vector (pCAGGS-flpE-puro, plasmid 20733, Addgene). 
 
Targeting of FRT sites in 5B3 ES cells resulted in the flip-out of the PGKneopA cassette (situated 
between those FRT sites in the Col1a-frt-hygro-pA plasmid) and the flip-in of the pgkATG cassette 
and the gene of interest (pCAGGS-losSTOPlox-Cla1 flp-in). Correctly targeted clones led to the in- 
frame expression of the hygromycin resistance gene (hygroR) (Beard et al., 2006). These correctly 
targeted ES cell clones were then used to generate transgenic mouse lines. 
 
7.2.1.2 Transgenic Pf4-Cre recombinase mice 
As noted in Chapters 4, 5 and 6, C57/BL6 mice were generated at WEHI with the transgenic 
expression of Cre-recombinase in the megakaryocytic lineage by the homologous recombination and 
replacement of the first exon of the platelet factor 4 (Pf4) (also called CXCL4) gene with a codon- 
improved Cre cDNA (Tiedt et al., 2007) These were transported to Kolling Institute for cross-breeding 
with transgenic knock-in human GFI1B mice (Figure 7.1(B)). 
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Figure 7. 1 Schematic representation of GFI1B genetic construct. 
(A) Insertions into Col1a1 locus of transgenic human GFI1B mice (see text). (B) Schematic 
representation of generation of transgenic mice expressing human GFI1B (see text). 
A 
B 
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7.2.2 Rationale 
The rationale behind this mouse model was to explore the role of human GFI1Bc880-881insC on the 
murine haematopoietic system. Two separate transgenic mouse lines were studied: human 
GFI1Bc880-881insC vs human GFI1BWT. Due to their location in the Col1a1 locus, it was postulated that 
these would be over-expressed compared to endogenous mouse Gfi1b. Transgenic constructs of the 
mutant human gene and of the wild-type human gene include vectors (pCAGGS) that use the CAG 
promoter (Hitoshi et al., 1991). This is a hybrid promoter consisting of a cytomegalovirus (CMV) 
immediate‐early enhancer, a chicken β‐actin transcription start site, and a rabbit β‐globin intron 
(Nitta et al., 2005). It has proved to be most effective at driving gene expression without 
compromising the ability of stem cells to differentiate, providing long term expression of transgenes 
in these cells, and inducing immediate and strong transcription (Alexopoulou et al., 2008, Seo et al., 
2010, Wang et al., 2017). 
 
The choice of the Col1a1 locus allowed for the more specific isolation of ES cells in which the 
transgene had been inserted. The targeted ES cells were modified to contain a specific genomic 
“landing pad” in the collagen locus which is considered to be more open to accepting the 
electroporated vectors containing the cloned gene constructs (McCreath et al., 2000). The collagen 
locus also is expressed in the majority of mouse tissues as has been demonstrated with a reporter 
allele, enhanced green fluorescent protein (EGFP) (Beard et al., 2006). The locus itself was not 
anticipated to impact on the phenotype that would be seen, and this would be controlled for by 
using a wild-type human allele in the same system. 
 
The gene insertions are then conditionally expressed with Cre recombinase excising the Lox-STOP 
CODONS-Lox 5’ to the gene promoter (Nagy, 2000, Sauer, 1998). In this study, this would be Pf4-Cre 
which is in the haemopoietic lineage and is megakaryocyte-specific. As the phenotype for the 
mutant GFI1B was confirmed as autosomal dominant inheritance, the premise behind the 
establishment of this model was that the human mutant allele expressed alongside the mouse 
endogenous gene allele may demonstrate a dominant negative effect. 
 
The inclusion of a FLAG epitope tag gene to the 5’-end of the inserted human GFI1B gene during the 
transgene construction (Einhauer and Jungbauer, 2001) was planned to allow for the detection of 
the translated protein in the event of too close an homology of expressed human GFI1B and 
endogenous mouse Gfi1b. 
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7.2.3 Mouse breeding protocols 
7.2.3.1 Transgenic human wild-type (WT) GFI1B mice 
Male mice with heterozygous human wild-type GFI1B (denoted +/TGGFI1B) were bred with female 
C57BL6/J wild-type mice (denoted WT) (Figure 7.2). +/TGGFI1B offspring were mated, and those 
resultant homozygous female TG/TGGFI1B offspring were bred to male mice with heterozygous Pf4- 
Cre (Pf4-Cre+/-) (transported from WEHI) to produce a generation of all heterozygous (+/TGGFI1B ) 
offspring with a fifty percent mix of heterozygous Pf4-Cre (Pf4-Cre+/-) or no Cre (-/-).Those offspring 
with genotype +/TGGFI1B x Pf4-Cre+/- were then bred back to TG/TGGFI1B -only mice to produce the 
required ultimate breeding mice of TG/TGGFI1B x Pf4-Cre+/- and TG/TGGFI1B x Pf4-Cre-/- . These then 
produced the final experimental mice of TG/TGGFI1B x Pf4-Cre+/- with littermates TG/TGGFI1B x Pf4-Cre-/- 
as controls. 
 
7.2.3.2 Transgenic human mutant (Mut) GFI1Bc.880-881insC mice 
Female offspring of original mated homozygous human mutant GFI1Bc.880-881insC (denoted 
TG/TGGFI1Bc.880-881insC) mice were bred to male mice with heterozygous Pf4-Cre (Pf4-Cre+/-) to produce 
a first generation of all heterozygous (+/TGGFI1Bc.880-881insC ) offspring and a fifty percent mix of 
heterozygous Pf4-Cre (Pf4-Cre+/-) or no Cre (-/-) (Figure 7.3).Those offspring with genotype 
+/TGGFI1Bc.880-881insC x Pf4-Cre+/- were then bred back to TG/TGGFI1Bc.880-881insC -only mice to produce the 
required ultimate breeding mice of TG/TGGFI1Bc.880-881insC x Pf4-Cre+/- and TG/TGGFI1Bc.880-881insC x Pf4-Cre- 
/- . These then produced the final experimental mice of TG/TGGFI1Bc.880-881insC x Pf4-Cre+/- with 
littermates TG/TGGFI1Bc.880-881insC x Pf4-Cre-/- as controls. 
7.2.3.3 Confirmation of genotype 
DNA extraction and PCR genotyping were carried out (section 2.1.3) on mouse tail tissue at each 
crucial breeding step. 
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Figure 7. 2 Mouse breeding strategy for generation of transgenic human GFI1BWT mice. 
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Figure 7. 3 Mouse breeding strategy for generation of transgenic human GFI1Bc.880-881insC mice. 
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7.3 Results 
7.3.1 Breeding and genotyping 
There were considerable technical issues with the genotyping and breeding of these mice which, 
once resolved, only allowed time to do some of the experiments that were planned with these mice. 
There were long lead-in times in the breeding program for the final generation of homozygous 
transgenic knock-in human wild-type (WT) GFI1B mice, and ongoing issues with the stability, 
reproducibility, and reliability of the genotyping assays for both mouse lines. The eventual use of the 
commercial genotyping company, Transnetyx, Inc. (Cordova, Tennessee, USA), who used real-time 
PCR to determine the presence of a hygromycin cassette (HYGRO) in either allele, along with an 
indication of an insertion in the Col1a1 locus (Col1a1-1 WT), allowed some experiments to progress 
in the time frame of the study. 
 
7.3.2 Phenotype investigations 
Initial haematological investigations were carried out on the transgenic human mutant (Mut) 
GFI1Bc.880-881insC mice (GFI1B Mut TG) with their Pf4-Cre-negative littermates as controls. As the 
generation of the transgenic human wild-type (WT) GFI1B mice progressed, comparative 
investigations into these were also included. In studying the effects of the mutant human GFI1B, we 
concentrated on those aspects which would definitively characterise a phenotype of the affected 
family, namely low platelet counts (thrombocytopaenia), evidence of abnormal megakaryocyte 
development, and signs of a bleeding diathesis. 
 
7.3.2.1 Haematological indices 
The first step to assess thrombocytopaenia was the determination of a full blood count. Blood was 
collected retro-orbitally via heparinised capillary tubes into K2EDTA paediatric tubes. Each GFI1B Mut 
TG mouse was matched with a litter mate control (age and gender). Full blood count was performed 
on Beckman-Coulter AcT Diff cell counter in veterinary mode. The measurement of haematological 
indices between littermate controls and GFI1B Mut TG mice showed no significant differences for all 
parameters studied (Table 7.1) (Figure 7.4). Platelet counts were similar between the two groups 
(control: 898 ± 137.5 (x103/μL); GFI1B Mut TG: 933 ± 221.5 (x103/μL); NS), with no differences seen 
in the red blood cell indices measured: red blood cell count (RBC), haemoglobin concentration (Hb), 
haematocrit (Hct), mean cell volume (MCV), haemoglobin (MCH), and haemoglobin concentration 
(MCHC) (student’s t-test). Any significantly reduced values for GFI1B Mut TG mice in these latter 
measurements may have suggested signs of bleeding (Tefferi et al., 2005). There was also no effect 
on white blood cell counts. 
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Figure 7. 4 Haematological indices are not altered in GFI1B Mut TG mice. 
No significant differences were found in any of the haematological indices between control mice 
and GFI1B Mut TG mice (n=5 pairs). Data are presented as range and mean; NS, no significance. 
(A) RBC – red blood cell count, x 104/μL; (B) haemoglobin, g/L; (C) haematocrit, L/L; (D) mean cell 
volume, fL; (E) mean cell haemoglobin, pg/cell; (F) mean cell haemoglobin concentration, g/L; (G) 
platelet count, x 103/μL; (H) WBC – white blood cell count, x 102/ μL. 
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Table 7. 1 Haematological values for control (GFI1B Mut x Pf4-Cre-) mice and GFI1B Mut TG (GFI1B 
Mut x Pf4-Cre+) mice. 
 
Peripheral blood 
(retro-orbital) 
 
Control 
 
GFI1B Mut TG 
n 
(pairs) 
Normal 
range+ 
p 
value 
Platelets (x103/μL) 898 ± 137.5 933 ± 221.5 5 1000 - 2000 NS 
White blood cells (x102/μL) 46.8 ± 15.7 45.0 ± 14.0 5 20 - 90 NS 
Red blood cells (x104/μL) 885.7 ± 36.7 850.4 ± 48.8 5 700 - 1100 NS 
Haemoglobin (g/L) 136.2 ± 8.6 130.9 ± 7.8 5 130 - 180 NS 
Haematocrit 0.41 ± 0.03 0.39 ± 0.02 5 0.4 – 0.5 NS 
MCV (fL) 45.2 ± 0.8 45.5 ± 0.6 5 40 - 55 NS 
MCH (pg/cell) 15.2 ± 0.6 15.2 ± 0.2 5 13 - 17 NS 
MCHC (g/L) 335.0 ± 8.9 334.7 ± 5.4 5 260 - 320 NS 
Data are presented as mean ± SD. No significant differences (NS) were found between control and 
GFI1B Mut TG mice for any haematological index (student’s t-test). 
MCV, mean cell volume; MCH, mean cell haemoglobin; MCHC, mean cell haemoglobin concentration. 
+Source: (Everds, 2007). 
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7.3.2.2 No differences in platelet and blood cell morphology seen in blood films of both groups of 
control and transgenic mice 
Analysis of May-Grünwald-Giemsa stained blood films from matched pairs of controls and GFI1B WT 
TG mice, and controls and GFI1B Mut TG mice showed similar morphology, distribution and size of 
platelets and normal blood cell morphology (Figure 7.5). 
 
Figure 7. 5 Representative blood films stained with May-Grünwald-Giemsa stain from 
transgenic mice. 
(A) GFI1B WT TG control mice; (B) GFI1B WT TG mice; (C) GFI1B Mut TG control mice; (D) GFI1B 
Mut TG mice; magnification x 40. Black arrows denote platelets, showing similar distribution 
and normal morphology of platelets between controls and transgenic mice of both pairs of 
groups. 
199  
7.3.2.3 No indication of differences in size or appearance of body organs between control mice and 
GFI1B Mut TG mice 
The body organs - spleen, kidneys, heart, lungs, thymus and liver - were harvested from control and 
experimental mice of the GFI1B Mut TG group only (n = 4 pairs). These were weighed and calculated 
as percentage (%) of total body weight for each mouse (Table 7.2). For all organs – spleen, dneys, 
heart, lungs, thymus and liver there were no significant differences (NS) in weight as % of total body 
weight between the two groups (Figure 7.5). 
 
 
 
 
 
 
 
Table 7. 2 Body organs for control (GFI1B Mut TG Pf4-Cre-) and GFI1B Mut TG (GFI1B Mut TG Pf4- 
Cre+) mice as percentage of total body weight for each mouse. 
 
 
Body organ 
%Total body 
Control 
weight 
GFI1B Mut TG 
n 
(per group in pair) 
p 
value 
Spleen 0.31 ± 0.27 0.53 ± 0.27 4 NS 
Kidneys 1.35 ± 0.31 1.14 ± 0.39 4 NS 
Heart 0.54 ± 0.08 0.56 ± 0.06 4 NS 
Lungs 0.91 ± 0.17 0.98 ± 0.30 4 NS 
Thymus 0.47 ± 0.23 0.21 ± 0.12 4 NS 
Liver 4.73 ± 0.62 4.85 ± 0.47 4 NS 
Body organs were harvested from control mice and GFI1B Mut TG mice and weighed. Each GFI1B 
Mut TG mouse was matched with a litter mate control (age and gender). Relative size of each organ 
was calculated as percentage of total body weight. Data are presented as mean ± SD. No 
statistically significant differences were observed in the relative sizes of any organs of the GFI1B 
Mut TG mice compared to those of the control mice (NS, no significance). 
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7.3.2.4 Similar distribution of megakaryocyte ploidy in bone marrow of control mice and of GFI1B Mut 
TG mice 
Cells from murine femoral bone marrow were harvested from control mice and GFI1B Mut TG mice, 
and stained for megakaryocytes (CD41) and DNA ploidy (propidium iodide, PI). Flow cytometric 
measurement of megakaryocytes in femoral bone marrow from control and experimental mice of 
the GFI1B Mut TG group only was performed. This was based on the gating strategy of CD41-positive 
cells (denoting megakaryocytes) showing propidium iodide (PI) staining (indicating DNA content – 
ploidy - of cells) (Figure 7.6 (A), left panels). Positive cells for both were further defined in a PI 
histogram, showing the range of PI fluorescence for those CD41-positive cells (Figure 7.6 (A), right 
panels). The resultant peaks denoted the distribution of DNA ploidy in the megakaryocyte 
population in the bone marrow. 
 
Individual ploidy values for each peak were calculated as a percentage of the total numbers of CD41- 
positive, PI-stained cells. Starting at ploidy 2N, the peaks were then grouped in classes indicating 
lower ploidy (2N – 8N) and higher ploidy (≥ 16N) (Table 7.3) (Figure 7.6(B)) to determine any changes 
in the range of megakaryocyte DNA content. No significant differences were seen in the percentage 
of megakaryocytes between the control mice and the GFI1B Mut TG mice in both these ploidy 
groups (2N-8N: control, 74.4 ± 11.4%; GFI1B Mut TG, 74.5 ± 7.1%; NS; ≥16N: control, 25.2 ± 11.8%; 
GFI1B Mut TG, 24.8 ± 7.3%; NS). This indicated that there was no differences in these cells to affect 
the proliferation of, or the distribution of DNA ploidy in, the megakaryocyte populations in the bone 
marrows of control and GFI1B Mut TG mice (Vassen and Moroy, 2011) (Beauchemin et al., 2017). 
 
 
Table 7. 3 Comparison of distribution of megakaryocyte DNA ploidy in femoral bone marrow for 
control mice and GFI1B Mut TG mice. 
 
Mouse %MK in ploidy class n p 
group 2N-8N 16N-256N (per group in pair) value 
Control 74.4 ± 11.4 25.2 ± 11.8 7 NS 
GFI1B Mut TG 74.5 ± 7.1 24.8 ± 7.3 7 NS 
Distribution of megakaryocyte ploidy for each group was calculated as percentage of total 
megakaryocyte population and grouped as 2N-8N and ≥16N. Data are presented as mean ± SD. No 
significant differences were observed in either of the DNA ploidy groups between control mice and 
GFI1B Mut TG mice (n=7 pairs) (student’s t-test). NS, not significant. 
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Figure 7. 6 No difference in ploidy distribution of megakaryocytes in bone marrow of GFI1B Mut TG 
compared to control mice. 
(A) Representative flow cytometry dot plots of gated populations (rectangle) of megakaryocytes (left panels) in 
bone marrow, redefined as histograms (right panels) showing distribution of cell ploidy (upper panels, control 
mouse; lower panels, GFI1B Mut TG mouse). (B) Comparison of distribution of megakaryocyte ploidy (2N-8N vs ≥ 
16N) between control mice (n=7) and GFI1B Mut TG mice (n=7) showed no significant difference s (NS) between 
the 2 groups 2N-8N, ≥16N: NS; student’s t-test). Data are expressed as mean ± SD. 
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7.3.2.5 Normal megakaryocyte morphology seen in cytospin of bone marrow cells of both groups of 
control and transgenic mice 
Harvested filtered bone marrow cells concentrated on glass slides by cytospin at approximately 5 x 
104 cells per glass slide were stained with May-Grünwald-Giemsa stain and analysed for 
megakaryocyte cell morphology and distribution. In both control and experimental groups, there 
was no apparent difference in the appearance of megakaryocytes. Those seen showed normal 
morphology, with multi-lobed, central nuclei, and pale cytoplasm (Figure 7.7). Distribution amongst 
the groups was also similar, numbering 1 -2 megakaryocytes per cytospin slide of ~5 x 104 cells. 
 
Figure 7. 7 Representative cytospin preparations of harvested filtered bone marrow cells (stained 
with May-Grünwald-Giemsa stain) from transgenic knock-in mice. 
(A) GFI1B WT TG control mice; (B) GFI1B WT TG mice; (C) GFI1B Mut TG control mice; (D) GFI1B 
Mut TG mice; magnification x 40. Red arrows denote megakaryocytes, showing similar 
distribution, and the centrally located, multi-lobed nucleus and pale cytoplasm of normal 
morphology of megakaryocytes between each pair. 
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7.3.2.6 No megakaryocytes seen in cytospin of spleen cells of control or transgenic mouse 
In a similar fashion to bone marrow cells, harvested filtered spleen cells were concentrated on glass 
slides by cytospin at approximately 5 x 104 cells per glass slide and were stained with May-Grünwald- 
Giemsa stain. These were then analysed for megakaryocyte cell morphology and distribution. In both 
control and experimental groups, there was no appearance of megakaryocytes on any of the 
processed slides (O'Connell et al., 2015). 
 
7.3.2.7 No increased erythropoiesis in bone marrow and in spleen of GFI1B Mut TG mice compared to 
control littermates 
Cells were harvested from femoral bone marrow and from the spleens of control mice (GFI1B Mut x 
Pf4-Cre-) and GFI1B Mut TG (GFI1B Mut x Pf4-Cre+) mice. GFI1B Mut TG mice were matched with 
litter mate controls (age and gender). Cells were stained with erythroid cell surface markers and 
gated according to size, producing subsets of erythroid cells denoting developmental stages. The 
measurement by flow cytometry of erythroid precursor groups in bone marrow cells (Figure 7.8) and 
in spleen cells (Figure 7.9) was carried out for the control and experimental mice of the GFI1B Mut 
TG group only. Cell surface markers CD71 (transferrin receptor), an effective erythroid cell marker 
(Marsee et al., 2010), and TER119 (murine glycophorin A), expressed on erythroid cells towards the 
later stages of erythroid development (Kina et al., 2000), were used in conjunction with the forward 
scatter parameter(FSC), which denotes cell size. 
 
The rationale for this combination of markers has been outlined previously (section 4.3.3). Briefly, 
investigation into the proportions of subsets of erythroblast cells (ProE, proerythroblasts; EryA, 
basophilic erythroblasts; EryB, poly-chromatic erythroblasts; EryC, orthochromatic erythroblasts 
(Socolovsky, 2007)) as a measurement of developmental sequence was carried out in order to 
ascertain any evidence of increased erythropoiesis either in the bone marrow or the spleen. This 
latter event, which is termed stress erythropoiesis (Kim et al., 2015) would indicate increased 
bleeding in the mice due to any attributable abnormalities in the haemostatic process – in this case, 
the effect of the mutant human GFI1B. 
 
However, in both the harvested bone marrow cells and in the spleen cells, there were no significant 
differences (NS) between control mice and GFI1B Mut TG mice in any of the erythroblast precursor 
groups (Table 7, Figures 7.8 (B) and 7.9 (B)). The largest populations were seen in the more mature 
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Figure 7. 8 No difference in populations of immature erythroid precursor cells in bone marrow of 
GFI1B Mut TG mice compared to control mice. 
(A) Representative flow cytometry dot plots of gating strategy (for both groups of mice) to produce 
erythroblast populations. Gated single cells (top right panel) are expressed according to erythroid cell 
surface markers, CD71 and Ter119 (lower left panel). High Ter119 cells are redefined as subsets 
according to their CD71 expression and cell size (forward scatter, FSC) (bottom right panel). 
Proerythroblasts are defined as the population CD71High Ter119Low (bottom left panel). (B) Comparison 
of subset distributions showed no significant differences (NS) between control mice and GFI1B Mut TG 
mice in any of the 4 subsets (n=3 pairs). Data are expressed as mean ± SD. ProE, proerythroblasts; 
EryA, basophilic erythroblasts; EryB, poly-chromatic erythroblasts; EryC, orthochromatic erythroblasts. 
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Figure 7. 9 No difference in populations of immature erythroid precursor cells in spleens of 
GFI1B Mut TG mice compared to those of control mice. 
(A) Representative flow cytometry dot plots of gating strategy (for both groups of mice) to produce 
erythroblast populations. Gated single cells (top right panel) are expressed according to erythroid 
cell surface markers, CD71 and Ter119 (lower left panel). High Ter119 cells are redefined as subsets 
according to their CD71 expression and cell size (forward scatter, FSC) (bottom right panel). 
Proerythroblasts are defined as the population CD71High Ter119Low (bottom left panel). (B) 
Comparison of subset distributions showed no significant differences (NS) between control mice and 
GFI1B Mut TG mice in any of the 4 subsets (n=3 pairs). Data are expressed as mean ± SD. ProE, 
proerythroblasts; EryA, basophilic erythroblasts; EryB, poly-chromatic erythroblasts; EryC, 
orthochromatic erythroblasts. 
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erythroid precursor groups, especially the most mature group, EryC, in the spleen (control, 72.0 ± 
13.9 %; GFI1B Mut TG, 75.7 ± 2.9%; NS), indicating no evidence of extramedullary haematopoiesis 
(Liu et al., 2013) as noted in Gfi1b knockout mice (Chapter 4, section 4.3.4). 
 
 
Table 7. 4 Proportion of erythroid precursor cell groups in femoral bone marrow and in spleen for 
control mice and GFI1B Mut TG mice. 
 
Body organ 
Erythroblast 
group 
%Total 
Control 
erythroid cells 
GFI1B Mut TG 
n 
(pairs) 
P 
value 
Bone marrow ProE 1.7 ± 0.6 2.7 ± 0.8 3 NS 
 EryA 3.5 ± 1.8 2.9 ± 2.1 3 NS 
 EryB 55.9 ± 6.3 55.9 ± 5.3 3 NS 
 EryC 32.1 ± 5.2 30.5 ± 10.3 3 NS 
Spleen ProE 0.9 ± 0.7 0.4 ± 0.1 3 NS 
 EryA 1.5 ± 1.3 1.4 ± 1.0 3 NS 
 EryB 10.2 ± 8.9 6.5 ± 8.10 3 NS 
 EryC 72.0 ± 13.9 75.7 ± 2.9 3 NS 
Each of these groups was calculated as percentage of total erythroid cells. Data are presented as 
mean ± SD. No significant differences (NS) were observed in either bone marrow or in spleen in the 
percentage of any of the erythroid subsets in the GFI1B Mut TG mice compared to those of the 
control mice. 
ProE, proerythroblasts; EryA, basophilic erythroblasts; EryB, poly-chromatic erythroblasts; EryC, 
orthochromatic erythroblasts. 
 
7.3.3 Investigation into confirmation of transgenic expression of human gene 
In the absence of a definitive phenotype, it was necessary to investigate the expression of the 
human GFI1B transgene (either WT or Mut) by the specific and sensitive detection (Lobbestael et al., 
2010) of the FLAG-tagged protein, GFI1B. As there is a high level of homology (approximately 85%) 
between the endogenous mouse protein, Gfi1b, and the human protein, GFIB (National Center for 
Biotechnology Information (NCBI) Blast (RID STMXA5PU11N): NP_004179.3, zinc finger protein 
GFI1B isoform 1[Homo sapiens]; NP_032140.1, zinc finger protein Gfi1b isoform 1 [Mus musculus]), 
it was essential to measure the presence of the FLAG tag attached to the human GFI1B. 
 
As construction of both of the transgenes GFI1B WT and GFI1B Mut was carried out in the same way 
(Figure 7.1(B)), both groups of mice were used to investigate the success of the transgenic model. 
To this end, various approaches were attempted: expression, by nested PCR, of FLAG gene in cDNA 
extracted from RNA of purified and / or cultured megakaryocytes from the bone marrow (femurs) of 
control and of transgenic mice; immunofluorescence of antibodies against FLAG protein in similarly 
prepared cultured megakaryocytes; immunohistochemistry for FLAG expression in formalin-fixed, 
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paraffin-embedded tissue (bone marrow [sternum] and spleen); and Western blot of FLAG-tagged 
GFI1B protein, also from cultured megakaryocytes. 
 
In order to obtain purified and / or cultured megakaryocytes for several of the above procedures, it 
was necessary to isolate, culture and purify the very low population of megakaryocytes that is 
usually found in bone marrow (Corash et al., 1989). Harvested, filtered femoral bone marrow cells 
that were separated and collected after application to a BSA gradient (section 2.1.15) were pelleted 
by centrifugation and had the supernatant aspirated. For sequencing studies, RNA was initially 
extracted from ~107 cells (section 7.3.3.1). For cell cultures, megakaryocytes progenitors were 
isolated and grown on complete DMEM medium with cytokines, and the resultant mature 
megakaryocytes harvested and processed for immunofluorescence microscopy (section 7.3.3.2). For 
immunofluorescence microscopy, Chinese hamster ovary (CHO) cells were transfected with FLAG 
plasmid DNA to act as a positive control. For Western blot studies, nuclear proteins were extracted 
from cultured megakaryocytes, and processed for antibody detection of FLAG-tagged GFI1B (section 
7.3.3.4). 
 
7.3.3.1 Sequencing of cDNA from extracted RNA of megakaryocytes for FLAG-tagged human GFI1B from 
bone marrow and from spleen in transgenic mice 
In order to investigate whether the FLAG-tagged human GFI1B was successfully transcribed in 
megakaryocytes in the transgenic mice after Pf4-Cre excision, purified or harvested cultured 
megakaryocytes from femoral bone marrow or from spleen had DNA sequencing carried out on the 
cDNA synthesised by reverse transcriptase (RT) PCR from the extracted RNA of these cells. Initially, 
PCR was carried out using primers that detected human GFI1B only. The resultant sequencing was 
aligned to that of murine Gfi1b cDNA to ascertain whether the results were human or mouse, using 
Clustal Omega, a multiple sequence online alignment tool from the European Molecular Biology 
Laboratory – European Bioinformatics Institute (EMBL-EBI) (Goujon et al., 2010) (Figure 7.10). 
 
In these initial investigations, only those cDNA preparations with enough material for sequencing 
were able to be analysed. In this case, there were only results from one control mouse (#794, spleen 
only) and two GFI1B Mut TG mice (#793, #802, bone marrow and spleen) (Figure 7.10 (B)). Sequence 
alignment showed that megakaryocytes from #793 bone marrow expressed human GFI1B, while 
those from the spleen of the same mouse showed mouse Gfi1b. This latter result was also seen in 
the alignment sequences in both types of tissue from the other mice tested. However, the cDNA 
sequence from #793 (GFI1B Mut TG mouse) did not show the expected C insertion in the mutant 
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transcript (red line in grey area). These differing results between tissues from the same mice led to 
the conclusion that there was likely genomic DNA contamination of the cDNA synthesised from the 
small amount of harvested material from the different tissues which obfuscated any clear detection 
of human GFI1B. 
 
The strategy to address this anomaly was to design a two-step nested PCR, a modification of PCR 
that involves the use of two primer sets and two successive PCR reactions. The first PCR run of the 
two-step nested PCR involved primers to target the entire FLAG-tagged inserted GFI1B gene (FLAG 
tag Forward, TgINS tail reverse). The products from this PCR (GFI1B WT TG: 1039 bp; GFI1B Mut TG: 
966 bp) were then used as DNA templates for the second step of the nested PCR, with primers 
(HGFI1B nested forward, TgINS tail reverse) targeting exon 7 of the GFI1B gene, where, in the 
mutant gene, as seen above, a single nucleotide, C, had been inserted. The DNA extracted from the 
amplicons of this second step (GFI1B WT TG: 292 bp; GFI1B Mut TG: 221 bp) (Figure 7.11) was used 
as a template for DNA sequencing by AGRF (Australian Genome Research Facility), Sydney. 
 
The expectation was that expression of the mutant human GFI1B transgene in Pf4-Cre-positive mice 
would be switched on by the Pf4-Cre excision of the lox-STOP-lox cassette, thus the presence of its 
transcription in this tissue would be detected, while in the Pf4-Cre-negative mice, the mutant human 
GFI1B transgene would not be switched on, and there would be no transcription of it. However, 
unfortunately, results from sequencing of the nested PCR products only denoted gDNA sequences. 
This was evident by the outcome that those GFI1B Mut KO deemed to be controls, i.e. Pf4-Cre 
negative, showed the extra C insertion in the presumed cDNA sequences. This had also been 
detected in previous sequencing results of mouse gDNA to confirm the actual presence (not 
sequence or transcription) of the transgenic human cDNA insertion in the mouse gDNA during 
mouse experiments (Figure 7.12). 
 
These discrepant results reveal that the experiments to detect evidence that the human mutant 
gene was transcribed were not conclusive. The indications here are that the difficulties encountered 
were secondary to the likelihood of the close homology between Gfi1b and GFI1B creating 
sequencing ambiguity, as well as the real possibility of DNA contamination of cDNA during its 
preparation. 
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CLUSTAL O (1.2.4) multiple sequence alignment 
 
HUMAN CCTGCTCATCCACTCAGACACGCGGCCCTACCCCTGCCAGTTCTGCGGCAAGCGTTTCCA 
MOUSE -CTGCTCATCCACTCGGACACTCGGCCCTACCCCTGCCAGTTCTGTGGGAAGCGCTTCCA 
************** ***** *********************** ** ***** ***** 
 
HUMAN CCAGAAGTCCGACATGAAGAAGCACACCTACATCCACACAGGTGAGAAGCCGCACAAGTG 
MOUSE CCAGAAGTCGGACATGAAGAAACACACCTACATCCACACAGGTGAGAAGCCCCACAAGTG 
********* *********** ***************************** ******** 
 
HUMAN CCAGGTGTGCGGAAAGGCCTTCAGCCAGAGCTCCAACCTCATCACCCACAGCCGCAAGCA 
MOUSE CCAGGTGTGTGGGAAAGCCTTCAGCCAGAGCTCCAACCTCATCACCCACAGCCGCAAGCA 
********* ** ** ******************************************** 
 
HUMAN CACAGGCTTCAAGCCCTTCAGCTGTGAGCTGTGCACCAAAGG 
MOUSE CACAGGCTTCAAGCCGTTCAGCTGTGAGCTGTGCACCAAGG- 
*************** *********************** * 
17.04.13 AGRF alignment 
 
human CCTGCTCATCCACTCAGACACGCGGCCCTACCCCTGCCAGTTCTGCGGCAAGCGTTTCCA 
793mk ------------------------------------ GNNNNNNNNNNTCTGCGGCAGCGTTTCCA 
794s ----------------------------------- NNNNCNNNNNAGTTCTGTGGGAGCGCTTCCA 
802s --------------------------------- NNNGNNCNNNGCNGTTCTGTGGGAGCGCTTCCA 
680mk -------------------------------- CNNCNNNNNNGCNGTTCTGTGGGAGCGCTTCCA 
793 ------------------------------------ NNNNNNNNGCNGTTCTGTGGGAGCGCTTCCA 
* **** ***** 
 
human CCAGAAGTCCGACATGAAGAAGCACACCTACATCCACACAGGTGAGAAGCCGCACAAGTG 
793mk CCAGAAGTCCGACATGAAGAAGCACACCTACATCCACACAGGTGAGAAGCCGCACAAGTG 
794s CCAGAAGTCGGACATGAAGAAACACACCTACATCCACACAGGTGAGAAGCCCCACAAGTG 
802s CCAGAAGTCGGACATGAAGAAACACACCTACATCCACACAGGTGAGAAGCCCCACAAGTG 
6802mk CCAGAAGTCGGACATGAAGAAACACACCTACATCCACACAGGTGAGAAGCCCCACAAGTG 
793 CCAGAAGTCGGACATGAAGAAACACACCTACATCCACACAGGTGAGAAGCCCCACAAGTG 
********* *********** ***************************** ******** 
 
human CCAGGTGTGCGGAAAGGCCTTCAGCCAGAGCTCCAACCTCATCACCCACAGCCGCAAGCA 
793mk CCAGGTGTGCGGAAAGGCCTTCAGCCAGAGCTCCAACCTCATCACCCACAGCCGCAAGCA 
794s CCAGGTGTGTGGGAAAGCCTTCAGCCAGAGCTCCAACCTCATCACCCACAGCCGCAAGCA 
802s CCAGGTGTGTGGGAAAGCCTTCAGCCAGAGCTCCAACCTCATCACCCACAGCCGCAAGCA 
680mk CCAGGTGTGTGGGAAAGCCTTCAGCCAGAGCTCCAACCTCATCACCCACAGCCGCAAGCA 
793 CCAGGTGTGTGGGAAAGCCTTCAGCCAGAGCTCCAACCTCATCACCCACAGCCGCAAGCA 
********* ** ** ******************************************** 
 
human CACAGGCTTCAAGCCCTTCAGCTGTGAGCTGTGCACCAAAGG-- 
793mk CACAGGCTTCAAGCCCTTCAGCTGTGAGCTGTGCACCAAAGAAG 
794s CACAGGCTTCAAGCCGTTCAGCTGTGAGCTGTGCACCAAAGA-- 
802s CACAGGCTTCAAGCCGTTCAGCTGTGAGCTGTGCACCAAAGA-- 
680mk CACAGGCTTCAAGCCGTTCAGCTGTGAGCTGTGCACCAAAGA-- 
793 CACAGGCTTCAAGCCGTTCAGCTGTGAGCTGTGCACCAAAGA-- 
*************** ************************* 
Figure 7. 10 Comparison of DNA sequencing of cDNA of human GFI1B and mouse Gfi1b. 
(A) Alignment of latter half of exon 6 and all of exon 7 of cDNA sequence of human GFI1B and of 
mouse Gfi1b showing base differences in red, and site (outlined in yellow) of insertion (red arrow, 
red line in grey area) where an extra C base would be situated in the human GFI1Bc.880-881insC. (B) 
Alignment against human GFI1B of sequenced cDNA from purified megakaryocytes from bone 
marrow and spleen of control and GFI1B Mut TG mice. 
793mk, megakaryocytes from bone marrow of mouse #793, GFI1B Mut TG 
794s, megakaryocytes from spleen of mouse #794, control 
802s, megakaryocytes from spleen of mouse #802, GFI1B Mut TG 
(6)80(2) mk, megakaryocytes from bone marrow of mouse #802, GFI1B Mut TG 
793, megakaryocytes from spleen of mouse #793, GFI1B Mut TG 
A 
B 
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Figure 7. 11 Representative 2% agarose gels of RT-PCR and nested PCR showing amplicon bands. 
(A) Reverse transcriptase (RT) PCR DNA amplicons at ~300bp. (B) Second amplicon products of 
nested PCR showing several bands, with the target band at ~300bp. DNA extracted from these 
target bands were sent to AGRF for sequencing. Red arrows show sizes of bands in molecular 
weight marker 
Mouse #1089, WC-: control for GFI1B WT TG 
Mouse #1092, WC+: GFI1B WT TG 
Mouse #1109, MC-: control for GFI1B Mut TG 
Mouse #1110, MC+: GFI1B Mut TG 
Hyp50: HyperLadder™ 50bp (Bioline) 
 
Figure 7. 12 Representative 2% agarose gels of PCR to detect both genomic DNA and cDNA of TG mice. 
A confirmatory PCR to detect the presence of human transgene insertions for GFI1B WT TG and 
GFI1B Mut TG on both genomic DNA (gDNA) and synthesised cDNA of the pairs of mice with 
sequencing results. gDNA and cDNA both showed similar band sizes (GFI1B WT TG, ~~380bp; GFI1B 
Mut TG, ~305bp). 
WT TG ctl (control), ~380bp; Mut TG ctl (control), ~305bp. 
Mouse #1104, WC-: control for GFI1B WT TG 
Mouse #1105, WC+: GFI1B WT TG 
Mouse #1066, WC-: control for GFI1B WT TG 
Mouse #1067, WC+: GFI1B WT TG 
Hyp50: HyperLadder™ 50bp (Bioline) 
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7.3.3.2 Immunofluorescent investigation of FLAG tag expression in cultured megakaryocytes of GFI1B 
Mut TG mice and control mice shows no presence of FLAG-GFI1B 
Control Chinese hamster ovary (CHO) cells were transfected with FLAG or GFIB and processed for 
immunofluorescent studies concurrently with cultured megakaryocytes. Lineage - depleted bone 
marrow cell suspensions containing megakaryocytic progenitors were cultured for 4 days at 37°C, 5% 
CO2, to differentiate in the presence of cytokines, stem cell factor (SCF), and thrombopoietin (TPO). 
Mature megakaryocytes of control and GFI1B Mut TG mice were then isolated from the cell culture by 
application on a 1.5%-3% BSA gradient. Both CHO control cells and differentiated megakaryocytes 
were fixed onto coverslips, permeabilised and incubated with anti-FLAG protein antibody or anti 
GFI1B protein antibody. Secondary antibody, containing Alexa Fluor 488 was then incubated with 
each coverslip. Mountant containing DAPI, a nuclear and chromosome counterstain, was applied and 
coverslips with stained cells were viewed under a confocal microscope. For a negative control, 
secondary antibody was used alone to show non-specific binding. 
 
Figures 7.13 (E) and (F) show merged images of the positive control CHO cells indicating the 
positions of positive immunofluorescence of GFI1B in the nuclear areas of the cells, as expected, and 
of FLAG, throughout the cells, respectively. Figure 7.14 shows merged images of TG control 
megakaryocytes (E) and GFI1B Mut TG megakaryocytes (F), showing no immunofluorescence of 
FLAG in the nuclei of the TG megakaryocytes (F) indicating no positive expression of FLAG-tagged 
GFI1B. 
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Figure 7. 13 Immunofluorescent images of FLAG and Gfi1b expression in control 
Chinese hamster ovary (CHO) cells. 
Control CHO cells showing detection of cell nuclei with DAPI (A) and (B); the 
expression of GFI1B only (C) and of transfected FLAG only (D) and the merged 
images showing the position of positive immunofluorescence of GFI1B (E) in the 
nuclear areas of the cells and of FLAG (F) throughout the cells. 
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Figure 7. 14 Immunofluorescent images of cultured megakaryocytes harvested 
from control mice and from GFI1B Mut TG mice. 
Megakaryocytes showing detection of cell nuclei with DAPI (A – TG control) and 
(B – GFI1B Mut TG); immunofluorescence level seen after FLAG antibodies (C – 
TG control; D – GFI1B Mut TG); and the merged images showing no 
immunofluorescence of a FLAG-tagged GFI1B in the expected area of the 
nucleus in either group of cells (E - control; F – GFI1B Mut TG); indicating no 
FLAG-GFI1B expression in the megakaryocytes of these knock-in mice. 
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7.3.3.3 Immunohistochemistry investigation into FLAG expression in bone marrow (sternum) and in 
spleen of knock-in mice shows no detection of FLAG in the nuclei of megakaryocytes in either tissue 
Formalin-fixed, paraffin-embedded (FFPE) bone marrow (sternum) and spleen were examined by 
immunohistochemistry for detection of FLAG using mouse anti-FLAG primary antibodies. Specimens 
were blocked several ways in order to minimise the reactivity of secondary anti-mouse antibody 
with endogenous immunoglobulin present in the mouse tissue. In one method, Dako ARKTM (Animal 
Research Kit) (#K3954, Dako) Peroxidase blocking reagent was incubated with mouse tissue for 5 
minutes at room temperature, then the biotinylated mouse anti-FLAG antibody was applied for 15 
minutes at room temperature at a dilution of 1:100. This was followed by a 15-minute incubation 
with streptavidin-peroxidase, then stained by a 5-minute incubation with DAB (diaminobenzidine)+ 
substrate-chromogen. 
 
This investigation proved to be challenging in achieving a clear expression of FLAG in positive control 
tissue as well as in TG control and TG mouse tissue. Retrieval of the FLAG epitope was difficult to 
detect, and there was some non-specific staining seen in the tissues tested. Figures 7.15 (A) and 7.16 
(A) show control TG specimens of sternum and spleen, respectively, indicating normal morphology 
of megakaryocytes (insets 7.15 (C) and 7.16 (C), respectively), with no FLAG staining of nuclear areas. 
There are indications, however, of some non-specific staining in both tissues, but not expressed in 
the megakaryocytes. Knock-in specimens were taken from GFI1B WT TG mice as the construction of 
the transgene was the same for both WT and Mut TG mice. These, however, showed similar lack of 
FLAG staining in the megakaryocyte nuclei, as well as a clear indication of normal megakaryocyte 
morphology (insets 7.15 (D) and 7.16 (D), respectively). 
 
Although there was no definitive proof that FLAG-tagged GFI1B was not expressed in the nuclei of 
megakaryocytes in the GFI1B WT TG tissue, these images indicate the normal morphology of the 
megakaryocytes – central multi-lobed nuclei with pale cytoplasm - as compared to control mouse 
tissue. This demonstrates that there were no morphological differences in megakaryocytes between 
the two groups of mice. 
215  
 
 
Figure 7. 15 Immunohistochemistry for FLAG antibody in formalin-fixed, paraffin 
embedded bone marrow (sternum). 
Specimens were taken from control mice (A) and GFI1B WT TG mice (B) as the 
construction of the transgene was the same for both WT and Mut TG mice 
(magnification, x25.06). There was no expression seen of FLAG in the nuclear 
areas of the megakaryocytes seen in either specimen of tissue. Black arrows 
indicate megakaryocytes; red arrows indicate non-specific binding of stain to 
tissue. Insets (C) and (D) show enlarged images of singular megakaryocytes, both 
with normal morphology of central, multi-lobed nucleus with pale cytoplasm 
(magnification, x35.44). 
216  
 
 
 
Figure 7. 16 Immunohistochemistry for FLAG antibody in formalin-fixed, paraffin 
embedded spleen. 
Specimens were taken from control mice (A) and GFI1B WT TG mice (B) as the 
construction of the transgene was the same for both WT and Mut TG mice 
(magnification, x25.06). There was no expression seen of FLAG in the nuclear 
areas of megakaryocytes of either specimen of tissue. Black arrows indicate 
megakaryocytes; red arrows indicate non-specific binding of stain to tissue. 
Insets (C) and (D) show enlarged images of singular megakaryocytes 
(magnification, x35.44). 
217  
7.3.3.4 Immunohistochemistry investigation into FLAG expression in Western blot of cultured 
megakaryocytes 
Megakaryocytes from GFI1B Mut knock-in (TG) and control (TG) mice were harvested, isolated, and 
cultured as for those prepared for immunofluorescence studies. FLAG-transfected CHO cells were 
processed concurrently for use as a positive control. Washed (PBS) cell pellets were processed for 
the extraction of nuclear proteins, through steps utilising cold hypotonic cytoplasm extraction 
buffer, cold nuclear extraction buffer. The final supernatant containing the nuclear fraction had 2% 
sodium dodecyl sulphate (SDS) added to it immediately prior to processing for Western blot. A 
modified version of the Lowry method was used to determine the protein concentration of the 
nuclear extraction samples against a standard curve of BSA (0 - 100μg/mL). The BoltTM system of 
reagents and apparatus (InvitrogenTM, ThermoFisher Scientific) was used to carry out SDS-PAGE on 
the extracted nuclear proteins, which were loaded onto a pre-cast 4-12% gel. The iBlot® Dry Blotting 
system (#IB1001, Gel Transfer Device, InvitrogenTM, ThermoFisher Scientific) was then used to 
transfer proteins from the gel to a nitrocellulose membrane (iBlot®Gel Transfer Stacks, #IB3010-01) 
for Western blotting. The membrane was blocked, and had primary antibodies for FLAG and for 
GFI1B applied and incubated overnight. Antibody to histone, a nuclear protein, was used as a loading 
control. Secondary antibody, goat anti-mouse-HRP, was applied, and imaging solution, containing 
luminol, was used to visualise the bands. Blots were viewed on ChemiDoc™ Gel Imaging System 
using Image Lab™ software. 
 
GFI1B has a molecular weight of approximately 37 kDa (kiloDaltons)(Vassen et al., 2005). FLAG 
peptide has a molecular weight of 1.012 kDa (Hopp et al., 1988, Einhauer and Jungbauer, 2001). 
FLAG-tagged GFI1B protein would then be expected to have a combined molecular weight of 
approximately 37-38kDa.Figure 7.17 (B) shows expression of a band at approximately 37kDa (protein 
ladder marker shown at 39kDa) for each cell nuclear fraction for positive control CHO cells, the TG 
control cells, and the GFI1B Mut TG cells, indicating GFI1B protein present in all of them. Figure 7.17 
(A) shows expression of FLAG-tagged GFI1B protein in transfected positive control CHO cells at a 
band at approximately 37-38 kDa (protein ladder marker shown at 39kDa), but no band in either of 
the control TG or GFI1B Mut TG nuclear fractions, indicating that the anti-FLAG antibody did not 
detect any FLAG-tagged protein in these fractions. Figure 7.17 (C) shows loading control, histone (15 
kDa). 
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Figure 7. 17 No FLAG-tagged GFI1B detected in Western blot of cultured megakaryocytes 
of GFI1B Mut TG mice. 
Western blot images showing detection of GFI1B protein at ~37kDa (B) for positive 
control CHO cells, control TG, and GFI1B WT TG nuclear fractions. FLAG-tagged GFI1B is 
present in CHO cells (A) but is not detected in either control TG or GFI1B WT TG cells. (C) 
shows loading control for nuclear protein, histone. 
Hyp50, HyperLadder 50 protein marker; CHO, Chinese hamster ovary cells; Ctrl, control 
TG mouse. 
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7.4 Discussion 
The aim of the establishment of this mouse model was to produce, essentially, a transgenic system 
to test the effect of the over-expression of the mutant human allele GFI1Bc.880-881insC on 
megakaryocytes and platelets in the mouse. This was to mimic the bleeding disorder found in a four- 
generation Australian family (Stevenson et al., 2013), which was caused by this mutation in the 
transcription factor, GFI1B. Mouse breeding protocols and experiments were designed to produce a 
model that would allow a basic analysis of the haematological system relevant to platelet formation 
with quantitation of bone marrow progenitors and megakaryocytes by histopathology and flow 
cytometry, among other methods. These investigations included those parameters that were used 
to assess the haematological system in the Gfi1b conditional knockout mice, as reported in Chapters 
4, 5 and 6 in this thesis. 
 
The findings in this study showed that, in all parameters investigated, there was no evidence of any 
phenotype in these mice of thrombocytopenia or any discernible platelet function defect that 
correlated to the bleeding disorder observed in the Australian family displaying this mutation. 
Indeed, no haematological anomaly was seen in any knock-in mouse characterised as having a 
genotype that was homozygous for the mutant human allele GFI1Bc.880-881insC (GFI1B Mut TG) with the 
presence of the Pf4-Cre transgene. Comparisons in all parameters studied showed no differences 
between these mice and control mice, either those with knock-in homozygous GFI1Bc.880-881insC but 
Pf4-Cre negative (GFI1B Mut TG control), or those with knock-in homozygous GFI1BWT and either 
Pf4-Cre positive (GFI1B WT TG) or negative (GFI1B WT TG control). 
 
 
Full blood counts, especially platelet counts, showed no significant differences between GFI1B Mut 
TG mice and controls. Blood films showed normal cell morphology with no irregularities seen, and 
normal size and distribution of platelets. Harvested body organs, in particular spleens, of control and 
GFI1B Mut TG mice, showed no significant differences in weight as a percentage of body weight. 
Studies into megakaryocyte formation and function in these mice showed May-Grünwald-Giemsa 
(MGG)-stained cytospin preparations of bone marrow with similar distribution, and the appearance 
of centrally located, multi-lobed nucleus and pale cytoplasm, of the normal morphology of 
megakaryocytes as was observed in control mice preparations. DNA ploidy determinations of 
megakaryocytes of these GFI1B Mut TG mice showed no significant differences in the ranges or 
proportions of megakaryocyte ploidy classes compared to controls, and displayed a similar ploidy 
profile. Analyses of behaviour and characteristics of erythroid precursor cells in bone marrow and in 
spleen showed no evidence of expansion of cell numbers in the more immature erythroid 
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populations, and showed no differences in ranges of proportions of all erythroid precursor 
populations between GFI1B Mut TG mice and controls. 
 
The lack of a definitive bleeding phenotype in these GFI1B Mut TG mice led our research to the 
investigation of whether this genetic construct was indeed a working model. The inclusion of a FLAG 
tag gene to the N-terminus of the GFI1B gene in this construct enabled us to test for its detection to 
confirm that transcription of the tagged gene was actually occurring. In the various attempts to 
discern this, it was concluded that there was no expression or detection of FLAG, either as an 
expressed protein, or as a translated gene. In assessment of this genetic construct and its apparent 
ineffectiveness to produce a working model for a human bleeding disorder, there are several factors 
which may have contributed to its inadequacy in providing a functioning system. The choice of the 
tagging position in the expressed protein, for example, is a consideration, since this is often tested 
empirically, as both N-terminal and C-terminal tags can often alter localisation and/or function of the 
protein function (Kanca et al., 2017). 
 
The main concern was that the knock-in human gene GFI1Bc.880-881insC was unable to be expressed at 
all, thus resulting in an unaffected normal murine haematological system in these mice. There was 
reliance on the provision of Cre-recombinase from the crossbreeding with transgenic Pf4-Cre to 
effectively ablate a floxed (loxP-flanked) STOP codon and initiate activation and subsequent 
translation of the inserted human gene. However, the efficiency with which Cre recombines loxP 
sites is affected by their genomic position and the distance between them. Therefore, the same Cre 
transgene can cut different floxed alleles with different efficiencies (Zheng et al., 2000). However, 
the same Cre mice were used in the Gfi1b conditional KO mouse model with much success, although 
in that case there was a different genetic construct, with the Cre recombinase-generated deletion of 
one exon. 
 
The general principles of this model were the choice of the Col1a1 locus as being the most open 
locus for allowed for accepting the electroporated vectors containing the cloned gene constructs; 
that the collagen locus is expressed in the majority of mouse tissues; and that the inherited 
phenotype for GFI1Bc.880-881insC was confirmed as autosomal dominant inheritance. The expectation 
was then that there would be an observed phenotype in the mice reflecting that of the affected 
human family, overriding the effects of endogenous mouse Gfi1b.However, the choice of the Col1a1 
locus does not always guarantee transgene expression in vivo (Quinn et al., 2014). The expression of 
transgenes depends on targeting constructs, those transgenes that are targeted, the types of the 
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cells (Zhu et al., 2007), and also the stages of the embryonic development (Wörtge et al., 2010). In 
the transgenic mouse model investigated in this thesis, the specific targeting of the human GFI1B 
transgenes into predefined sites was carried out with the help of site-specific recombinases such as 
Flpe and Cre. However, the interaction of cassettes carrying regulatory elements that are introduced 
into specific sites, however, (such as the Col1a1 locus), with the chromosomal environment around 
those sites, is still not predictable and can result in the silencing of these transgene cassettes 
(Gödecke et al., 2017). This can also occur when more specific techniques are used to target the 
integration of such cassettes (Gaj et al., 2013). This may be one explanation why this model did not 
produce the anticipated results. 
 
The reproduction of a human disease in a mouse model may result in the human mutation not 
having the same effect on the mouse haematological system (Beer and Eaves, 2015, Schmitt et al., 
2001). However, one pertinent consideration of this proposal was the expected efficacy of the effect 
of this inserted mutant human gene on murine megakaryocytes, given that it was inserted at the 
collagen locus. A more targeted approach in creating a more megakaryocyte-specific model would 
be the creation of a model system that more closely replicates the dysfunction of the family being 
investigated. In recent years, the increasing use of customised nucleases with the ability to 
specifically target the genomic region of interest has been developed. The idea behind these 
genome editing tools is that the stimulation of DNA double-strand breaks (DSBs) at a target region, 
could enable the endogenous repair machinery of the cell to introduce targeted mutations (Rocha- 
Martins et al., 2015). The use of the CRISPR (Clustered Regularly Interspaced Short Palindromic 
Repeats) /Cas 9 system, a technology using RNA-guided endonucleases that allow the targeting of 
multiple DNA sites, has increasingly become a common method in creating genetically modified 
systems (Zhang et al., 2014). These techniques, however, were not available in our laboratory at the 
time that the genetically modified mouse lines for this research were created. 
 
Ideally, in order to test the true effects of this human mutation in a mouse model, a study 
comprising of the genetic replacement of the mouse endogenous gene, Gfi1b, with the mutant 
human gene, GFI1Bc.880-881insC, would provide the opportunity to investigate these effects. Studies 
whereby replacement of mouse TPO by its human homologue has been established (Rongvaux et al., 
2011) and the substitution of the native murine rhodopsin gene (linked to the neurodegenerative 
disease, retinitis pigmentosa) with the corresponding human DNA modified to encode an enhanced 
GFP fusion (Chan et al., 2004). The lethality associated with the ablation of the Gfi1b gene in mice 
would present some challenges in accomplishing this, but such a model would be able to more 
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closely replicate and define the function of this human mutant GFI1B gene on megakaryocyte, and 
hence platelet, formation in haematopoietic tissue. 
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CHAPTER 8: 
GENERAL DISCUSSION 
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8. Discussion 
8.1 Background of research 
Bleeding disorders are common clinical problems, and assessment and diagnoses of their aetiology 
often involve a multistep approach (Bashawri and Ahmed, 2007). The investigation of a bleeding 
disorder in four generations of an Australian family by our group resulted in the identification of a 
mutation in the gene for the transcription factor, GFI1B, which consisted of a heterozygous insertion 
of the C nucleotide (GFI1Bc.880-881insC) in exon 7, as being the cause for the disorder (Stevenson et al., 
2013). Characterisation of this disorder revealed severe defects in platelets, their structure and 
granular content, their function, as well as anisopoikilocytosis of red blood cells, and indications of 
increased level of haemoglobin F (HbF) compared to that of normal adults. The pattern of 
inheritance in this family for this mutation was autosomal dominant which led to the proposed 
hypothesis for this thesis that GFI1B acted as a dominant negative modulator of platelet and red cell 
differentiation, producing changes in cell development, morphology and function. 
 
8.2 Implementation of aims 
The first aim of this thesis was to investigate the effects of GFI1Bc.880-881insC on erythropoiesis (red cell 
development), for which a cell culture model was set up. Chapter 3 describes the establishment, for 
this purpose, of several separate cell lines of the erythroleukaemic K562 line, which has been used as 
a model of the common progenitor of megakaryocytes and erythroblasts. K562 cells can be 
differentiated into megakaryocytic and erythroid lineages, depending on the agent used. In this case, 
the cytidine analogue, AraC, was used to differentiate these cells into the erythroid lineage (Gambari 
et al., 1984, Luisi-DeLuca et al., 1984). For this cell model, two separate K562 cell lines were 
transfected, one with GFI1Bc.880-881insC, as well as a control cell line, which was transfected with 
GFI1BWT. A third cell line of untransfected K562 cells was included as untransfected control. 
 
Indications that the cell lines did not tolerate the transfected mutant gene well were realised with 
inconsistent results. While initial investigations were promising, with suggestions of increased 
expression of HbF by immunofluorescence and Western blotting in cells transfected with mutant 
GFI1b, subsequent experiments gave variable results. Confirmatory DNA sequencing assessments of 
the presence of the mutant GFI1B showed loss of the transfected gene with prolonged cell culture, 
at various times throughout the study. With the method employed, transfection rates were less than 
50%, so the effects of the genetic mutation may have been reduced. Also, the viability of the 
transfected cells may have been compromised, since parameters that increase the efficiency of the 
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transfection often result in higher cell death rates (Delgado-Canedo et al., 2006).These findings 
showed that transfected K562 cells were not a suitable in vitro model for our purposes in 
investigating the red cell changes wrought by this mutation. 
 
A more robust and relevant cell culture model to characterise the effects of GFI1Bc.880-881insC on the 
formation of red cells would involve the establishment of an induced pluripotent stem cell (iPSC) line 
from unaffected and affected members of the original family. Such a model was set up successfully 
to investigate megakaryocytic changes for this family (Rabbolini et al., 2017a). This was also 
attempted by this researcher, as an adjunct to this study, to set up such a cell line for erythropoiesis 
with limited success, but, due to time constraints, this was discontinued. Ideally, this would deal 
with actual cell changes of the affected family members involved, with a better chance of 
understanding the mechanism responsible for the aberrant red cell characteristics. 
 
The second aim of this thesis was to Investigate the function of the Gfi1b gene on blood formation 
in the bone marrow of conditional knockout mice (Gfi1b KO), especially in its control of platelet 
development. Chapters 4, 5, and 6 deal with the successful establishment of this mouse model. In 
Chapters 4 and 5, the effects of the loss of this gene along the megakaryocytic lineage were seen in 
the 60-fold reduction in platelet count; aberrant megakaryocyte morphology, with high numbers of 
malformed megakaryocytes detected in bone marrow and in spleen, which also expressed CD34; 
significantly increased plasma levels of TPO, the primary hormone for the production of platelets; 
reduced values in the haematological indices for red cells for all parameters investigated; and 
indications of extramedullary haematopoiesis in enlarged spleens. DNA ploidy of these abnormal 
megakaryocytes was significantly increased, with no indication of proplatelet growth or formation of 
platelets seen in TEM images of the cytoplasm. 
 
The significance of the two-fold increase in TPO plasma levels in Gfi1b KO mice was interpreted as 
being an increased response to the reduced platelet mass in these mice, as it has been reported in 
its role as a regulatory cytokine of this process (Machlus et al., 2014). The effect of TPO on 
endomitosis (Guo et al., 2015) was demonstrated in the increased DNA ploidy in the megakaryocytes 
in affected mice, as the effects of the loss of Gfi1b were seen in those megakaryocytes that were 
arrested in development at this stage, without being able to progress through to terminal 
differentiation and the production of viable platelets. The effect of low platelet count could also be 
as instrumental in raising the rate of endomitosis, creating higher ploidy megakaryocytes in a 
feedback loop (Patel et al., 2005). 
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The evidence of extramedullary haematopoiesis seen in the spleens of the Gfi1b KO mice was 
identified as the presence of the enlarged organs (up to 3-fold), with significantly increased 
subpopulations of erythroid precursors, compared to control mice. This phenomenon of stress 
erythropoiesis in the spleens of mice is in response to perceived anaemia or loss of blood, and is 
distinct from steady-state haematopoiesis (Paulson et al., 2011). Interestingly, compared to humans, 
this response is profound in the spleen in mice, with almost no response from the bone marrow, as 
was confirmed in our findings. 
 
The aberrant morphology seen in the megakaryocytes of the GFi1b KO mice in bone marrow and in 
spleen was characterised by eccentric nuclei with peripherally placed lobes, rare α-granules, poorly 
defined or no platelet territories, and immature DMS, concentrated at one end of the 
megakaryocyte. There was a two-fold increase in the numbers of these abnormal megakaryocytes 
seen in bone marrow compared to the numbers of normal megakaryocytes of control mice. In 
comparison, there was a 10-fold increase of abnormal megakaryocytes observed in spleens of Gfi1b 
KO mice, over those normal megakaryocytes seen in control spleens. This was also an indication of 
extramedullary haematopoiesis in the spleen in these mice. 
 
Immunohistochemical detection of CD34, a regulator of cell adhesion in the haematopoietic system, 
was observed in the megakaryocytes of Gfi1b KO mice, both in bone marrow and in spleen, with 
none detected in control megakaryocytes. This marker is usually expressed in early progenitors, 
promegakaryoblasts and megakaryoblasts, with declining expression as megakaryocytes mature 
(Insuasti-Beltran et al., 2012, Tomer, 2004). Expression of CD34 on mature megakaryocytes has been 
associated with myelodysplastic syndromes (Tang et al., 2011). More importantly and pertinently, 
however, its expression has been observed on megakaryocytes and platelets in families with 
mutations or variants of GFI1B (Rabbolini et al., 2017a). Normally, GFI1B represses the CD34 
promoter, but in reported mutations in the GFI1B zinc-finger (ZnF) DNA-binding domain have had 
the effect of weakening this repressive action, leading to expression of CD34 in these mature cells. 
 
These findings tally with those observed in a study to investigate the effect of a megakaryocyte- 
specific Gfi1b deletion on cytoskeletal organisation in megakaryocytes in mice (Beauchemin et al., 
2017). This research was published during the course of our own investigations, and goes towards 
validating our own findings. Much of their work, however, was carried out on cultured 
megakaryocyte colonies, and had a two-pronged approach to examine megakaryocyte development 
at early and late periods of differentiation. Controls used by these authors were either heterozygous 
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or homozygous for the floxed Gfi1b allele, as they found that both produced the control phenotype. 
In our study, however, controls were homozygous floxed Gfi1b, as were the KO mice, in order to 
minimise any potentially confounding factors. 
 
Earlier studies in the investigation of conditionally knocked out Gfi1b in the megakaryocytic lineage 
in mice (Vassen and Moroy, 2011) also showed similar results to our own with regard to severe 
thrombocytopenia, abnormal megakaryocyte morphology, with increased numbers and DNA ploidy, 
and splenic erythropoiesis. However, due to episodes of severe internal bleeding, these Gfi1b KO 
mice only survived 6 – 8 weeks, whereas in our model, Gfi1b KO mice were surviving for periods of 
up to 6 – 8 months, particularly females. 
 
In Chapter 6, examination of Gfi1b KO mouse foetal pups at age E16-17, in an investigation to 
determine sources of foetal loss due to bleeding events, also showed indications in the foetal liver of 
increased haematopoiesis and proliferation of aberrant megakaryocytes, which displayed the 
abnormal morphology and expression of CD34 as those observed in adult Gfi1b KO mice. However, 
these foetuses were viable, well-perfused, and showed no differences in weight, size, and 
appearance compared to control foetuses, which suggests that the effects of this loss of Gfi1b that 
have been seen in a definitive phenotype, are not manifested until after birth. 
 
The third aim of this thesis was to establish a mouse model that would reproduce the bleeding 
disorder observed in the original family of the dominant negative effects of GFI1Bc.880-881insC on 
megakaryocyte and platelet development. This model consisted of two mouse colonies: a colony of 
transgenic mice with a GFI1Bc.880-881insC knock-in at the Col1a1 locus, and a control mouse colony with 
GFI1BWT also inserted at the Col1a1 locus, to minimise any impact that the locus would have on the 
expected phenotype. Haematological investigations carried out on the two mouse colonies for a 
similar range of parameters as those studied in the Gfi1b KO mouse model, showed no discernible 
differences in any indices or characteristics between them. This lack of any indication of a bleeding 
diathesis in the transgenic GFI1Bc.880-881insC mice prompted further investigation into whether the 
actual genetic construct of these mice constituted a working model. The inclusion of a FLAG tag on 
both versions of the inserted GFI1B meant that the expressed FLAG-tagged GFI1B protein could be 
distinguished from mouse endogenous Gfi1b. However, investigations by different methods to 
detect this FLAG-GFI1B protein were unsuccessful, indicating that no transcription of the tagged 
protein was occurring, and that any effects of the mutant human GFI1B on murine haematopoiesis 
would not be observed. 
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8.3 Conclusions, comparisons, and future directions 
8.3.1 Red cell model 
Indications of anisopoikilocytosis seen in the red cells of the affected members of the original family 
signal abnormal erythropoiesis (Bain et al., 2012). While the K562 cell model outlined in this thesis 
was not effective in the investigation of the red cell anomalies associated with GFI1Bc.880-881insC, an 
iPSC red cell model, as suggested, similar to that established for platelet investigations (Rabbolini et 
al., 2017a) from unaffected and affected family members, would give a more relevant and accurate 
vehicle in which to study these phenomena. 
 
It is interesting to note that of the GFI1B variants that have been reported to cluster in the DNA- 
binding zinc finger (ZnF) domains 3- 5 of the transcription factor, as GFI1Bc.880-881insC does, many 
appear to have associated anisopoikilocytosis, with varying degrees of resultant platelet phenotypes, 
while those variants in other parts of the protein, including the remaining ZnF domains, do not 
(Rabbolini et al., 2017b). An acquired GFI1B point mutation in the fourth ZnF domain, identified in 
acute myeloid leukaemia (AML) arising from myelodysplastic syndrome (MDS), was also shown to 
have anisopoikilocytosis (Anguita et al., 2016). However, a study of three mutations, one of which is 
situated at the splice donor site of exon 6 in GFI1B, while the other two (including our reported 
mutation) are in exon 7, has characterised the disruptive effects of the mutations on ZnFs 4 and 5 
(Kitamura et al., 2016). Although the variants are situated close to each other, only two of the three 
display anisopoikilocytosis. Alternate splicing (the formation of several transcripts from a single 
gene) of GFI1B where a variant was associated with severe bleeding has also been reported 
(Rabbolini et al., 2017b). GFI1B is usually expressed as a long (L) transcript, producing a 330-amino 
acid protein, while an alternative splicing of the locus with the removal of exon 4 results in in a short 
(S) transcript, producing a 284-amino acid protein, which lacks the first two Zn-finger domains of 
GFI1B. Interestingly, the L-isoform appears to be important for megakaryopoiesis and platelet 
production, whereas the S-isoform is necessary for erythropoiesis (McClellan et al., 2017).  
 
Studies using an iPSC model could include measurement of variations in expression of cytoskeletal 
and cytoplasmic proteins, and investigation, through RNA-seq and ChIP-seq, into those GFI1B target 
genes which are not transcribed by the mutant GFI1B, which can be confirmed by a dual-luciferase 
reporter system to determine if aberrant transcriptional activation or repression is the underlying 
causative mechanism. This may give more of an insight into why some GFI1B variants display red cell 
abnormalities, while others with mutations in very close proximity to these other variants do not. 
 
8.3.2 Gfi1b conditional knockout mouse model 
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The successful implementation of this mouse model in characterising the effects of the loss of Gfi1b 
on haematopoiesis in mice, with particular attention to megakaryopoiesis and thrombopoiesis, has 
led to further investigations in our group into the mechanism of the observed aberrant 
development of megakaryocytes. Some pertinent insights into the possible mechanism for the 
failure of Gfi1b- deficient megakaryocytes to mobilise the DMS into forming proplatelets have been 
proposed from results from cell culture studies by (Beauchemin et al., 2017). Their experiments 
with time-lapse video microscopy showed reduced motility in culture of these megakaryocytes to 
fibronectin, fibrinogen, and collagen. They found that these deficient megakaryocytes displayed 
lower levels of actin filaments, and seemed unable to produce microtubule fibres. Intracellular 
localisation of β- tubulin was concentrated in the centre of the cells, surrounded by a ring-shaped 
nucleus, compared to the central and peripheral distribution seen in normal megakaryocytes. The 
failure of the formation of microtubule polymerisation in these abnormal cells led to Western blot 
analyses of both of β-tubulin and of α-tubulin, which showed normal β-tubulin content, but 
markedly reduced α-tubulin content. 
 
Correspondingly, preliminary experiments, by Dr Marie Levade in our group, on proplatelet 
formation in cultured megakaryocytes from our Gfi1b KO mice, have shown failure to form 
proplatelet extrusions in Gfi1b KO mice compared to controls (data not shown). Other ongoing 
studies include investigating the deposition of reticulin in bone marrow (BM) as an indication of 
fibrosis. Megakaryocyte proliferation and differentiation have been linked with the pathogenesis of 
fibrosis (Malara et al., 2018). Premature release of granule contents contributes to the fibrotic 
reaction produced by BM stromal cells, usually seen in clusters of immature and necrotic 
megakaryocytes. In other preliminary studies of our mouse model by Dr Levade, the observed 
increase in proliferation of abnormal, immature megakaryocytes, especially in older surviving mice, 
has not been seen to contribute to increased detection of reticulin in these tissues. The almost 
complete absence of α- and other granules in aberrant megakaryocyte cytoplasm is mooted as 
attesting to this outcome. Examination of the process of defective endocytosis in these abnormal 
megakaryocytes by detection of markers of early endosomes (early endosome antigen 1, EEA1) and 
late endosomes (lysosome-associated membrane protein, LAMP1), and the formation of invaginated 
vesicles by detection of the protein, clathrin (Banerjee and Whiteheart, 2017), are other approaches 
being established in these ongoing investigations. Analyses of cell surface receptors for 
thrombopoietin (TPO), which is increased in these mutant mice, are also being planned. 
 
8.3.3 GFI1B transgenic mouse model 
The establishment of a transgenic mouse model to mimic a human disease has to allow for the 
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possibility that the human mutation may not produce the same (or any) effect in the murine system 
(Schmitt et al., 2001, Beer and Eaves, 2015). The genetic construct of the transgenic mice in our 
model had a number of factors which could have contributed to the lack of altered phenotype 
observed. Expression of transgenes depends on such factors as these targeting constructs, the 
targeted transgenes, the types of the cells, as well as the stages of the embryonic development 
(Wörtge et al., 2010). The use of the Col1a1 locus as the location for the insertion of the human 
transgenes does not always guarantee that this will provide an appropriate platform for the correct 
expression of these human genes (Quinn et al., 2014). The failure of the detection of the FLAG- 
tagged protein from the analysis of RNA expression suggested that there may have been incomplete 
Pf4-Cre excision of the lox-STOP-lox cassette in the construct (Bao et al., 2013). 
 
The use of more recent techniques such as ZnF nucleases, Transcription Activator-Like Effector 
Nucleases (TALEN - restriction enzymes that can be engineered to cut specific sequences of DNA), 
and Clustered Regularly Interspaced Short Palindromic Repeats / CRISPR-associated protein 9 
(CRISPR/Cas 9 genome editing system) has enabled the targeting of integration of genetic constructs 
into virtually any site of the genome (Gödecke et al., 2017). The replacement of the murine 
endogenous Gfi1b gene with the human GFI1Bc.880-881insC may provide an appropriate mouse model to 
investigate the effects of the mutant GFI1B on the haematological system. This type of approach has 
been established in other mouse models (Rongvaux et al., 2011, Chan et al., 2004) with varying 
degrees of success. However, the implications of potential lethality of deleting the endogenous Gfi1b 
would present some challenges in establishing this model. 
 
8.3.4 Summary 
 
The basis of this thesis was the investigation into the characteristics of the transcription factor, 
GFI1B, which was identified as the cause of a bleeding disorder in an Australian family (Stevenson et 
al., 2013). The establishment of a cell culture model was designed to study the dyserythropoietic 
manifestations seen in this disorder. Mouse models to investigate loss of gene function (Gfi1b 
conditional knockout), and to mimic the dominant negative phenotype observed in affected family 
members, were constructed. The successful implementation of the Gfi1b conditional KO model gave 
invaluable insights into the effects of the loss of this gene on megakaryocyte and platelet 
development and formation. The in vitro cell model for erythropoietic investigations proved to be 
inconclusive, but an alternative model using iPSC cells from family members would likely provide a 
more stable system. The transgenic mouse model provisionally designed to observe the effects of 
the human GFI1B mutation in the murine haematological system also proved to be inadequate in 
achieving this aim. Alternative transgenic mouse models involving the replacement of endogenous 
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Gfi1b with transgenic GFI1Bc.880-881insC may provide a workable solution to thoroughly investigate the 
effect of this mutation on haematopoiesis. 
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